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AIC: Akaike criterion
AIDS: Acquired Immune Deficiency Syn-
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ASC: Antibody-secreting cell
cART: Combination Antiretroviral Therapy
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ELISA: Enzyme-linked immunosorbent as-
say
EVD: Ebola virus disease
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HAV: Hepatitis A virus
HBV: Hepatitis B virus
HIV: Human Immunodeficiency Virus
HPV: Human Papillomavirus
IFN: Interferon
Ig: Immunoglobulin
IL: Interleukin
LCVa: Approximation of the leave-one-out
cross validation criterion
MAP: Maximum a Posteriori
MARV: Marburg virus
MCMC: Markov chain Monte Carlo
MHC: Major Histocompatibility complex
mRNA: Messenger Ribonucleic acid
MVA: Modified Vaccinia Ankara
NHP: Non-Human Primate
NK: Natural Killer
NP: Nucleoprotein
ODE: Ordinary Differential Equation
PEB: Parametric Empirical Bayes
PDMP: Piecewise Deterministic Markov
Process
RNA: Ribonucleic acid
RVS: Robust-variance scoring
rVSV: Recombinant Vesicular Stomatitis
Virus
SDE: Stochastic Differential Equation
SUDV: Sudan ebolavirus
TAFV: Tai Forest ebolavirus
TNF: Tumor Necrosis Factor
VV: Vaccinia Virus
ZEBOV: Zaire ebolavirus
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ABBREVIATIONS AND NOTATIONS
Notations
— In chapter 3 "Modeling the immune response to Ebola vaccine":
• x: scalar x
• x: vector x
• X: vector X
• xT : x transpose
• p(A|B): probability of A conditional on B
• Eθ[X]: expectation of X under the distribution of θ
• Tr(M): trace of matrix M
— In chapter 4 "Optimizing immune therapies in HIV-infected patients":
• x: scalar x
• x: vector x
• X: space X
• Eux0 : expectation under strategy u with starting point x0
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Résumé substantiel
Introduction
Les vaccins ont constitué une avancée majeure de la médecine des dernières décennies
et ont permis l’éradication de certaines maladies telles que la variole ou la rougeole. Le
principe de la vaccination est basé sur la mémoire immunitaire : après exposition à un pa-
thogène, l’organisme est capable de générer une meilleure réponse en cas de ré-exposition.
Cette réponse est spécifique au pathogène et se produit de manière plus rapide et plus
efficacement, en termes qualitatif et quantitatif. Cependant, les mécanismes permettant
de générer et maintenir cette mémoire immunitaire ne sont pas encore totalement connus,
et les connaissances immunologiques à propos de la vaccination sont principalement em-
piriques. Cela pose donc problème quant au développement de vaccins efficaces contre
certaines maladies infectieuses plus complexes, telles que le VIH, Ebola ou bien le palu-
disme. Certaines stratégies vaccinales récentes ont engendré des résultats encourageants :
ces stratégies, dites "prime-boost", consistent à combiner plusieurs produits en injections
répétées. Cependant, l’utilisation de ces nouveaux vaccins soulève de nouvelles questions :
en particulier, combien d’injections sont nécessaires ? Dans quel ordre ? A quel délai ? En
effet, on considère que si l’injection de boost est effectuée trop tôt, les cellules sont trop
sollicitées et la différentiation en cellules mémoires n’est pas encore terminée. La réponse
secondaire n’est donc pas optimale. Si l’on attend trop longtemps, la quantité de cellules
mémoires aura déjà commencé à diminuer et la réponse ne sera pas optimale non plus. Il
est difficile de mettre en place un essai clinique pour répondre à chacune de ces questions,
car ceux-ci sont très longs et coûteux. De plus, un autre défi dans le développement vacci-
nal réside dans la variabilité populationnelle de la réponse immunitaire à une stimulation
antigénique. En effet, de nombreux facteurs peuvent influencer la réponse immunitaire,
que ce soit des facteurs génétiques, démographiques, environnementaux, ou bien liés au
microbiome. Ces facteurs ne sont pas indépendants les uns des autres et il est donc encore
difficile de les prendre en compte et de quantifier leur impact sur la réponse immunitaire.
Pour répondre à ces questions, de nombreuses données sont générées dans le cadre d’essais
cliniques vaccinaux chez des humains. Ces données sont de différents types : génomiques,
protéomiques, métaboliques, ... Cependant, il est aussi difficile d’intégrer toutes ces don-
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nées et d’en retirer l’information nécessaire pour comprendre les mécanismes d’action des
vaccins.
L’approche dite de biologie systémique a pour objectif de mieux comprendre le fonc-
tionnement du système immunitaire en analysant sa dynamique dans son ensemble, grâce
à l’intégration de données de multiples marqueurs de la réponse immunitaire. Cela passe en
particulier par la modélisation mathématique du système immunitaire. En effet, les inter-
actions biologiques entre les acteurs du système immunitaire sont généralement complexes
et non linéaires. Le comportement global est donc difficile à prédire. La modélisation ma-
thématique permet de prendre en compte cette complexité. L’intérêt des modèles réside
aussi et surtout dans leur capacité à quantifier les dynamiques du processus biologique étu-
dié et à capturer l’impact de certains facteurs sur la variabilité du processus. Les modèles,
bien calibrés et estimés, représentent également un vrai outil de prédiction. De nombreux
modèles du système immunitaire ont déjà été proposés dans la littérature et leur intérêt
a largement été discuté. Il y a cependant peu de modèles concernant spécifiquement la
réponse à un vaccin.
Le travail de cette thèse s’inscrit dans l’approche de biologie systémique, avec deux
objectifs particuliers : le premier est de modéliser la dynamique de la réponse immuni-
taire à un vaccin, et le suivant est de proposer un outil numérique pour optimiser les
protocoles d’injections répétées. En pratique, le travail est divisé en deux projets. Dans le
premier, nous proposons l’application d’un modèle de la réponse immunitaire humorale,
basé sur un système d’équations différentielles et nous estimons les paramètres du mo-
dèle en utilisant des données provenant d’essais cliniques de phase 1 sur un vaccin contre
Ebola. L’estimation du modèle permet de quantifier la dynamique du système immuni-
taire, de prédire la durabilité de la réponse, ainsi que de déterminer l’impact de facteurs
environnementaux et liés au vaccin sur la variabilité de cette réponse. Dans le deuxième
projet, nous nous intéressons à des problèmes d’optimisation. En effet, l’idée principale est
d’utiliser les modèles mathématiques de la réponse vaccinale pour déterminer le schéma
optimal de prime-boost, et en particulier le délai optimal entre les injections. Nous pro-
posons donc un outil numérique, basé sur la théorie du contrôle optimal et permettant
d’optimiser des schémas d’injections. En particulier, cet outil est appliqué à des protocoles
d’immunothérapie injectée à des patients atteints par le VIH.
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Modélisation de la réponse immunitaire à un vaccin contre
Ebola
L’épidémie d’Ebola de grande envergure qui a eu lieu en Afrique de l’Ouest entre 2014
et 2016 a mis en évidence le manque de produits thérapeutiques et/ou vaccinaux efficaces
contre le virus Ebola. Cela a engendré la mise en place de nombreux projets visant à
accélérer le développement de vaccins ou médicaments contre le virus. En particulier, un
vaccin prime-boost consistant en une injection avec le vecteur adénovirus 26 (Ad26) et
le vecteur Modified Vaccinia Ankara (MVA) est évalué dans des essais cliniques de phase
1 à 3. Certains de ces essais sont réalisés dans le cadre du consortium EBOVAC, qui est
inclus dans le programme Ebola+ de l’Innovative Medicines Initiative (IMI). Ce consor-
tium réunit des partenaires académiques avec le laboratoire pharmaceutique fabriquant
le vaccin. L’INSERM faisant partie de ce consortium, nous avons eu accès aux données
de 3 essais cliniques de phase 1 réalisés sur des adultes volontaires sains dans 4 pays :
Royaume Uni, Kenya et Ouganda/Tanzanie. Dans ces essais cliniques, les participants ont
été randomisés pour recevoir soit Ad26 puis MVA ou MVA puis Ad26 à 28 ou 56 jours
d’intervalle. Des mesures des marqueurs de la réponse immunitaire ont été effectuées à
des temps consécutifs jusqu’à 1 an après la première injection vaccinale. En particulier,
le niveau d’anticorps a été mesuré ; on ne sait pas encore si un niveau donné d’anticorps
engendre une protection contre l’infection par le virus Ebola, mais des études chez des
primates non humains ont montré que la survie après une injection intramusculaire du
virus était associée à un niveau élevé d’anticorps. C’est donc actuellement le marqueur
préférentiel pour évaluer l’immunogénicité des vaccins candidats dans les essais cliniques.
Une question majeure concerne la durabilité de la réponse immunitaire ainsi que les fac-
teurs pouvant influencer cette durabilité. En particulier, certaines études ont montré que
les anticorps étaient maintenus dans l’organisme grâce à une population de cellules B pro-
ductrices d’anticorps ayant une longue demi-vie. Cependant, il semblerait qu’une autre
population de cellules B soit capable de réagir rapidement après rencontre avec l’antigène
pour produire un certain nombre d’anticorps avant de rapidement mourir.
Nous avons donc utilisé un modèle pour la dynamique de la réponse humorale après
l’injection de boost, constitué de deux populations distinctes de cellules productrices d’an-
ticorps, ayant des demi-vies différentes et des taux de production d’anticorps différents.
La dynamique de chaque compartiment du modèle est décrite à l’aide d’une équation dif-
férentielle ordinaire. L’intérêt étant de quantifier la dynamique de la réponse immunitaire
humorale après l’injection, les paramètres du système d’équations différentielles ont été
estimés en utilisant les données des 3 essais cliniques de phase 1 réalisés en Europe et
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Afrique de l’Est. Cette estimation est basée sur une approche populationnelle, utilisant
des modèles linéaires mixtes sur chacun des paramètres. Cela permet d’estimer une valeur
moyenne du paramètre dans la population, ainsi que l’impact de covariables (facteurs liés
au vaccin ou à l’environnement géographique) sur ces paramètres et également la varia-
bilité intra-individuelle, induite par un effet aléatoire normalement distribué autour de la
valeur moyenne. De plus, l’estimation est basée sur un modèle d’observation, qui suppose
que les observations cliniques correspondent à une fonction des compartiments du mo-
dèle mathématique à laquelle s’ajoute une erreur d’observation normalement distribuée.
Concrètement, l’estimation est effectuée en maximisant la vraisemblance globale, obtenue
en calculant les vraisemblances individuelles et en intégrant sur les effets aléatoires. La
maximisation est ensuite effectuée en utilisant un algorithme de type Newton, qui est
basé sur une approximation de la matrice hessienne utilisant seulement les dérivées pre-
mières de la log vraisemblance, ce qui facilite les calculs numériques. De plus, plusieurs
critères sont utilisés afin de s’assurer de la convergence de l’algorithme. Un autre aspect
du programme de maximisation est qu’il permet d’utiliser des connaissances biologiques
obtenues à partir d’expérimentations ou d’autres estimations en définissant des distribu-
tions a priori sur les paramètres. Dans ce cas, on réalise une approximation normale de la
distribution a posteriori et on estime le maximum a posteriori du paramètre en question.
Cela se traduit numériquement par la maximisation d’une vraisemblance pénalisée par les
connaissances a priori.
Après sélection et estimation du modèle, les résultats suivants ont été obtenus : la
demi-vie moyenne des anticorps a été estimée à 24 jours (intervalle de confiance [22,26]
jours). Cette estimation semble cohérente avec des études précédentes ayant estimé la
demi-vie des anticorps entre 3 semaines et 2 mois. De plus, deux populations de cellules
productrices d’anticorps ont pu être bien distinguées : la première a une demi-vie variant
de 1 à 5 jours, selon le régime de vaccination. Cette estimation est également cohérente
avec d’autres études qui montrent que les cellules productrices d’anticorps sont sujettes à
un pic autour de 7 jours après injection vaccinale et disparaissent après 10 à 14 jours. La
deuxième population de cellules a une demi-vie de plusieurs années. Comme les données
ne sont disponibles que jusqu’à 1 an après la première injection vaccinale, il est diffi-
cile d’identifier avec précision un intervalle de confiance autour de la demi-vie de cette
population à longue durée de vie. Cependant, un profil de vraisemblance a été effectué
et a permis de déterminer une valeur minimale de 5 années. Cela signifie que la moi-
tié des cellules présentes 7 jours après l’injection de boost persiste au moins 5 ans dans
l’organisme, tout en continuant à produire des anticorps. D’autres études concernant des
vaccins différents ont également permis d’identifier une persistance des anticorps pendant
plusieurs années, suggérant le maintien par une population de cellules B capables de vivre
20
RÉSUMÉ SUBSTANTIEL
longtemps dans l’organisme. Nous avons également identifié comment certains facteurs
influencent la dynamique de la réponse immunitaire humorale. Le régime vaccinal semble
notamment modifier la demi-vie des cellules productrices d’anticorps qui répondent rapi-
dement. Cette modification n’a pas d’impact sur la persistance des anticorps à long terme.
En revanche, la localisation géographique a un impact sur les niveaux de persistance des
anticorps. En effet, les participants d’Europe ont des niveaux d’anticorps à long terme
plus élevés que les participants d’Afrique de l’Est. Dans le modèle, cela est dû à une dif-
férence significative de valeur d’un paramètre signifiant que les cellules ayant une longue
durée de vie produisent plus d’anticorps et/ou sont présentes à un niveau plus élevé 7
jours après l’injection de boost chez les européens que chez les africains. Cette différence
pourrait être liée à l’environnement immunitaire, les participants africains étant plus su-
jets à un environnement immunitaire activé par d’autres co-infections ou parasites. Nous
avons également examiné l’impact potentiel de la réponse cellulaire de lymphocytes T
CD4 produisant des cytokines sur la dynamique humorale. Cependant, nous n’avons pas
pu identifier d’effet significatif de la réponse cellulaire. Cela peut être dû au fait que la
réponse mesurée correspond aux cellules circulant dans le sang, alors que les interactions
entre les cellules T et B se produisent généralement dans les centre germinatifs dans les
organes lymphoïdes.
Ce premier modèle de la réponse immunitaire humorale à un vaccin contre Ebola a
donc engendré des résultats intéressants, tant sur l’aspect quantitatif de la dynamique que
sur l’identification des facteurs de variabilité de la réponse immunitaire. Il peut cependant
être amélioré, notamment en prenant en compte la mémoire immunitaire. En effet, c’est
la génération de la mémoire immunitaire qui est d’intérêt principal lors d’une vaccination.
Pour cela, un travail a été commencé dans l’équipe afin de proposer des modèles pour la
réponse immunitaire dès la première injection vaccinale dans lesquels les cellules B mé-
moires sont générées. Ces cellules sont rapidement capables de se différencier en cellules
productrices d’anticorps après la deuxième injection vaccinale. Un premier travail a dé-
terminé l’identifiabilité du modèle, la sensibilité de la dynamique des compartiments par
rapport aux paramètres, ainsi que la calibration du modèle. Des données supplémentaires,
en particulier celles concernant les cellules B, doivent être utilisées pour pouvoir estimer
ce modèle.
Dans le cadre d’une modélisation qui s’inscrit dans une approche de biologie systé-
mique, il serait également intéressant d’intégrer d’autres marqueurs de la réponse immu-
nitaire, et en particulier des acteurs de la réponse innée. Cela pourrait être effectué en
utilisant des valeurs de certains marqueurs majeurs à certains moments de la réponse
comme covariable dans un modèle de la réponse adaptative. Il serait également envisa-
geable d’utiliser un système d’équations différentielles modélisant les dynamiques de tous
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les acteurs d’intérêt mais cela engendre plus de difficultés en terme d’estimation des pa-
ramètres. Une autre possibilité serait d’intégrer les données d’expression génique dans un
modèle mécaniste de la réponse immunitaire. A l’heure actuelle, cela représente un vrai
défi méthodologique. Le choix du type de modèle est également crucial, car les mécanismes
de transcription et expression génique contiennent une stochasticité intrinsèque qu’il est
difficile d’ignorer. Des modèles de réseaux de gènes ainsi que des méthodes d’inférence ont
déjà été développés et il serait intéressant d’évaluer la possibilité d’utiliser ces méthodes
et de les intégrer dans un modèle mécaniste de la réponse immunitaire. Cela permettrait
à long terme de définir des modèles intégratifs de la réponse vaccinale, permettant d’aider
à la mise en place de futurs essais cliniques.
Optimisation d’immunothérapies pour des patients in-
fectés par le VIH
Un autre aspect de la thèse consiste à développer des méthodes d’optimisation de
régimes d’injections répétées. Cela a été effectué en particulier dans le cadre clinique de
patients atteints par le VIH. Ces patients reçoivent un traitement antirétroviral, ce qui
leur permet de contrôler le virus et d’avoir une charge virale indétectable. Cependant,
leur système immunitaire n’est pas totalement reconstruit suite à la prise du traitement,
et les niveaux de lymphocytes T CD4 sont effectivement trop bas, inférieurs à 500 cellules
par µL de sang. Des études ont montré que des patients infectés par le VIH avec des
niveaux de CD4 plus élevés que cette limite ont un état de santé aussi satisfaisant qu’une
personne saine. Il est donc crucial de développer des thérapies permettant d’augmenter les
niveaux immunitaires de ces patients. L’immunothérapie par injections d’une cytokine,
l’interleukine 7 (IL-7) est donc envisagée, cette cytokine stimulant la prolifération des
lymphocytes T CD4 et augmentant potentiellement leur production thymique, leur survie
et leur maturation. Des essais cliniques ont évalué l’effet d’injections répétées d’IL-7 sur
la reconstitution de l’ensemble des lymphocytes T CD4 et ont montré que des injections
réalisées en cycles de 3 injections espacées d’une semaine pouvaient aider à maintenir les
niveaux de CD4 au-dessus de 500 cellules par µL de sang.
Afin de mieux comprendre et quantifier les mécanismes d’action de l’IL-7, des modèles
ont déjà été développés et estimés sur les données des essais cliniques précédemment
évoqués. Un modèle simple contient deux populations de CD4, une population étant au
repos et l’autre étant en train de proliférer. Ces deux populations ont des taux de mort
différents et les cellules au repos peuvent entrer en prolifération au taux π alors que
celles en prolifération arrêtent de proliférer après une dernière division au taux ρ. Ce
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modèle a permis d’évaluer l’effet des différentes injections dans un même cycle sur la
prolifération des cellules, ainsi que leur effet sur la survie des cellules. Ce modèle ayant
également montré un pouvoir prédictif certain, il est possible de l’utiliser pour simuler
l’effet de différents protocoles d’injections sur des patients infectés par le VIH. L’étape
suivante est donc d’optimiser les protocoles d’injections, c’est-à-dire utiliser un minimum
d’injections d’IL-7 tout en maximisant le temps passé avec le nombre de lymphocytes T
CD4 au-dessus de 500. Pour cela nous avons développé une méthode basée sur la théorie
du contrôle optimal, et cette méthode a été évaluée sur un ensemble de pseudo-patients.
Ce sont des patients fictifs générés en tirant aléatoirement un ensemble de paramètres
suivant la loi a posteriori estimée sur les données des essais cliniques. Cela permet d’avoir
un ensemble de patients représentatif de la population d’étude.
Afin d’appliquer des résultats récents de la théorie du contrôle optimal, nous avons
d’abord décrit le processus à l’aide d’un modèle spécifique : un processus de Markov dé-
terministe par morceaux (PDMP). Cette classe de modèles correspond à un processus qui
suit une trajectoire déterministe ponctuée de sauts aléatoires. Un PDMP peut être défini
de manière itérative : à partir d’un point de l’espace d’état, le processus suit une trajec-
toire définie par le flot (par exemple la solution d’un système d’équations différentielles)
jusqu’à ce qu’un saut se produise. Cela peut arriver de manière aléatoire, selon une cer-
taine intensité, ou bien de manière déterministe lorsque le processus atteint une frontière
de l’espace d’état. Dans les deux cas, la mesure de transition permet de déterminer l’état
à partir duquel le processus reprend. Dans le cas particulier du contrôle impulsionnel à la
frontière, il est possible d’effectuer des actions ponctuelles lorsque le processus atteint la
frontière de l’espace, ce qui peut modifier l’état à partir duquel le processus recommence.
Dans notre cas particulier, nous suivons la trajectoire des CD4 et les injections d’IL-7
peuvent modifier la valeur du paramètre de prolifération des cellules pendant un temps
aléatoire de plusieurs jours. Une stratégie (ici un protocole d’injections) correspond à un
ensemble d’actions réalisées jusqu’à un certain horizon. A chaque stratégie, il est possible
d’associer un critère de performance qui compile en fait l’ensemble des coûts engendrés
par chacune des actions. Ici, le critère combine le nombre d’injections d’IL-7 effectuées
ainsi que le temps passé avec un nombre de cellules CD4 inférieur à 500 cellules par µL.
L’objectif est de minimiser ce critère de performance et de déterminer la stratégie corres-
pondante. Pour cela, un opérateur intégro-différentiel, aussi appelé opérateur de Bellman
dans la littérature, est défini à partir des caractéristiques du PDMP. En itérant l’opérateur
de Bellman, on obtient une suite de fonctions qui converge théoriquement vers la valeur
minimale du critère de performance, encore appelée la fonction valeur. Celle-ci permet
alors de déterminer la stratégie optimale.
A l’heure actuelle, il n’y a pas de méthode générale pour résoudre les problèmes de
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contrôle optimal. La résolution du problème optimal par l’itération d’une suite nous a
permis de développer une méthode numérique basée sur la programmation dynamique.
Pour cela, la suite est approchée sur une grille de l’espace d’état. La difficulté numérique
réside non seulement dans l’organisation de la grille pour permettre de calculer la suite
itérative sur la grille, mais également dans la taille de la grille qui peut engendrer des temps
computationnels assez élevés. L’algorithme itératif a été développé sur le logiciel de calcul
Matlab, et a été appliqué à un ensemble de 50 pseudo-patients afin de vérifier l’efficacité
de la méthode. Le critère de performance a été calculé sur la stratégie optimale ainsi
déterminée, et comparé à d’autres protocoles cliniques "naïfs". Les résultats obtenus sur
les pseudo-patients ont montré que la stratégie optimale déterminée avait un coût moins
élevé que les 5 autres protocoles cliniques envisagés. En effet, même si le nombre moyen de
CD4 sur un horizon d’1 an était plus faible que celui obtenu avec des protocoles contenant
plus d’injections, le temps passé en dessous de 500 était similaire, tout en utilisant moins
d’injections. Cela montre que la stratégie ainsi déterminée est bien capable de réaliser un
équilibre entre ces 2 quantités. De plus, la stratégie optimale ainsi déterminée est assez
intuitive, puisqu’il s’agit d’utiliser 2 injections par cycle tant que les niveaux de CD4 du
patient sont faibles (inférieur à 500), puis des injections seules permettant de maintenir
le patient au-dessus de la limite de 500. Les résultats suggèrent donc que la méthode de
détermination d’un protocole optimal d’injection fonctionne sur ces pseudo-patients, et
pourrait être utilisée dans le cadre d’optimisation de protocoles de futurs essais cliniques.
Une limitation majeure de cette méthode est qu’elle suppose que les paramètres du
patient sont parfaitement connus. Même si les méthodes d’estimation se sont montrées
efficaces dans ces cas de modélisation, il y a cependant de l’incertitude lorsque les pa-
ramètres d’un nouveau patient inclus dans l’essai clinique sont estimés. Il est néanmoins
difficile de gérer les problèmes d’estimation et d’optimisation de manière simultanée. L’es-
timation engendre une stochasticité due à l’incertitude autour de la valeur des paramètres
biologiques du patient étudié, tandis que lors de l’optimisation du PDMP, la stochasticité
est intrinsèque au modèle biologique en lui-même. Dans ce dernier cas, il pourrait être
intéressant d’appliquer la méthode provenant de la théorie du contrôle optimal à d’autres
processus biologiques. En particulier, les réseaux de gènes, déjà évoqués dans le cadre
d’une approche de biologique systémique, peuvent être modélisés par des PDMP. L’ex-
pression génique pourrait être intégrée dans un modèle de la dynamique de marqueurs
majeurs de la réponse immunitaire. Il pourrait alors être envisagé d’utiliser les méthodes
de contrôle pour optimiser l’expression de ces gènes. Cela permettrait de contrôler de
manière précoce la réponse vaccinale.
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Conclusion
Dans cette thèse, nous avons donc réalisé des travaux à la fois mathématiques, im-
munologiques et biostatistiques afin de comprendre, quantifier et optimiser la réponse
immunitaire à des interventions préventives et thérapeutiques contre des maladies infec-
tieuses. Cela montre que des outils méthodologiques complexes peuvent être utilisés pour
répondre à des questions cliniques concrètes et analyser des données longitudinales obte-
nues lors d’essais cliniques. Ces outils permettent la mise en place d’essais cliniques dits
in silico, qui consistent à utiliser des simulations computationnelles spécifiques à chacun
des patients étudiés, afin d’améliorer les développements cliniques. Ces essais pourraient
à terme réduire le nombre de sujets recrutés dans les essais cliniques ou bien même rem-
placer des études animales ou humaines. Concernant les essais vaccinaux, une approche
in silico pourraient également être proposée grâce aux outils de modélisation et d’optimi-
sation : après avoir développé et estimé un modèle mécaniste intégrant toutes les informa-
tions disponibles (génomiques, protéomiques, microbiome, facteurs environnementaux),
des pseudo-patients peuvent être simulés en utilisant les distributions des paramètres dans
la population d’étude. Ensuite, des méthodes d’optimisation peuvent être utilisées pour
déterminer, à titre individuel ou populationnel, quelle(s) serai(en)t la (les) meilleure(s)
stratégie(s) optimale(s) à tester dans un futur essai clinique. Des choix devront être effec-
tués dans la modélisation, notamment concernant la complexité du modèle au regard des
données disponibles, mais également la stochasticité qui ne peut être négligée lorsque la
dynamique de certaines acteurs, notamment à l’échelle génomique, est modélisée. Ces mé-
thodes pourront permettre d’adopter une approche de biologie systémique pour de futurs
développements vaccinaux.
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1 Introduction
Even though vaccines have contributed to a major improvement of global public health,
the development of effective immune interventions against infectious diseases such as Hu-
man Immunodeficiency Virus (HIV), Ebola or malaria is more difficult. These interven-
tions can be preventive – to avoid infection by the virus, or therapeutic – to help the
immune system to get rid of the virus. The development of vaccines remains a chal-
lenge not only because we need a better understanding of the mechanisms of protection
generated by immunological memory after vaccination, but also because clinical trials
assessing the safety, tolerability, immunogenicity and efficacy of vaccines are very long
and expensive. Moreover, recent developments in vaccines have been based on "prime-
boost" regimens, which combine several products in consecutive immunizations. This has
induced new questions regarding the design of clinical trials, in particular: how many
immunizations should be made ? In which order ? How long should we wait between
the immunizations ? The "systems biology" approach aims at addressing these questions
and understanding the whole operating mode of the immune system by integrating data
from several markers of the immune response. This is difficult, as the immune system
is composed of a large number of actors, connected by complex, non linear interactions.
Mathematic models and computational methods are major useful tools in this approach.
The work presented in this thesis aims to fit in this approach, with two particular
objectives: the first is to model the dynamic of the immune response following vaccine
immunizations. It helps quantifying the biological process, especially by estimating the
parameters associated to the model, based on data generated in human clinical trials.
Determining a suitable model could also help predicting the immune response of a newly
studied participant and to numerically compare several vaccine regimens. Defining a
model complex enough to capture the dynamics of the immune response, but also not too
complicated regarding the availability of the data for parameter estimation represents a
challenge in itself. The second objective of the work is to optimize the clinical protocol
for generating an efficient immune response. This is obtained by the development of a nu-
merical tool based on optimal control theory, to determine the best product combinations
that should be tested in a protocol of clinical interventions.
In practice, my work was separated into two main projects. The first is part of a
European project, funded by IMI (Innovative Medicines Initiative) and based on interna-
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tional collaborations with both private and academic partners. This project consists in
developing a mathematical model for the humoral immune response to an Ebola vaccine,
tested in humans in phase 1 to 3 clinical trials. The models allows not only to evaluate the
durability of the immune response, as measured by the persistence of antibody concentra-
tions, but also to determine some factors explaining the variability of the response across
the studied population. The model is mechanistic: it aims at translating the knowledge
about the biological process into mathematical equations. In particular, we worked on
a basic mechanistic model, based on a system of ordinary differential equations (ODEs).
The estimation of parameters relies on a population approach: each of the parameters
is assumed to admit a mean value in the population, and individual variation can be
observed around this value. This variability can also be explained thanks to environmen-
tal or vaccine-related factors. The parameters are estimated through a statistical method
based on likelihood maximization. The second project consists in developing optimization
tools for protocols based on consecutive injections. A first application of interest consists
in the optimization of immunotherapeutic interventions in HIV-infected patients. The
optimization of these injections (time and doses) is obtained by solving an optimal con-
trol problem. The method requires to model the process with another mathematical tool,
piecewise deterministic Markov models (PDMP), where the system follows a deterministic
trajectory and changes in the system can occur discretely after some random time periods.
These models have been widely studied and some recent theoretical results allow to solve
the optimal control by computing an iterative sequence based on an integro-differential
operator. All together, these projects aim at developing mathematical and computational
methods for the analysis of the dynamics of the immune system, in order to improve the
understanding of the mechanisms of action of the immune system and to propose opti-
mized and/or personalized immune interventions that should be tested in future clinical
trials.
The thesis is organized as follows: as the modeling work is based on immunological
knowledge, the first chapter aims at introducing the major notions of immunology, nec-
essary to understand the principle of vaccinations. We focus in particular on the interest
of prime-boost regimens. We also emphasize the different factors of variability influenc-
ing the immune response to vaccination. In this chapter, we also underline the role of
mathematical modeling for understanding the key mechanisms of the immune response,
quantifying the dynamics of the different actors and predicting the outcome of some in-
terventions on the immune system.
The second chapter is devoted to the first project of modeling the humoral response
to Ebola vaccine. We review in this chapter the latest clinical developments of Ebola
vaccines, which were accelerated by the recent large West Africa epidemic: this helps
28
INTRODUCTION
understanding the context of the generation of the data used for the estimation of the
model. We also remind the existing methods of modeling the humoral immune response,
to justify the choice of the model. Then, we present the model and its possible extensions.
In the third chapter, we develop the second project of optimizing the design of clinical
trials. The theory of optimal control is applied to a particular biological framework (IL-7
immune therapy), which results are reminded, to understand the context of the study
and the necessity for developing sophisticated methods of optimization. The theoretical
results previously obtained for controlling PDMP are presented and the numerical method
is applied on a number of pseudo-patients.
Finally, we conclude on how both modeling and optimizing approaches coul be com-
bined in a systems vaccinology approach relying on in silico trials.
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2 Immunological challenges
Abstract: In this chapter, we introduce some key notions in immunology. In particular,
we focus on the establishment and maintenance of the immunological memory, which is
crucial in vaccine development. We explain the principle of vaccination and the challenges
that still remain in developing efficient vaccines against infectious diseases. Finally, we
underline the role of mathematical modeling in understanding the mechanisms of the
immune response and quantifying the dynamics of the biological processes. These models,
coupled with optimization tools, could help improving the design of future clinical trials
and accelerate the clinical development of vaccines.
Key Words: Immunological memory; vaccine; clinical trial; prime-boost regimens;
factors of variability; mechanistic models; ordinary differential equations.
2.1 Generalities on the human immune system
2.1.1 Actors of the immune response
This introduction on the immune response is mostly adapted from the book of Abbas
et al. [2010]. The immune system is composed of cells and molecules able to detect and
react to different varieties of pathogens, inducing in this way immunity. Their organized
response to protect the organism against the pathogens constitutes the immune response.
The initial response is generated by the innate immunity, followed by the response of
adaptive immunity. The innate response is non-specific and provides a first quick re-
sponse against infection by microbes. In particular, it includes the physical and chemical
barriers through the action of the skin and the mucous membranes, the activity of phago-
cytes (neutrophils, macrophages) which ingest pathogens and of natural killer (NK) cells,
which trigger death of viral-infected cells through the release of some specific cell-secreted
proteins, called cytokines.
The adaptive immunity, for its part, adapts to the infection by developing better re-
sponse abilities, acquired with repeated exposures to the pathogen. It consists in the
recognition of the pathogen, the development of a specific response and the generation of
immune memory. It is mediated by the cell population of lymphocytes, produced from dif-
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ferentiation of stem cells into the bone marrow. The adaptive response is itself composed
of two types of responses: the humoral immunity and the cellular immunity. Humoral
immunity is generated by antibodies, circulating in the blood and mucosal secretions and
produced by the B lymphocytes. Antibodies are proteins with the shape of a Y, also
called immunoglobulins (Ig), with one constant region at their base and one variable re-
gion able to recognize the antigen. They are composed of two heavy chains and two light
chains. The heavy chains can be classified in 5 categories, determining 5 types of anti-
bodies: IgA, IgD, IgE, IgG and IgM. Antibodies can either be found on the membrane of
B lymphocytes and they act in this case as surface receptors for recognizing the antigen,
or they are secreted by plasma cells (coming from activated B cells) and in this case they
reside in the circulation, tissue and mucosal sites to eliminate the pathogen. Antibodies
act against the pathogens by different mechanisms. They can bind to the antigen and
promote its elimination by phagocytes. This way, they represent the first line of defense
against extracellular antigens. They can also block the binding of viruses to target cells
and neutralize in this way their infectivity.
Cellular immunity is achieved by the action of T lymphocytes. They are specifically
committed when the antigen is intracellular and proliferates inside host cells, such as
viruses: in that case, antibodies cannot access the antigen and T lymphocytes can en-
hance its elimination by killing infected cells. T lymphocytes can be divided into several
categories of cells with different functions. Helper T cells, expressing the CD4 glycoprotein
at their surface (also written CD4+ T cells), secrete cytokines inducing proliferation and
differentiation of the main actors of the immune response (T cells, B cells, macrophages),
and stimulating antibodies production by B cells. Cytotoxic T cells, expressing the CD8
glycoprotein at their surface (also written CD8+ T cells or CTLs), release cytokines able
to eliminate virally infected cells and tumor cells. Finally, regulatory T cells (written
Treg) are active in suppressing inflammatory responses and reducing the risk of auto-
immune diseases. NK cells, which are part of the innate response also constitute a class
of lymphocytes. The different categories of lymphocytes and their role in the immune
response are summarized in figure 2.1.
The functions of the lymphocytes are mainly mediated through the presence of cy-
tokines, which are proteins secreted by the cells playing a role in the immune response.
Cytokines impact on the differentiation of lymphocytes and their effector functions, as
well as on the hematopoiesis (formation and development of blood cells). Some are also
called interleukins (IL), as they are produced by leukocytes (macrophages or T lympho-
cytes) and act on other leukocytes, with a standard nomenclature written with a number
(IL-1, IL-2, ..). We do not intend here to review the role of all cytokines, but we will
focus on some cytokines of interest, which will be useful for the work done in this thesis:
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Figure 2.1 – Classes of lymphocytes. Taken from Abbas AK, Lichtman AJ, Pillai S,
Cellular and Molecular Immunology, edition 11, Copyright Elsevier 2011.
— Interleukin-2 (IL-2): IL-2 plays a major role in the adaptive immune response.
In particular, it is mainly produced by CD4+ T lymphocytes and enhances the
survival, proliferation and differentiation of activated T lymphocytes. It also has
an impact on the proliferation of B cells and stimulates the production of anti-
bodies. Moreover, IL-2 also has a role in the innate response, by stimulating the
proliferation and differentiation of NK cells and Tregs.
— Interferon γ (IFN-γ): IFN-γ is produced by both NK cells and T lymphocytes
and has functions in both innate and adaptive immunity. First, IFN-γ enhances
phagocytose by macrophages. It also stimulates the differentiation of naive CD4+
T cells and the recognition of antigens by T lymphocytes. Finally, it has an action
on B cells and promotes the antibody response.
— Tumor Necrosis Factor (TNFα): TNFα is a cytokine of the innate immunity,
mainly produced by phagocytes, but can also be produced by T lymphocytes and
NK cells. Its main role is to improve the recruitment and the activation of neu-
trophils and monocytes (precursors of macrophages) to eliminate the pathogen at
the site of infection. It can also induce the programmed death of some cell types.
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— Interleukin-7 (IL-7): IL-7 is a cytokine produced by stromal cells in the bone mar-
row and the thymus. It stimulates the early development of B and T lymphocytes
(before any immune response occurs) and is necessary for the survival of mature
cells, including CD4+ naive and memory T cells [Seddon et al., 2003] and CD8+
naive T cells.
2.1.2 Phases of the adaptive immune response
Adaptive immune response is characterized by several phases: recognition of the anti-
gen, activation of lymphocytes, elimination of the pathogen, before a return to baseline
state and maintenance of the generated memory. This phases are represented in figure
2.2.
Figure 2.2 – Phases of the adaptive immune response. Taken from Abbas AK, Lichtman
AJ, Pillai S, Cellular and Molecular Immunology, 3rd edition, Copyright
Elsevier 2008.
The adaptive immune response is initiated by antigen recognition. T lymphocytes can
only recognize peptide antigens expressed on the cell surface and encoded by genes in a
particular locus defined as the major histocompatibility complex (MHC), but not soluble
antigens. The MHC molecules are recognized by a receptor on the T cell surface called the
T cell receptor (TCR). T cells expressing the same TCR correspond to a same clone of T
cells. The possibility to recognize antigen is ensured by the large diversity of clones within
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a given individual, each clone corresponding to a distinct antigen. To enable recognition
by T cells, antigens should be captured and presented to their corresponding specific
lymphocytes. This role is played by antigen-presenting cells, in particular by dendritic
cells (DCs), able to transport the antigen to lymphoid organs and present it to naive T
lymphocytes to trigger the immune response. In particular, DCs express at their surface
class II molecules of the MHC, which are recognized by CD4+ T cells. On the other side,
CD8+ T cells are able to recognize class I molecules of the MHC, expressed by any cells.
Therefore, CD8+ T cells can target any virus-infected cell for elimination. Naive B cells
are situated in peripheral lymphoid tissues and can be activated when the antigen for
which they are specific bind to their membrane receptor. Naive B cells express first the
IgM and IgD antigen receptors, but can produce other antibodies after being activated
by a pathogen, such as IgA, IgE and most particularly IgG. This process is called isotype
switching. A selection of the B cells producing antibodies with higher affinity to the
antigen is made before expansion of these cells. Most of the time, the activation of B cells
and antibody production is dependent on the CD4+ T cell response [Crotty, 2015].
Antigen recognition by the lymphocytes induces a phase of activation, during which
lymphocytes undergo a large clonal expansion due to proliferation of the activated cells.
For the T lymphocytes, differentiation into effector and memory cells occurs simultane-
ously. These T cells can either stay in the lymphoid organs or migrate to non-lymphoid
tissues. For the humoral response, B cells can differentiate into antibody-secreting plasma
cells or into memory cells. Most of the affinity maturation and memory generation happen
through B-T cells interaction in germinal centers, a region in the lymphoid follicles. Anti-
bodies can enter the circulation, while plasma cells migrate from the peripheral lymphoid
organs to the bone marrow. Both B and T effector cells can act quickly to eliminate the
pathogen during the effector phase, while memory cells will remain in the organism, ready
to respond at the next encounter with the pathogen.
Most of the effector lymphocytes are short-lived and die by apoptosis at the end of
the immune response (after elimination of the pathogen). Apoptosis is a programmed
cell death, induced by different pathways. In the case of an immune response, it is due
to the fact that the survival of lymphocytes can depend on the presence of antigen and
also because the organism is auto-regulated and limits its own number of specific cells by
homeostasis process.
A small proportion of the activated lymphocytes with memory phenotype survive
after the end of the immune response and sustain in the organism. These cells are able to
respond quicker and more intensely in case of re exposure to the pathogen, as explained
in the following section.
Lymphocytes can be classified in different subsets depending on their phenotypes
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(such as effector and memory phenotypes). These phenotypes are defined by specific
combinations of markers. Markers are molecules expressed at the surface of the cells. For
example, as previously defined, T helper cells express the CD4 marker on their surface
and are then written CD4+ T cells. New technologies such as flow cytometry and more
recently mass cytometry allow the identification of the co-expression of a large number
of markers at the surface of the cells, and the level of expression can also be measured.
Combination of markers help defining a number of cell subtypes (e.g., central and effector
within the memory cells), but will not be detailed in this thesis. We can although mention
the Ki67 marker, which is used for detecting the proliferation of cells. We will consider
in this thesis that cells expressing Ki67 are in a proliferating state.
2.1.3 Immunological memory and secondary responses
After primary exposure to a pathogen, the organism acquires the ability to generate
a better response in case of a secondary exposure: it is called immunological memory
[Ahmed and Gray, 1996]. Several definitions can be given to immunological memory
[Farber et al., 2016], but most of them agree to say that this antigen-specific response
occurs faster and is quantitatively and qualitatively better at eliminating the pathogen
compared to the primary response. This is due to two main reasons. First, the number
of antigen-specific lymphocytes increases at each encounter with the pathogen, and then
more cells can recognize the pathogen and expand. Moreover, as mentioned in section
2.1.2, the immune response generates a number of memory cells which have different
characteristics than naive ones, including more efficiency in eliminating the pathogen. As
an example, after a first encounter, B cells can produce antibodies with better affinity and
binding properties than antibodies produced by naive B cells activated during a primary
response. Thus, the antibody level increases after repeated immunization, as well as the
affinity of these antibodies, as shown in figure 2.3. For T lymphocytes, although there are
differences in the differentiation and memory generation of CD4+ and CD8+ lymphocytes
[Seder and Ahmed, 2003], both memory populations show an increased sensitivity to the
antigen and require less stimulation pathways for activation than naive cells. It should be
noted here that there is still poor understanding of human memory T cells, whether it be
the diversity of the memory T cell subsets, the mechanisms involved in the maintenance
of the memory, their migration in the organism or their reactivation, and there is a large
literature on these questions [van Leeuwen et al., 2009; MacLeod et al., 2010; Martin and
Badovinac, 2014; Fraser et al., 2013]. Similarly, the relative roles of long-lived plasma
cells and memory B cells after re-encounter of a pathogen are not completely clear and
more studies should be realized to address these questions [Pape et al., 2011; Nutt et al.,
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Figure 2.3 – Evolution of the number of antibodies and their affinity through repeated
immunizations. Antigen-specific IgGs have more affinity than IgM to the
pathogen. Taken from Janeway et al..
2015; Taylor et al., 2012]. However, it is beyond the scope of this work to develop these
points in details. We will focus on vaccine development, as the principle of vaccination
relies on immunological memory.
2.2 Vaccine development
2.2.1 Principle of vaccination
The development of vaccines has been empirical, following Edward Jenner’s discovery
at the end of the 18th century: he observed that humans infected by an animal poxvirus
underwent an attenuated disease and could be protected against smallpox [Plotkin, 2014].
This led to the eradication of smallpox by 1980 and the development of a large number of
successful vaccines: polio is almost completely eliminated, and the incidence of diphteria,
tetanus, pertussis has been reduced by more than 95% in the last decades [Rappuoli
et al., 2011]. Globally, 2-3 millions of deaths are currently prevented every year thanks
to immunization against diphteria, tetanus, pertussis and measles [WHO, 2018d]. For
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example, measles vaccination is estimated to having helped reducing the number of deaths
by 20.4 millions between 2000 and 2016 [WHO, 2018e]. In the specific case of Human
Papillomavirus (HPV), an elimination sounds possible [Brisson et al., 2016] with the
vaccine as reported especially in Australia [Patel et al., 2018].
The basis of vaccination relies on the immunological memory: the immune system
is able to generate a better response to a pathogen after a primary exposure, inducing
protection and preventing the recipient from infection by the pathogen. Exposure to
an attenuated virus can therefore develop an immunological memory to the pathogen
without putting the recipient at risk of developing the disease. This approach has been
very successful for some viruses but revealed insufficient and unsafe for other pathogens
for which there is no natural recovery after infection, with high levels of mutations, or
for which the antibody response is not sufficient to protect against the disease [Germain,
2010]. New technologies have allowed developing new vaccine platforms, such as DNA
vaccines, virus-like particles, viral subunits, fusion proteins and peptids, or viral vector-
based vaccines; they rely on the same initial idea of vaccination and aim at presenting
one particular part of the antigen to the immune system to generate a strong and long-
lived immunological memory able to protect against infection in case of encounter with
the real antigen. In particular, viral-based vaccines are gene-depleted viruses in which are
inserted genes of the targeted virus. These vaccines are effective as they can generate high
immunogenicity through both humoral and cellular responses [Ura et al., 2014]. For safety
purpose, non replicative and low pathogenic viruses are usually selected. However, their
efficacy can be limited by the pre-existing immunity to the vector: previous exposures can
have induced the development of neutralizing antibodies specific to the viral vector [Mast
et al., 2010; Priddy et al., 2008]. In particular, the class of adenoviruses (Ad) is widely
evaluated in clinical trials [Hammer et al., 2013; Gurwith et al., 2013]; there exists a large
number of human serotypes causing, among others, cold and sore throats. Vaccinia virus
is also generally used: it is a member of the poxvirus family, used in the smallpox vaccine.
More specifically, modified vaccinia Ankara (MVA), an attenuated strain of this virus,
has been evaluated in several clinical trials for vaccines against several diseases, e.g. HIV
[Gómez et al., 2011] and malaria [Bejon et al., 2007].
2.2.2 Challenges in vaccine development for infectious diseases
Even though vaccines have allowed major progresses in reducing the incidence of some
diseases worldwide, we are still lacking effective vaccine against some infectious diseases
such as HIV, malaria and Ebola virus disease. This represents a major public health
challenge. The current difficulties to develop effective vaccines against these infectious
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diseases is due to our lack of deep knowledge in immunology and the mechanisms of
action of immune memory [Hagan et al., 2015; Pulendran and Ahmed, 2011; Germain,
2010]. We will develop in this section some specific difficulties faced by researchers in the
development of effective vaccines.
2.2.2.1 Clinical development
The development of vaccine is a long and expensive process. As every other drug, it
needs to be tested in several phases before approval process by the health authorities,
such as the Food and Drug Administration (FDA) in the USA or the European Medicines
Agency (EMA) in Europe. Before evaluating the vaccine in human studies, it is first
tested on animals in preclinical studies, such as mice or non-human primates (NHP).
Clinical development undergoes a process in three phases. Phase 1 clinical trials recruit
a small number of subjects (less than one hundred), usually healthy, to assess the safety
and tolerability of the vaccine. These trials can also be dose-escalating, where increasing
doses are tested until finding a dose inducing an acceptable level of the immune response
while limiting the amount of adverse events. Phase 2 trials are realized on more sub-
jects (100-300), representative of the vaccine target population, and aim at evaluating
the immunogenicity of the vaccine, while still monitoring its safety. They can last several
months to years. Phase 2 trials are sometimes divided in phase 2a and 2b trials, where
phase 2b trials are specifically designed to evaluate the efficacy of the vaccine. Phase 3
trials aim at evaluating the effectiveness of the vaccine intervention. For that, a large
number of subjects are recruited (300 to thousands) and are randomized in a placebo arm
(or other reference if another vaccine already exists) and a vaccine recipient arm. For
a prophylactic vaccine, effectiveness corresponds to the ability to prevent from infection
when at risk. Finally, after the vaccine has been licensed and is made available, it under-
goes a so-called phase 4, corresponding to the long-term surveillance of the product. So
far, only a few HIV vaccine candidates have been evaluated in efficacy trials [Stephenson
et al., 2016], but encouraging results were recently obtained from a phase 1/2 clinical
trial [Bekker et al., 2018] and initiated a phase 2b/3 efficacy trial to assess the capacity
of the vaccine to confer protection against HIV infection in South Africa [Barouch, 2018].
The beneficial effect of some vaccine, such as HIV or Ebola vaccine are very difficult to
assess in phase 3 trials: indeed, due to its mode of transmission and the preventive actions
taken in parallel to vaccine studies, it is difficult to assess the real amount of protection
induced by an HIV vaccine candidate. For Ebola, it would be necessary to observe the
potential protection induced during an epidemic, during which vaccine transmission is
active. These diseases require then the use of surrogates of protection, which can be used
to replace the disease incidence criterion. Although some surrogates of protection exist
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for other diseases, as reviewed in Plotkin [2010], it is not yet the case for HIV and Ebola.
This will be developed in more details for Ebola in section 3.1.2.2. This issue constitutes
a real challenge in developing and evaluating new vaccines.
2.2.2.2 Prime-boost regimens
In the last few years, there has been some growing interest in the so-called "prime-
boost" regimens for developing new vaccines [Ramshaw and Ramsay, 2000]. These regi-
mens combine several products in distinct, consecutive immunizations. They can either
be homogeneous, by using the same product, or heterogeneous when different products are
injected. They are expected to produce a better immune response, both quantitatively
and qualitatively. The only clinical trial that showed moderate classical efficacy (31.2
% with confidence interval 1.1-52.1) of a vaccine against HIV infection was based on a
prime-boost regimen, consisting of four priming immunizations of a first vaccine followed
by two booster immunizations of another type of vaccine [Rerks-Ngarm et al., 2009]. Fol-
lowing this study, there has been a wide range of clinical trials evaluating prime-boost
regimens for HIV or Ebola vaccines [Baden et al., 2016; De Rosa et al., 2011; Tapia et al.,
2016; Milligan et al., 2016]. However, these regimens raise a number of questions that
are still to be answered by improving our immunological knowledge [Sallusto et al., 2010].
In particular, we have not yet determined how many immunizations are necessary, and
how the order of administration has an impact on the immune response, in the case of
heterogeneous regimens. Moreover, the interval of time that should be considered between
immunizations is still an open question of research. There is some consensus on the fact
that boosting the immune response too early is sub-optimal [Sallusto et al., 2010], as some
time is needed for the cells to acquire a memory phenotype [Wherry and Ahmed, 2004],
and the cells of the immune system have a limited capacity of expansion and could be
exhausted with intense stimulation [Pollard et al., 2009]; waiting too long before the next
immunization can also be sub-optimal as the immunity wanes with time as the number of
immune cells decreases. Determining the optimal window of time for booster immuniza-
tions can also depend on other factors, such as the type of vaccine, the strength of the
primary immunization or the baseline state of the immune system [Wherry and Ahmed,
2004]. It represents then a real challenge in the development of new efficient vaccines.
2.2.2.3 Variability of the immune response
The variability of the immune response at both individual and population levels has
been observed in several vaccination studies. It can be induced by a large number of
factors, including genetic factors, demographic factors, environmental factors and micro-
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biome. These factors were widely covered in Van Loveren et al. [2001] and Pulendran
[2014], and their effect in the case of HIV vaccine was reviewed in de Bruyn [2010]. This
section does not intend to establish a review of all factors impacting the immune response,
but rather to give some insights on previously conducted studies and the difficulty to as-
sess the relative and causal effect of all these factors. The influence of genetic factors was
described in particular in studies on identical twins: they have shown that the heritability
for antibody response to several vaccines was at least of 40% [Lee et al., 2006; Newport
et al., 2004]. A summary of the studies correlating genomic and transcriptomics varia-
tions to the immune response can be found in O’Connor and Pollard [2013]. In term of
demographic factors, sex has been regularly shown to induce different immune response to
both infectious diseases and vaccines. In a review on human vaccines, Cook [2008] shows
that a large number of studies have found differences in antibody response between men
and women, associated to a difference in the clinical efficacy in some vaccines - against in-
fluenza, hepatitis A virus (HAV), hepatitis B virus (HBV), pneumococcal polysaccharide,
diphteria and to a difference of adverse effects - for rubella, measles and yellow fever vac-
cines. The difference was not consistent among all vaccines, meaning that in some cases
female had greater antibody concentrations than male and it was the other way around
in other cases. These observed differences could be due to genetic factors (genes from
the X chromosome), hormones levels or anatomic differences [Fish, 2008]. In addition
to sex, age is also known to be associated with vaccine efficacy, especially for influenza
vaccine [Seidman et al., 2012; Nakaya et al., 2015] and dengue vaccine, where efficacy was
observed to increase with age [Capeding et al., 2014], especially against severe disease.
This variation could however be partly explained by increased prevalence of baseline im-
munity with age [Dans et al., 2018; Sridhar et al., 2018]. Moreover, higher variations in
the immune response seem to be observed in aging populations [Shen-Orr and Furman,
2013]. The effect of nutrition was also studied as a potential factor impacting on the
immune response [Savy et al., 2009], and oral polio vaccine was shown to be less effective
in infants with malnutrition [Haque et al., 2014]. Of interest is also the observed differ-
ence of immune response between different populations (due to geographic settings and/or
ethnicity). A study of demographic factors influencing the immune response to an HIV
vaccine candidate showed that African Americans secreted more neutralizing antibodies
after vaccination compared to White Americans, suggesting that ethnicity itself could
affect the immune response to some immunogens [Montefiori et al., 2004]. In this study,
the effects of age and sex on the immune response were not found significant. In other
studies comparing African subjects to Western countries subjects, the immune response
was mostly found lower in Africa. A study assessing the immunogenicity of Ad-based
strategies for prophylactic HIV vaccine showed that T cell responses were lower in East
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Africa compared to South Africa and the United States, although no difference in anti-
body concentrations was observed [Baden et al., 2016]. An interesting study on yellow
fever vaccine showed the induced CD8+ T cell and B cell responses were lower in subjects
recruited in Uganda compared to subjects in Switzerland [Muyanja et al., 2014]. Prior to
vaccination, the immune environment was more activated in African subjects, as shown by
higher frequencies of differentiated T and B cell subsets and proinflammatory monocytes,
as well as exhausted and activated NK cells. This immune activation at baseline was
negatively correlated with yellow fever specific neutralizing antibody concentrations after
vaccination. Altogether these results showed that the state of the immune environment
before vaccination was different between African and European subjects and could impair
the efficacy of the vaccine. Some studies showed the efficacy of Bacille Calmette-Guérin
vaccination was lower in African infants compared to European ones [Black et al., 2002;
Lalor et al., 2009]. This difference was actually explained by pre-existing immunity, as
the percentage of subjects with IFNγ response at baseline (before vaccination) was higher
in Malawi than in the UK and the fold-increase of IFNγ response after vaccination was
higher in the UK compared to Malawi. Vector-based approaches for developing vaccines
are also affected by this point, as pre-existing immunity to the vector can also have in-
fluence on the outcome of the vaccination. It was especially shown in the Step trial,
which was interrupted after an increased rate of HIV infection was observed in vaccinated
subjects who were seropositive for Ad5 at baseline compared to placebo recipients [Buch-
binder et al., 2008]. Other factors such as co-existing infections are also considered as
factors influencing the immune response to vaccination, in particular with infectious dis-
eases (HIV, HBV, cytomegalovirus [Nielsen et al., 2015]) or parasites [Da’dara and Harn,
2010]. In addition to all these factors, the microbiome has been recently suggested to
affect the response to some vaccines [Ferreira et al., 2010], possibly due to cross-reaction
between some microbiota peptides and agents of the immune system. In particular, the
impact of microbiome on vaccine response was studied on HIV vaccine [Williams et al.,
2018] and oral rotavirus vaccines [Magwira and Taylor, 2018]. The effect of gut/intesti-
nal microbiome could also reflect the effect of nutrition on the vaccine response. It also
suggests the interest of assessing the effect of prebiotics, probiotics and antibiotics on the
immunogenicity of vaccines: some studies have shown that probiotics could increase the
immunogenicity of polio vaccination [de Vrese et al., 2005] and oral rotavirus vaccination
[Isolauri et al., 1995]. However, in a study on Indian infants, an antibiotic therapy modi-
fied the intestinal environment without improving the immunogenicity of oral poliovirus
vaccine [Grassly et al., 2016]. Finally, all these factors (genetic, environmental, micro-
biome) are not independent from each other and the way they affect the immune response
still remains a key question in vaccinology.
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2.3 The role of mathematical modeling
Mathematical modeling of the dynamics of the immune system is part of the effort
of systems biology, mentioned in the introduction, to understand more deeply the whole
process of immunity and the mechanisms establishing the immune memory. The necessity
for using mathematical tools comes from both the limitation in immunological knowledge
and the availability of more and more immune data that should be precisely analyzed to
improve our understanding of the immune system. Modeling offers the opportunity to
integrate the information of several datasets. Moreover, biological interactions are usually
very complex and lead to non-linear behaviors of the systems: it can be due to feedbacks
processes or amplification of effects due to high proliferation [Germain, 2001]. It can make
it difficult to experimentally predict the reaction of the immune system to stimulations.
Models can help understanding the underlying mechanisms of the biological process and
generating new hypotheses. More than that, the value of the models reside in their ability
to quantify the dynamics of biological process [Germain, 2017] and the factors impacting
on these dynamics, but also the variability of dynamics within a given population. Finally,
well calibrated and estimated models can be useful for predicting the outcome of interest
using observed factors.
There exist different types of models, but we can mainly distinguish descriptive from
mechanistic models. Descriptive models are data-driven and aim at best fitting the data
and trying to explain an outcome (such as a biological marker) from other factors. They
are mainly composed of statistical models, such as, for example, linear or non linear mixed
models when the data is constituted of repeated measurements. On the other hand, mech-
anistic models are based on biological knowledge and aim at describing the mechanisms
of action of a process: the initial knowledge of how the process evolves is translated into
mathematical equations which can then be applied and compared to experimental results
[Vodovotz et al., 2017]. These models can better account for the complex nonlinear re-
lationships between biological components than descriptive models. We will focus here
on mechanistic models composed of systems of ODEs, as it will be the main tool in this
thesis. However, other tools can be used such as agent-based models, where each agent
is an individual model entity and evolves in a complex system by interacting with other
agents and following established rules [Bonabeau, 2002]. This type of models is relevant
when studying spatial and local interactions between cells and they were for example de-
veloped for antigen recognition and activation of lymphocytes [Seiden and Celada, 1992],
interactions between innate and adaptive responses [Folcik et al., 2007] or in multi-scale
models of the cellular immune response [Prokopiou et al., 2014]. However, it presents some
limitations, as the outcome is usually only a computational simulation of the evolution
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of the system and it is difficult to obtain a mechanistic interpretation of the dynamics of
the system.
Rather than considering individual agents, systems of ODEs model population sizes
and concentrations. They constitute a widely-used, flexible tool for modeling the dynam-
ics of the immune system and their utility in immunology have been reviewed in several
papers [Yates et al., 2001; Callard and Yates, 2005; Castro et al., 2016]. One of the main
challenges when modeling the immune system is to find a good balance between the com-
plexity of the model, the scientific question and the availability of the information/data.
For example, there are quite a number of studies aiming at modeling the whole immune
system using systems of ODEs. These models account for the dynamics of a large number
of actors of the immune system and include the spatial dimensions [Lee et al., 2009; Kim
et al., 2007]. However this leads to systems with many equations and parameters, and
we do believe that the complexity of these models is too high compared to the amount
of data available to correctly estimate, or at least calibrate the model. Smaller systems
of ODEs have been successfully used for modeling the dynamics of infectious diseases. In
particular, HIV infection has been substantially studied [Perelson et al., 1993; Perelson,
2002; Perelson and Ribeiro, 2013] which allowed, among others, better understanding of
the CD4-HIV interactions, quantification of rates of HIV production, prediction of the
effect on some antiretroviral treatments and offered more recently the possibility to indi-
vidualize the treatment strategies [Prague et al., 2013b]. This subject is however beyond
the scope of the thesis.
Regarding the establishment of the immune memory, ODE models have been useful
for quantifying the generation of immune cells and determining the pathway of differenti-
ations leading to different subset of immune cells. In particular, a model of the CD8+ T
cells dynamics following infection by lymphocytic choriomeningitis virus in mice was first
developed in de Boer et al. [2001] and allowed quantifying the magnitude of the response
to different epitopes of the virus. It consisted in antigen-specific naive cells becoming ac-
tivated cells after encounter with pathogen, a proportion of them able to differentiate into
memory cells after some given time. This model was then used in several studies [de Boer
et al., 2003; Kohler, 2007; Graw et al., 2012] and helped predicting the generation of
memory cells. This model was also extended in Antia et al. [2003] and Antia et al. [2005]
to determine the pathway of differentiation from naive to memory cells, by comparing
two models (one where proliferating effector cells differentiate into memory cells and one
where proliferating memory cells differentiate into effectors) and trying to fit mice data
with both models. This allowed to identify a preferential pathway of differentiation, as
the other model was not able to fit the data within biologically reasonable ranges of pa-
rameters values. Pathways of differentiation were also studied in Crauste et al. [2017], by
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considering more subsets of effector and memory cells, defined by combinations of mark-
ers. This model allowed predictions of the quantity of memory cells generated during the
immune response using early measurements during the effector phase.
Mechanistic models have proved valuables in both understanding the mechanisms of
the immune response and predicting the quantity of memory response generated after
infection. However, there is less literature on mechanistic models for the response to
vaccine immunizations and the study of the interval between prime-boost immunizations.
Some papers studied the immune response to yellow fever and vaccinia virus vaccination
in humans [Le et al., 2015], and hepatitis A vaccination [Andraud et al., 2012]. They will
be described in more details in section 3.1.3. For the study of the interval between prime-
boost immunizations, we can mention the work of Castiglione et al. [2012], where authors
developed an agent-based model for the dynamics of innate and adaptive immunity dur-
ing the different phases of antigen recognition and response to pathogen, accounting for
affinity between the different actors of the immune response. The model was calibrated on
real data and allowed identification of an optimal time window for a boost immunization.
A combined agent-based and ODE-based model accounting for the spatial aspects of the
immune response, with actors in the lymph nodes and the blood, was also developed by
Gong et al. [2014] and allowed the simulation of the response to a boost immunization.
Both models gave insights into the determination of optimal schedule of secondary immu-
nization, but were lacking a clinical application, due to the fact that the model was not
estimated on real data. More generally, there is some literature on determining optimal
schedules of repeated injections in other applications than vaccine, as will be developed
in section 4.2.1.1, and these type of methods could be applied in other frameworks, such
as optimization of vaccine regimens. Control theory applied to immunology should help
designing future immune interventions for preventing and curing infectious diseases.
This justifies our approach in this thesis, of first developing a model of the immune
response to an Ebola vaccine and estimating its parameters on data from clinical trials,
and then applying the theory of optimal control to establish a tool for the optimization
of repeated injections, applied in particular to the HIV framework. Both aspects of this
work are developed in the following chapters.
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3 Modeling the immune response to Ebola
vaccine
Abstract: In this chapter, we show how Ebola vaccine development has accelerated
in the past few years. In particular, prime-boost strategies combining Ad26 and MVA
platforms have been tested in phase 1 to 3 clinical trials in Europe, Africa and the USA.
We present a model for the dynamics of the humoral response following the boost immu-
nization, in order to quantify the contribution of two populations of ASC (differing by
their half-life) and estimate the factors impacting the immune response. The parameters
are estimated using binding antibody concentrations data from 177 subjects in Europe
and East Africa, with a population approach accounting for the effect of covariates and
unexplained inter-individual variability. In particular, the different vaccine regimens seem
to affect only the peak of the antibody response, but the geographical location has an
impact on the dynamics of the long-lived ASCs: it induces a persistence of antibodies
at higher levels in European subjects compared to East African ones. This could have
an impact in the implementation of future clinical vaccination strategies. Models of the
immune response could be improved by integrating more data and compartments.
Key Words: Ebola virus disease; vaccine; EBOVAC consortium; humoral response;
antibodies; antibody-secreting cells; mechanistic model; ordinary differential equations;
population approach; linear mixed models; parameters estimation; likelihood maximiza-
tion; factors of variability.
3.1 Biological and clinical context
3.1.1 General introduction on Ebola
3.1.1.1 Ebola virus disease
Ebola virus disease (EVD) is a pathology that has repeatedly caused deadly epidemics
of hemorrhagic fever in African countries [Peters and Peters, 1999] since its discovery in
1976 in the Democractic Republic of Congo (DRC) and Sudan [Johnson et al., 1977]. EVD
is due to Ebola virus (EBOV), a filovirus of the genus Ebolavirus. Filoviruses also include
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of infected animals found in the rainforest or during hunt-related activities. Human-to-
human transmission of EBOV occurs via direct contact with body fluids of infected people
and surfaces and/or materials contaminated with these fluids. High risk of transmission
are also induced by burial rituals involving direct contact with the body of the deceased.
This close-contact mode of transmission explains why relatives and health-care workers
are frequently infected [WHO, 2018a]. Sexual transmission from survival patients could
induce EBOV infections even after West African countries are declared Ebola-free [Butler,
2015]. Studies have shown viable Ebola virus can persist in semen for months and there
is a risk of sexual transmission [Thorson et al., 2016]. Additional surveillance data and
research are necessary to better assess this risk.
EBOV penetrates the body through lymphatic and blood vessels by direct contact with
broken skin of mucous membrane. The main target cells of the virus are the dendritic
cells and macrophages. These cells circulate in the body and allow the virus to spread
in the body. It induces a systemic inflammatory response syndrome and multiple tissue
damages, especially in the liver.
The incubation period can last up to 21 days. The first symptoms are not specific and
include headache, fatigue and muscle pain. It is usually followed by vomiting, diarrhea,
symptoms of impaired kidney and liver function and in some cases, internal and external
bleeding (especially from the digestive system). Laboratory tests are necessary to confirm
diagnosis [Liu et al., 2015].
EVD is often fatal in humans, with a case fatality rate around 50%, varying from 25%
to 90 % in previous outbreaks. Filoviruses have been classified as Category A potential
bioterrorism agents by the Centers for Disease Control and Prevention [CDC, 2018], which
corresponds to the highest risk pathogens for public health.
3.1.1.2 West Africa epidemic
The recent outbreak that occured in 2014-2016 in West Africa caused 28 616 cases
and 11 310 fatalities [WHO, 2016b]. The epidemic was due to an outlier strain (Makona)
of ZEBOV, sharing a common ancestor with the known DRC and Gabon strains, but in
a different clade [Baize et al., 2014]. It started in Gueckedou rainforest region, on the
east of Guinea, in December 2013, closely followed by infections in Macenta region. A
first press release was issued by the World Health Organization on March 23, 2014. Cases
then spread to Sierra Leone and Liberia, which are bordering countries of Guinea. These
3 countries were the most affected by the epidemic, but some travel-related cases were
reported in other African countries (Mali, Nigeria, Senegal), Europe (UK, Italie, Spain)
and the USA. The Public Health Emergency of International Concern was started by
WHO on August 8, 2014 and terminated on March 29, 2016. The unprecedented scale
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of the epidemic was not found to come from higher rates of infection and transmissibility
than already observed [WHO Ebola Response Team, 2014]. The infection was easily
spread due to the large number of connections between Guinea, Liberia and Sierra Leone
populations in the border area, with high traffic between rural and urban areas. Moreover,
control measures were not set quickly enough to contain the epidemic.
An additional outbreak started in the western part of DRC on April 4, 2018. This
outbreak was declared by the Ministry of Health on May 8, 2018. A total of 54 cases were
reported, including 33 fatalities. The last laboratory confirmed EVD case was found on
June 2, 2018 and the end of the outbreak was declared on July 24, 2018 [WHO, 2018b].
However, another (unrelated) outbreak in the eastern part of the country was reported
to WHO by the Ministry of Health on August 1, 2018. As of August 20, 2018, a total of
102 cases were reported, including 59 deaths [WHO, 2018c]. Both outbreaks were caused
by the ZEBOV species.
3.1.1.3 Prevention measures and therapeutic developments
There is no licensed therapeutic treatment for EVD at the moment, and most of the
patient care constitutes of rehydration with oral or intravenous fluids, and treatment of
his/her specific symptoms. To limit outbreaks, prevention and control measures should
be implemented. They mainly concern the reduction of the risk of human-to-human
transmission in households and health-care facilities, but also the reduction of wildlife-
to-human transmission and of the risk of sexual transmission [WHO, 2018a]. Isolation
of patients with suspected or confirmed EVD is necessary to allow them access to care
and prevent them from transmitting the disease. Persons who have been in contact with
an infected patient should be monitored for 21 days to detect a possible infection. As
burial traditions induce high transmission risks, precautions should be taken with dead
bodies and communicated to the community. The population should be informed of
simple hygiene measures, such as hand hygiene. It is also necessary to train all health-
care workers to use personal protective equipment [WHO, 2016a]. However, in the case
of large-scale epidemics, it can be problematic to establish rapidly and effectively these
control and prevention measures.
Having developed preventive vaccines or efficient treatments before the next epidemic
could help preventing a similar large-scale epidemic by reducing both transmission rate
and fatality rate of the virus. In this section, we will only speak of the therapeutic
treatments. Several products are currently being evaluated, but no antiviral drug could
demonstrate a significant effect on the survival rate in humans. Most of the products have
been tested in animals during the past years (mice or NHP), but not in humans. The
West Africa outbreak accelerated the evaluation of some candidate products, which have
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been undergoing phase 1 to 3 trials since then [WHO, 2015]. However, these products
have experienced low enrollments of patients (due to late initiation during outbreaks),
making it difficult to assess their efficacy with enough statistical power and to validate
their effect on different populations. The treatment candidates can be divided in two
categories [Liu et al., 2017]: small molecule inhibitors (including the antiviral molecule
Favipiravir and the small inhibitory RNA TKM-100802) and immune-based therapeu-
tics (including interferons, convalescent plasma, combination of monoclonal antibodies
ZMapp). In particular, the antiviral Favipiravir has shown activity against EBOV in
mice and tolerance in phase 1 clinical trials on healthy humans and phase 2/3 clinical
trials on humans infected with influenza. A clinical efficacy trial was started in Guinea
in December 2014 and enrolled 126 patients but showed no efficacy in reducing mortality
of patients infected with EVD [Sissoko et al., 2016]. Recent encouraging results from a
macaque study suggest the drug efficacy could be improved at higher doses [Guedj et al.,
2018]. The combination of monoclonal antibodies ZMapp showed 100% survival in NHP
when administered 5 days after virus challenge and safety was evaluated in phase 1 clinical
trials. A randomized controlled efficacy study was run in 2015 in Liberia, Sierra Leone
and Guinea but showed no efficacy on survival in infected humans [PREVAIL II Writing
Group, 2016]. The TKM-100802 inhibitory RNA treatment showed some limited efficacy
in NHP and some related side effects were found in phase 1 trials. It was tested in a single
arm phase 2 clinical trial in Sierra Leone, showing no efficacy [Dunning et al., 2016b]. The
Brincidofovir, a small antiviral molecule, was also tested with no efficacy on 4 patients in
2015 [Dunning et al., 2016a] but trial was incomplete and the product was withdrawn by
the company. Overall, treatments against EVD have not yet showed convincing results of
efficacy in reducing mortality in infected patients, but some are still under investigation
and development.
3.1.2 Ebola vaccine development
3.1.2.1 Clinical state of the art
Similar to therapeutic development, Ebola vaccine research has been accelerated fol-
lowing the West Africa outbreak. A large number of platforms have been considered as
vaccine candidates against EVD. All contain a viral component of EBOV, usually the GP
and/or NP of the virus, coming from potential different species and strains. Reviews of
Ebola vaccine development can be found in Venkatraman et al. [2018], Keshwara et al.
[2017], Lambe et al. [2017] and Wang et al. [2017]. We also realized a review and a meta-
analysis in the team [Gross et al., 2018]; details will be given in the following section.
In addition, we searched for Ebola vaccine in clinicaltrials.gov to determine a list of the
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different platforms and their state of development.
Similar to hepatitis A or flu vaccine, the first attempt was the use of an inactivated
whole virus, which raised safety concerns, and other types of vaccines were developed.
DNA vaccines consist in a circular DNA molecule (plasmid) encoding one or several
genes of viral proteins. The first human clinical trial tested in 2003 a DNA vaccine
and showed that 3 immunizations were safe and immunogenic [Martin et al., 2006]. It
was followed a few years after by a phase 1 [Sarwar et al., 2014] and a phase 1b trial
[Kibuuka et al., 2015], showing that multiple doses were needed to sustain the immune
response. Several other platforms have also been tested in phase 1 clinical trials, including
a vaccine based on human parainfluenza virus 3 (HPIV3) in the USA, human monoclonal
antibodies in the USA or an EBOV GP nanoparticle vaccine (with or without adjuvant)
in Australia. In parallel, a replication-defective recombinant Ad5 platform (rAd5) was
first tested in the USA [Ledgerwood et al., 2010], then in China [Zhu et al., 2015; Li
et al., 2017] and Sierra Leone [Zhu et al., 2017]. However, some concern was raised on the
pre-existing immunity in the population to Ad5 virus. Research on replication-defective
recombinant vectors focused then on serotypes with low human seroprevalence. It included
chimpanzee adenovirus (ChAd), and in particular ChAd3 alone [Ledgerwood et al., 2015,
2017; Rampling et al., 2015; De Santis et al., 2016] or combined with MVA [Tapia et al.,
2016; Ewer et al., 2016] or with Ad26. The ChAd3 vaccine has been evaluated in phase 2
trials in West Africa. It has also been investigated simultaneously with the VSV platform
in a phase 2 trial under the Partnership for Research on Ebola Virus in Liberia (PREVAIL)
[Kennedy et al., 2017]. Adenoviruses Ad26 and Ad35 were also considered as potential
vectors for Ebola vaccine. After showing its beneficial boosting effects, MVA platform has
also been tested in combination with adenoviruses [Tapia et al., 2016; Ewer et al., 2016],
and in particular, Ad26/MVA regimens have been undergoing phase 1 to 3 trials. Some
of these trials have been realized in the EBOVAC consortium, as part of the Innovative
Medicines Initiative Ebola+ program [Eurosurveillance editorial team, 2015], which aims
to assess a novel prime-boost preventive vaccine regimen against EVD. This consortium
associates academic European partners (University of Oxford, London School of Hygiene
and Tropical Medicine, INSERM and INSERM transfert) with the manufacturer of the
vaccine (Janssen). In particular, as part of this consortium, we had access to the data
of three phase 1 trials realized on healthy adult volunteers in four countries - United
Kindgom [Milligan et al., 2016; Winslow et al., 2017], Kenya and Uganda/Tanzania. In
these trials, participants were randomized to received either Ad26 then MVA or MVA
then Ad26 with a delay of 28 or 56 days. Another arm tested a 15 days delay in the UK
only. In addition, phase 2 trials have been conducted under this consortium in Europe
(France, UK) and Africa (Burkina Faso, Uganda, Kenya, Ivory Coast), and a phase 2b
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trial is ongoing in Sierra Leone. All assess the Ad26 then MVA regimen at 28, 56 or
84 days of delay. In parallel, a recombinant replication-competent platform, using the
recombinant vesicular stomatitis virus (rVSV) has been developed [Regules et al., 2017;
Agnandji et al., 2016; Huttner et al., 2015; Heppner Jr et al., 2017] and tested during the
2014-2015 epidemic using a ring-vaccination approach: after diagnosis of a new infected
patient, all people who were in contact with that case in the previous 21 days were defined
as a ring. A total of 117 rings were identified, containing a mean number of 80 people.
Randomization was applied to the rings in a 1:1 ratio to receive the vaccine either one
day after identification or 21 days after. The outcome was considered to be only cases
of Ebola virus disease with an onset 10 or more days from randomization. In that sense,
vaccine efficacy was estimated 100% (95% confidence interval 68.9–100.0), but this perfect
efficacy was questioned due to differences of interventions in the placebo and treated
clusters [Metzger and Vivas-Martínez, 2018]. The ring vaccination was also implemented
in DRC during the epidemics of 2018. In the first epidemic, vaccination was realized
between May 21 and June 26, 2018 with a total of 3481 people vaccinated, including
health professionals, contacts of confirmed EVD cases and contacts of these contacts. In
the second epidemic, vaccination started on August 8, 2018. As of August 19, 2018, health
care workers were first vaccinated and immunizations were realized in 10 vaccination rings
around 28 recently confirmed cases. Additional investigations on potential Ebola vaccines
are necessary and still undergoing, especially under the Partnership for Research on Ebola
VACcinations (PREVAC), a phase 2b trial on healthy individuals in Guinea, Liberia, Mali
and Sierra Leone [Lévy et al., 2018]. In this trial, participants are randomized in a 2:1:2:1:1
ratio to receive either Ad26/MVA or placebo/placebo or rVSV/placebo or rVSV/rVSV
or placebo/placebo, all with a 56 days delay. If funding permits, participants will be
followed up to 5 years under the PREVAC-UP project. Finally, longer follow-ups will
also be realized for some participants of EBOVAC1 and EBOVAC 2, and an additional
phase 2 trial will be conducted in Sierra Leone, Guinea and DRC to evaluate the safety and
immunogenicity of the Ad26/MVA vaccine candidate in children, under the EBOVAC3
project. A summary of the trials recorded in clinicaltrials.gov and assessing platforms
that reached the phase 2 clinical development can be found in table 3.1.
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Table 3.1 – Clinical trials assessing Ebola virus vaccine platforms. N indicates the number of patients enrolled in trial (including placebos)
if recruitment is completed. If the trial is still recruiting or has not yet started recruitment, N∗ indicates the estimated targeted
number of enrolled participants. Regarding the status, "ongoing: long follow-up" means that all participants were recruited,
vaccination was administered and only long-term (more than 1 year) measurements still need to be made. Grey colored trials
correspond to EBOVAC1, blue to EBOVAC2, green to EBOVAC3, yellow to PREVAC.
Platform Immunogen Phase Country Population (N) Published results/status
rAd5 EBOV GP, SUDV GP
1 USA Adults (31) Ledgerwood et al. [2010]
1 China Adults (120) Li et al. [2017]
2 Sierra Leone Adults (500) Zhu et al. [2017]
ChAd3
EBOV GP, SUDV GP 1 USA Adults (20) Ledgerwood et al. [2015]
EBOV GP
1 UK Adults (60) Rampling et al. [2015]
1 Switzerland Adults (120) De Santis et al. [2016]
2 Cameroon, Mali, Adults (3013) Completed
Nigeria, Senegal
2 Mali, Senegal Children (600) Completed
ChAd3/MVA
ChAd3: EBOV GP 1a UK Adults (38) Completed
(or EBOV, SUDV GP). 1b Senegal Adults (40) Completed
MVA: EBOV GP 1b Uganda Adults (90) Completed
1b USA Adults (143) Completed
ChAd3: EBOV GP. 1b Mali Adults (91) Tapia et al. [2016]
MVA: TAFV NP, 1 UK Adults (60) Ewer et al. [2016]
EBOV GP, SUDV GP 1 USA Adults (60∗) Not yet recruiting
ChAd3/Ad26 EBOV GP 1 UK Adults (32) Completed
ChAd3 // rVSV
ChAd3: EBOV GP. 2 Liberia Adults (1500) Kennedy et al. [2017]
rVSV: EBOV GP
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Ad26/MVA
1 USA Adults (65) Ongoing: long follow-up
1 USA Adults (164) Completed
3 USA Adults (525) Completed
3 USA Adults (329) Completed
2 USA, Kenya, Mozambique, Adults (578) Ongoing: long follow-up
Nigeria, Tanzania, Uganda
Ad26: EBOV GP. 1 UK Adults (87) Winslow et al. [2017]
MVA: TAFV NP, 1 Kenya Adults (72) Ongoing: long folllow-up
EBOV GP, SUDV GP 1 Uganda, Tanzania Adults (72) Ongoing: long follow-up
2b Sierra Leone Adults, children (1019) Ongoing: long follow-up
2 UK, France, Adults (290) Ongoing: long follow-up
2 Burkina Faso, Uganda, Adults: healthy (616), HIV+ (141) Ongoing: long follow-up
Kenya, Ivory Coast Adolescents (129), children (131) +additional immunization
2 Guinea, DRC, Adolescents & children HIV -/+ (600∗) Not yet recruiting
Sierra Leone
rVSV EBOV GP
1 USA Adults (78) Regules et al. [2017]
1 Germany, Switzerland, Adults (158) Agnandji et al. [2016]
1 Gabon, Kenya
1 USA Adults (513) Heppner Jr et al. [2017]
1/2 Switzerland Adults (56) Huttner et al. [2015]
2 Canada, Burkina Faso, Adults & adolescents HIV+ (200∗) Ongoing: recruitment
Senegal
2 USA, Canada Adults at occupational risk (18∗) Ongoing: recruitment
3 Guinea Adults (5643), children (194) Henao-Restrepo et al. [2017]
Ad26/MVA // rVSV
Ad26: EBOV GP. 2b Guinea, Liberia, Adults (1400∗) Ongoing: recruitment
MVA: TAFV NP, Mali, Sierra Leone Adolescents (466∗)
EBOV GP, SUDV GP. Children (934∗)
rVSV: EBOV GP55
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3.1.2.2 Immune marker of interest
A prophylactic (preventive) vaccine is assessed on its ability to prevent the infection
by a pathogen. Vaccine efficacy is estimated by comparing the incidence of the disease
among vaccinated subjects to equally exposed unvaccinated subjects and computing the
percentage of reduction of risk between these two populations. However, EVD epidemics
are usually localized and induce moderate numbers of fatalities (< 100), making it difficult
to evaluate the efficacy of a vaccine candidate during active transmission. A substitute
endpoint should then be used; it is a quantity (e.g., a biological marker) that can be
measured instead of the clinical endpoint. More precisely, in vaccine development, a
surrogate of protection is needed. It has to be statistically associated with the occurrence
of the disease and situated on the causal pathway between vaccination and protection
[WHO, 2013].
No immune surrogate of protection has been identified so far for the evaluation of
Ebola vaccine. Some studies on animals have shown that humoral response and survival
were associated. In particular, protection against lethal challenge of EBOV in rVSV vac-
cinated macaques was found to be correlated with high titers of EBOV-specific IgG [Wong
et al., 2012; Marzi et al., 2015], although a large variation of level value was observed,
possibly due to differences in assays. Also, heterologous prime-boost regimens combining
Ad26 vector with either Ad35 or MVA induced protection in NHP after intramuscular
challenge, and survival was particularly associated with high humoral response and less
so with cellular response [Callendret et al., 2018]. With rVSV vaccine, neutralizing anti-
bodies were not always detected after immunization, meaning that they may not correlate
with protection. In the case of non-replicating, Ad-based vaccines injected to NHP, anti-
body response was associated to protection against EBOV challenge [Sullivan et al., 2011]
but the cellular response may also play a role, especially for long-term protection [Stan-
ley et al., 2014]. Although no surrogate of protection has been identified and bridging
studies between NHP models and humans are undergoing but have not been completed
yet [Golding et al., 2018; Sullivan et al., 2009], the community has focused on using the
antibody response as main criterion for assessing Ebola vaccine candidates in phase 1/2
trials [Krause et al., 2015].
The binding antibody response is measured with the enzyme-linked immunosorbent
assay (ELISA). This assay is used to detect the presence of antigens or antibodies in a
sample. When used to assess the binding antibody levels, the protocol is the following:
Ebola protein samples are fixed in probes on a microplate. The analysis sample is then
added to the protein mixture. If the sample contains Ebola-specific antibodies, they will
bind to the proteins situated on the microplate. A step of washing is realized, to make
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sure that only specific binding relationships are maintained. Secondary antibodies are
then added to the plate. These antibodies are labeled with enzymes which are activated
with an additional substrate and can be detected using fluorescence technologies. The
signal detected is proportional to the number of binding antibodies in the sample. The
optical density of the sample is compared to a standard curve, which allows to determine
an equivalent concentration of binding antibodies (in ELISA units).
As mentioned in section 2.2.2.3, many factors can have an impact on the quality and
quantity of the immune response to vaccine immunizations. In order to assess the factors
influencing the antibody response variability after Ebola vaccination, a meta-analysis was
conducted in the team. This work, Ebola vaccine development: Systematic review
of pre-clinical and clinical studies, and meta-analysis of determinants of an-
tibody response variability after vaccination, L. Gross, E. Lhomme, C. Pasin, L.
Richert, R. Thiébaut was published in the International Journal of Infectious Diseases
(september 2018), volume 74, pp 83-96 [Gross et al., 2018]. The article can be found
in appendix A. In short, a review of Ebola vaccine studies was conducted and a meta-
regression was estimated on human groups including at least 8 subjects. Among different
factors, related to the vaccine (platform, route of administration, insert), to the mea-
surement (delay between immunization and measure, method, antigen, strain, similarity
between strain and vaccine insert) or to the population (geographic location, age, sex),
only vaccine platforms and viral strains used for antibody detection were associated with
antibody response. However most of the heterogeneity of the response remained unex-
plained (95%), suggesting that other factors could impact the antibody response, such as
genetics, as previously mentioned, or the measurement technique for ELISA. It justifies
the interest of randomized clinical trials for formal comparisons of vaccine immunogenic-
ity. This study also underlined the opportunity we had to work on data generated in the
context of the EBOVAC1 consortium, as the clinical trials were realized with very similar
study protocols, reducing the risk of variation induced by factors related to the vaccine
and the measurement technique.
3.1.3 Modeling the humoral immune response: state of the art
3.1.3.1 Dynamics of the humoral immune response
As previously shown, antibodies represent the marker of interest when evaluating vac-
cines against Ebola virus. They actually play a crucial role in preventing many infections
and represent a good correlate of protection for a lot of vaccines [Plotkin, 2010]. Anti-
bodies are actors of the humoral response, which also include B cells. After activation,
B cells differentiate into either ASCs producers of antibodies, or into memory B cells
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with an ability of quick reaction during secondary encounters. It has been observed that
ASCs peak a few days (7-10) after encounter with the pathogen, and levels drop after a
few weeks [Lanzavecchia and Sallusto, 2009; Fink, 2012; Huang et al., 2014; Frölich et al.,
2010; Odendahl et al., 2005]. In the meantime, antibody concentrations also increase until
reaching a peak around 20-30 days after encounter, before decreasing with time. Main-
tenance of antibodies has been studied and can last several years [Amanna et al., 2007;
Amanna and Slifka, 2010; Pool et al., 2018]. Yet, antibodies are known to be short-lived,
with a half-life depending on the antibody subtype: around 2-3 days for IgDs and IgEs
[Abbas et al., 2010], 5-8 days for IgMs and IgAs [Abbas et al., 2010; Brekke and Sandlie,
2003] and estimations vary between 20 and 50 days in different studies of intravenous
IgG preparations [Berkman et al., 1990; Brekke and Sandlie, 2003] and passive immunity
through maternal antibodies [O’Dempsey et al., 1996; Leuridan et al., 2011; Brinkhof
et al., 2013; Vilajeliu et al., 2016; Voysey et al., 2017]. The maintenance of the antibodies
is actually explained by the existence of a population of long-lived ASCs which produce
and sustain antibodies over time [Slifka et al., 1998; Radbruch et al., 2006; Hammarlund
et al., 2017]. In parallel, memory B cells remain in the organism, ready to react faster
and to differentiate into ASCs producing antibodies with higher affinity to the antigen
[Tarlinton and Good-Jacobson, 2013; Inoue et al., 2018]. Modeling the whole process of
the humoral response is very challenging, and most of the models in the literature have
focused on modeling the antibody decay, in order to predict the duration of the response
and the time at which a threshold of interest is reached (e.g., the value corresponding to
a correlate of protection).
3.1.3.2 Models for the antibody decay
One of the first modeling work for the decrease of antibodies was realized in the case
of hepatitis B vaccine. A threshold of antibody concentrations under which subjects are
at risk of infection was defined in Jilg et al. [1984]. Below this value, an additional im-
munization was required to boost the immune system and the time of this additional
immunization needed to be determined. A simple model was used to quantify the vari-
ability of antibody decline among the population [Nommensen et al., 1989] and led the
authors to recommend that the duration of protection against HBV should be individually
estimated with a second measurement of antibody concentrations. In this paper, authors
assumed an exponential decline on the antibodies. It actually comes from the assumption
that after the observed peak, antibodies decline with a time-independent decay rate δ. In
that case, the differential equation verified by the antibodies (Ab) is the following:
dAb(t)
dt
= −δAb(t), (1)
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which can be solved in:
Ab(t) = Abpe
−δ(t−tp), (2)
with tp the time of peak and Abp the antibody concentration at tp. As antibody concen-
trations are usually transformed using the log10, equation (2) can be written as:
log10(Ab(t))− log10(Abp) = −
δ
log(10)
(t− tp), (3)
which corresponds to a linear decrease of the log10-transformed antibodies. By using a
measurement at tp and an additional measurement at a time after tp, parameter δ can be
estimated for each subject and the time at which antibodies will reach the given threshold
can also be determined.
Basically, assuming an exponential decrease of the antibodies corresponds to using a
linear model on the log-transformed antibodies. This linear decay has also been applied to
geometric mean titers following Hepatitis A Vaccine injections [Van Damme et al., 1994].
Similar to Nommensen et al. [1989], individual estimates of the decline of antibodies follow-
ing hepatitis A vaccine immunization were estimated to account for the between-subjects
variability [Wiens et al., 1996]. Accounting for this variability by treating individual data
instead of using the mean titers over the studied population can actually be addressed
by using linear mixed models: these statistical tools allow to evaluate the inter-individual
variability through random effects and the possible influence of other factors, such as age,
gender or environmental factors on the antibodies dynamics, as detailed in section 2.2.2.3.
In that case, if we consider that t = 0 corresponds to the time at which antibodies reach
their peak, the antibody concentration for individual i at time j can be written:
log10(Ab(tij)) = β0 + γ0i + β
TZi + (β1 + γ1i)tij + β
T
s Zsitij + ǫij, (4)
with β0 the population mean value at time of peak, β1 the population mean value of
the decreasing slope. Z are covariates modifying the value at time of peak and β their
associated effects, and Zs are covariates affecting the decreasing slope, with βS their
associated effects. Z and Zs can be similar and share common variables. Random effects
γ on the intercept and the slope are such that:(
γ0i
γ1i
)
∼ N
((
0
0
)
,
(
σ20 σ01
σ01 σ
2
1
))
, (5)
Finally, ǫ is a normally distributed error ǫij ∼ N (0, σ2). Linear mixed models were used
in several studies to predict the persistence of antibodies following vaccinations or natural
infections. In particular, they were applied in studies with a follow-up data between 3 and
6 years after the last vaccine immunization to model the decline of antibodies and predict
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their persistence up to 10 to 20 years. Applications include hepatitis A vaccine [Bovier
et al., 2002], diphteria, tetanus and pertussis vaccine [Cheuvart et al., 2004; Bailleux et al.,
2008] and Japanese Encephalitis vaccine [Abe et al., 2007]. Linear mixed models were
also used in the case of hepatitis B vaccine [Renard et al., 2001], by including data up to
11 years after the vaccine immunization and predicting the antibodies concentrations at
year 12. Another interesting application was proposed by Amanna et al. [2007] to assess
the long-term duration of humoral immunity to common antigens.
However, using a linear mixed model to describe the decrease of antibodies after
their peak relies on the strong assumption that the decay rate is independent of time
and induce a single-slope decrease. Some studies have shown that this assumption is
simplistic. In particular, a biphasic decay of the antibodies has been widely observed
in experiments, with a strong decrease right after the peak of the antibody response
followed by a slower decline [Vidor, 2010; White et al., 2015]. Some early mention of
the necessity to model the biphasic decay of the antibody response can be found in
Wiedermann et al. [1997], as authors found that classical models could not fit their data
and proposed a "two-component model" accounting for the two phases of the dynamic.
Several ways to improve the linear modeling have been proposed. One natural method to
account for time-changing slope values and still consider the between-subject variability
is to use piecewise linear mixed models: it corresponds to using linear mixed models with
parameters differing on some time intervals, in particular slope values. Other methods
consider non-linear models. Indeed, instead of considering the log-transformed antibody
concentrations as a linear function of time, "exponential-type" models assume a power of
time. In that case, the modeling equation is of the form:
log(Ab(t)) = c+K(t− t0)a. (6)
Note that when a = 1, we obtain the particular case of a linear model. These exponential-
type models were applied in particular in the case of Haemophilus influenzae type b
infections, with data up to 4 years and predictions up to 10 years [Leino et al., 2000].
Linear-mixed models, piecewise linear-mixed models and non linear model based on an
exponential-type function were compared in some studies: in particular, estimations on
data from Japanese Encephalitis vaccine [Desai et al., 2012] and hepatitis A [López et al.,
2015; Theeten et al., 2015] showed that piecewise linear-mixed models induce better fit
and can help predict the persistence of antibodies after immunization. Another non-linear
approach is the "power-law" model [Fraser et al., 2007]: it accounts for the heterogeneity
in the rate of decay of several populations of ASCs by using a Gamma distribution, which
leads to the following equation for the antibody dynamics:
log(Ab(t)) = k − a log(c+ t). (7)
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This model was proposed to be extended in the same article by considering two distinct
populations of ASCs: one population is active, with an heterogeneous decay rate modeled
by a Gamma distribution and a given proportion of the cell population is memory, with
a null decay. This model induces a long-term antibody plateau. It is written as:
log(Ab(t)) = k + log[(1− π)−a(c+ t) + π], (8)
with π > 0 inducing a long-term antibody persistence. Modified power-law model was
shown to fit better the data from HPV vaccination compared to the simple power-law
model [Fraser et al., 2007]. Still in the HPV context, the data was better fitted by a
modified power-law model compared to a power-law model and piecewise linear models
[David et al., 2009]. In both cases, models were fitted on follow-up data up to 6 years
and used for predictions between 20 and 30 years after vaccine immunization. Power-law
and modified power-law models were also fitted on hepatitis E vaccine data up to 6 years
after immunization [Chen et al., 2015]. Both models allowed predictions of persistence up
to 30 years, but their performances could not be clearly distinguished with the available
data. Finally, models of the antibody dynamics using fractional polynomial models were
proposed and estimated on hepatitis A vaccine data [Hens et al., 2014]: a piecewise linear-
mixed model with 3 slopes was found to fit the best the data up to 17 years and allowed
prediction of persistence up to 25 years.
Overall these models represent a good tool to predict the long-term persistence of
antibodies after vaccination, when data is already available up to a few years after the
immunization. However, they only model the decreasing phase of the antibody dynamics
and do not account for the previous temporal phase or the dynamics of ASCs. Moreover,
the biological interpretation of complex descriptive statistical models is difficult, as men-
tioned in section 2.3. A good alternative to model the dynamics of the humoral response,
accounting for both ASCs and antibodies dynamics, is to use mechanistic, ODE-based
models.
3.1.3.3 Mechanistic models for the humoral response to vaccine
Mechanistic models are based on the knowledge from the biological process, and are
able to account for the non-linear interactions between the actors of the process. They can
be based on ODEs from which parameters can be estimated to quantify the characteristics
of the process. In the case of the humoral immune response following vaccination, only
a few ODE-based models were used. In Wilson et al. [2007], the dynamics of circulating
antigen, immunological memory and antibody concentrations after hepatitis B vaccine
immunization were modeled with ODEs to quantify the mechanisms of the immune re-
sponse. The interest is focused on immunological memory, as defined by the ability to
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produce circulating antibody. Protection from infection is driven by this immunological
memory, as some patients with low anti-HBVs antibody concentrations can also be pro-
tected, thanks to reactivation of their immunological memory. Immunological memory
does not correspond to a given population of cells but more to the expansion capacity of
memory B and T lymphocytes, changes in cytokine production, and affinity phenomena.
Vaccine antigen (V) is supposed to decrease at constant rate σ. Memory (M) is assumed
to be generated at both antigen-dependent and independent rates, with a limited capacity
N . Memory has the capacity to produce antibodies (A) in presence of vaccine antigen
at rate δ, with a maximum level N . Antibodies decrease at a time-dependent rate µ/T ,
with T the time since last vaccination. The equations of the dynamics following a booster
immunization are the following:

dV
dt
= −σV,
dM
dt
= (γV + βM)
(
1− M
N
)
,
dA
dt
= δMV
(
1− A
N
)
− µA
T
.
(9)
The model was used to fit antibodies concentration data from several clinical trials as-
sessing the effect of different vaccines (three generations of vaccines have been used up to
now). The estimation showed that quantity of memory and the time before its generation
significantly varied between the different vaccines. As the amount of memory (and not
the antibody concentrations) is supposed to generate protection, predictions of the model
supported the hypothesis that a single dose of vaccination could be sufficient to induce
protective immunological memory.
Another study by Le et al. [2015] modeled the dynamics of ASCs after vaccinia virus
(VV) vaccination in human volunteers with ODEs. The model was actually an extension
of a widely known model for the CD8+ T cell response, developed in de Boer et al. [2001]
and Antia et al. [2003], as mentioned in 2.3. After VV vaccination, it takes some time Ton
until ASCs (written B in the article) are activated and start proliferating. Then, after
a few days, a contraction phase arises and most of the ASCs die at rate δB; it happens
during some given period of time. Some memory cells remain in the organism and die
with a much lower rate δM . The equation of the dynamics can be written as:
dB(t)
dt
=

0 if t < Ton,
ρB(t) if Ton ≤ t < Toff ,
−δBB(t) if Toff ≤ t < Tmem,
−δMB(t) if Tmem < t.
(10)
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Antibodies (Ab) are produced by ASCs cells at rate θ(t) and die at rate δAb:
dA(t)
dt
= θ(t)B(t)− δAbAb(t). (11)
A first model considered a rate θ constant with time and another rate linearly increasing
with time after Ton. Finally, an improvement of this model was also proposed in the same
paper, in order to account for the hypothesis that antibodies are produced by several
populations of ASCs. Authors included in the model circulating ASCs, that were able
to migrate to the bone marrow and differentiate at rate m into long-lived plasma cells.
Antibodies are then produced at constant rate θ by both circulating cells and cells from
the bone marrow. A patient-by-patient estimation method allowed good fit of the data
by the models. Unfortunately, due to the few number of data measurements and the
increased number of parameters in the alternative models, statistical differences between
the three models could not be assessed. The models helped quantifying the kinetics of
the immune response following vaccination, but could not help distinguishing the main
mechanisms involved in the production of antibodies by ASCs.
Finally, in Andraud et al. [2012], authors aimed at applying the "plasma-cell imprinted
lifespan" model developed by Amanna and Slifka [2010]: it assumes that antibodies are
maintained by a population of long-lived plasma cells, located in survival niches and with
an "imprinted" lifespan, independent from the replenishment from memory B cells (due
to boost immunizations of possible re infections). In the model, the plasma cells are then
divided in two populations with two different lifespans (one short and one long). These
populations are assumed not to be renewed and to decline with time at two different decay
rates. Model equations are then:
dPs
dt
= −µsPs,
dPl
dt
= −µlPl,
dAb
dt
= φsPs + φlPl − µAbAb.
(12)
The system has an analytic solution, as plasma cells admit an exponential decline. By
writing Φs = φsPs0 and Φl = φlPl0, we obtain:
Ab(t) =
Φs
µAb − µs e
−µst +
Φl
µAb − µl e
−µlt +
(
A0 − Φs
µAb − µs −
Φl
µAb − µl
)
e−µAbt. (13)
Additional hypothesis can simplify the model; especially, a model where µl = 0 was tested,
as long-lived cells are expected to have a very long lifespan. Moreover, a model assuming
that antibodies die much faster than ASCs was also tested (with µAb ≫ µs and µl).
These models were used to fit data of antibody concentrations from 1 to 10 years after
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hepatitis A vaccine immunizations and compared with power-law decay models. They
were estimated with a population approach and allowed both individual and population
prediction of immunity waning. The asymptotic model, assuming that µl = 0 was found
to be the best for fitting the data. However, additional measurement of the early antibody
response (before one year) were found to help improving parameters estimation, and in
particular those related with the long-lived ASCs. It could mean that early measurements
would help better distinguishing between the role of short-lived and long-lived ASCs. This
modeling work succeeded in estimating three scales of the humoral response dynamics,
corresponding to the lifespan of antibodies (around 20-30 days), short-lived plasma cells
(several months) and long-lived ones (decades).
There has been a large interest in modeling the humoral immune response to vaccine
immunizations, but only a few studies accounted for the dynamics of the ASCs in addition
to the antibodies. This is also related to the availability of the data, as most of the
time only the antibody concentrations are measured. Moreover, we have seen that both
individual and population fitting are used to estimate the key parameters of the dynamics
of the response. In our work, we have focused on using a population approach to estimate
the parameters of an ODE-based mechanistic model for the dynamics of the humoral
response to Ebola vaccine. We will detail in the next section the method for the estimation.
3.2 Method: parameters estimation
3.2.1 The population approach
A first way to use ODE-based mechanistic models is to simulate trajectories with
a certain range of parameters values to assess the ability of the model to reproduce
qualitatively the dynamics of the biological process. These simulations also allow to get
an idea of how parameters may impact the trajectories of the compartments of the system.
Parameters of the model can also be chosen by calibration: it consists in determining
some well-chosen combinations of the parameters that allow to reproduce quantitatively
the clinical data. This is done by comparing the predicted compartment trajectories to
the data. Both approaches can be valuable for running simulations and comparing several
models related to different biological hypotheses. They actually represent a first step of
study when developing a model. However, ODE systems can almost never be solved with
an analytic solution and the output is usually non-linear in the parameters. Simulations
with a given number of parameter combinations does not allow to explore the whole space
of possible solutions and do not ensure to determine the optimal values corresponding to
the clinical data. One way to deal with this issue is to estimate the parameters of the
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ODEs. However, due to the complexity of the models and the clinical constraints on the
data, estimation of parameters is not that easy and represents a real statistical challenge.
Patients-by-patients fits have been widely used [Ribeiro et al., 2002; Dixit and Perelson,
2005; Le et al., 2015]: parameters are determined for each patient, by minimizing a given
criterion – usually the mean squared error on the patient’s data and population parameters
are generally obtained by computing empirical means of the patients’ estimated values.
Our approach is based on population estimation, for several reasons. First, data can be
unbalanced in biological experiments. It means that measurement timings and availability
can differ between subjects. This additional constraint can make it difficult to estimate
parameters of some individual with only a few measurement. Using the whole population
data can handle that issue [Thiébaut and Walker, 2008]. Another argument for the
statistical power of the approach relies on a simple analogy with statistical regression
models. Indeed, if several groups of individuals can be defined based on a covariate (e.g.,
immune intervention), it is possible to stratify the estimation within each intervention
group, but more powerful to use the data on all subjects and include the covariate in
the model. Finally, the variability between patients adds information to the model; for
example, it can help constraining the parameters value of the model. Indeed, if a model
is considered to be acceptable for both a placebo and an immune intervention group,
with the intervention affecting only the value of some parameters, the estimation on the
placebo dynamics will help constraining the values of other parameters that are supposed
to be shared between the two groups. The population approach can also help determining
which parameters induce more or less variability between subjects behaviors. Here, linear-
mixed models are applied to the parameters of the ODE system; covariate effects can be
estimated on these parameters, and the unexplained inter-individual variability is modeled
with random effects.
3.2.2 Estimation with NIMROD
Parameter estimation of ODE systems was mostly realized using NIMROD (normal
approximation inference in models with random effects based on ordinary differential
equations) tool, which was previously developed in the team [Prague et al., 2013a]. This
method of estimation was implemented in Fortran. In this section, we present the general
model of ODEs handled by NIMROD and the statistical method of estimation. It relies on
likelihood maximization using a Newton-like algorithm which approximates the Hessian
using first derivatives. Acceptable computation times are achieved thanks to parallel
computation.
65
MODELING THE IMMUNE RESPONSE TO EBOLA VACCINE
3.2.2.1 General model
The general model is based on three layers. First, we consider the mathematical
model, which consists of a system of ODEs modeling the biological compartments (e.g.
population of cells), represented by the vector X(t) = (X1(t), . . . , XK(t)). In a given
population of n independent subjects, the ODE system for subject i is written:
dXi(t)
dt
= f(Xi(t), ξi(t)),
Xi(0) = h(ξi(0)).
(14)
ξ is the vector of nb biological parameters. The parameters can be transformed to account
for biological constraints (e.g., logarithmic transformation if parameters correspond to
rates and are positive). We use one-to-one transformation functions ψl, l = 1 . . . nb:
ξ˜il (t) = ψl(ξ
i
l (t)). (15)
From now, we will consider that ψ = log. The population approach includes statistical
linear-mixed models on the biological parameters. This allows to introduce covariates on
parameters and to account for the between-subjects variability. For every parameter ξl
and patient i, we write:
ξ˜il (t) = ξ˜l0 + β
T
l z
i
l(t) + u
i
l, (16)
where ξ˜l0 is the intercept and represents the mean value of parameter over the population,
βl is a vector of regression coefficients, z
i
l is a vector of ne explanatory variables and u
i
l
is an individual random effect, following a centered normal distribution with variance ω2l .
Random effects are independent and applied on a subset of q biological parameters. The
last aspect of the model is the observation model, as in practice not all compartments of the
model are directly observed and we only have access to discrete time observations Yi(tij)
of some function of Xi(t). We suppose there are known link functions gm, m = 1, . . . ,M
allowing an additive measurement error model:
Y im(tij) = gm(X
i(tij)) + ǫijm, (17)
with ǫijm ∼ N (0, σ2m). The estimation problem corresponds to the determination of all
parameters: intercepts, regression coefficients, variance of random effects and variance of
measurement errors. It corresponds to the vector of parameters θ such that:
θ =
[
(ξl0)l=1..nb , (βl)l=1..ne , (ωl)l=1..q, (σl)l=1..M
]
. (18)
3.2.2.2 Likelihood and scores computation
For each individual i at time j and each link function m, we assume that the error
follows a normal distribution: ǫijm ∼ N (0, σ2m). The individual likelihood of subject i
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given the random effects can be computed as in Guedj et al. [2007a]:
LFi|ui =
∏
m=1..M
j=1..ni
1
σm
√
2π
exp
1
2
(
Y im(tij)− gm(Xi(tijm, ξ˜i))
σm
)2 . (19)
The observed individual likelihood is obtained by integration over the random effects:
LOi =
∫
Rq
LFi|ui(u)Φ(u) du, (20)
where Φ is the normal density of N (0, Iq). Then the full (given random effects) and
observed individual log likelihood are : LFi|ui = logLFi|ui and LOi = logLOi . Finally, the
global observed log likelihood is obtained by summing all individual contributions:
LO =
n∑
i=1
LOi . (21)
The likelihood is computed thanks to adaptative gaussian quadrature [Guedj et al., 2007a].
Indeed, it has been shown that this method may be more precise than others, and es-
pecially Laplacian methods [Lesaffre and Spiessens, 2001]. The likelihood is then maxi-
mized through a Newton-like algorithm using only the first derivatives of the log likelihood
(scores). The observed individual scores are deduced by Louis’ formula [Louis, 1982] :
UOi =
∂LOi
∂θ
= (LOi)−1
∫
Rq
LFi|ui(u)UFi|ui(u)Φ(u) du. (22)
These scores have analytic expressions. As an example, we will present here the formula
for the fixed effects φ and refer to Guedj et al. [2007a] for the other parameters. The score
is computed given the random effect of subject i:
Uφl
Fi|ui
(θ) =
∂LFi|ui
∂ξ˜il
=
∑
m,j
1
σ2m
∂gm(X
i(tijm, ξ˜
i))
∂ξ˜il
[
Yijm − gm(X(tijm, ξ˜i)
]
. (23)
This computation requires the determination of the sensitivity equations of the ODE
system,
∂Xk(t, ξ˜
i)
∂ξ˜il
, as:
∂gm(X
i(t, ξ˜i))
∂ξ˜il
=
∑
k≤K
∂gm(X(ti, ξ˜
i))
∂Xk
∂Xk(t, ξ˜
i)
∂ξ˜il
. (24)
The observed individual scores are obtained by numerical integration, using an adaptive
Gaussian quadrature, similar to the computation of the individual log likelihood.
3.2.2.3 Newton-like algorithm for likelihood maximization
The maximization of the likelihood is usually realized using a Newton method. The
method implemented in NIMROD is an extension of the Newton-Raphson algorithm using
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an approximation of the Hessian matrix based on the scores only. Consider a model
(Pθ)θ∈Θ with Θ an open subset of R
m. In a population of n independent subjects, LOi =
logLOi is the observed individual log likelihood for subject i and Lθ =
∑n
i=1 L
θ
i is the
global observed log likelihood. The maximum likelihood estimator is defined by :
θˆ = argmax
θ∈Θ
Lθ. (25)
The method requires the computation of the score and the Hessian matrix (assuming that
the log likelihood is twice differentiable):
Uθi =
∂Lθi
∂θ
, (26)
Uθ =
n∑
i=1
Uθi , (27)
H(θ) =
∂2Lθi
∂θ2
. (28)
The information matrix is
I(θ) = Eθ[−H(θ)] = Eθ[−Uθ(Uθ)T ]. (29)
Assume that the Lθi are iid, then we can write I(θ) = nI(θ), with I(θ) independent
from n. Moreover, assuming that ∃θ∗ ∈ Θ such that Pθ∗ = P∗, the maximum likelihood
estimator θˆ verifies the following:
n−1/2(θˆ − θ∗)→ N (0, I(θ∗)−1). (30)
The likelihood maximization can be realized with the Newton-Raphson iterative algo-
rithm, defined by the following iteration:
θk+1 = θk −H−1(θk)U(θk). (31)
The idea of the algorithm comes from Taylor’s formula. We will explain the principle for
a function f : R→ R twice differentiable. For x and x0 ∈ R, we can write:
f ′(x) = f ′(x0) + (x− x0)f ′′(x0) +O((x− x0)2). (32)
As the aim is to maximize f , we are looking for x such that f ′(x) = 0. It comes from
equation (32) that if x and x0 are close enough:
x ≈ x0 − (f ′′(x0))−1f ′(x0). (33)
The iterative sequence such that:
xk+1 = xk − (f ′′(xk))−1f ′(xk) (34)
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Algorithm Value of G
Marquart G = H + λdiag(H)
Levenberg G = H + λId
RVS algorithm G(θk) =
∑
i≤n
Ui(θk)U
T
i (θk)− n−1U(θk)UT (θk)
Table 3.2 – Different types of Newton-like algorithms
converges to x such that f(x) is a maximum of f . A classical Newton-Raphson algorithm,
as expressed in (31), requires an inversion of matrix H. Some extensions of the algorithm
have been proposed to handle more general cases where H is not positive definite. The
iterative step is of the form:
θk+1 = θk −G−1(θk)U(θk), (35)
where G(θ) has to be positive definite for all θ and close to H(θk) when θk → θˆ. As
shown in table 3.2, Marquart and Levenberg algorithms [Marquardt, 1963] propose to
use matrix H with modifications of its diagonal. The Robust-variance scoring (RVS)
algorithm, developed in Commenges et al. [2006], is based on an expression of G from
Berndt et al. [1974]. This algorithm was shown to have a good convergence rate and
to run faster that the Marquardt algorithm, as it only requires the computation of the
scores, which is less computationally demanding than computing the Hessian matrix. This
advantage is even more interesting when the number of parameters is large. Convergence
of the RVS algorithm is ensured by three criteria. A stopping criterion is a condition of
the form Ck < c, computed at each iteration of the algorithm, with c a given stopping
value. The first two criteria are based on the evolution of the algorithm on the parameter
space and on the log likelihood value (with d a distance defined on both spaces):
d(θk+1,θk) ≤ η1 (36)
and
d(L(θk+1), L(θk)) ≤ η2. (37)
However, both criteria could be small even when the algorithm is fixed on a wrong di-
rection (close to local maxima for example). A criterion was proposed in Commenges
et al. [2006], with a stopping value independent from the problem of estimation. It corre-
sponds to the ratio of the numerical approximation error d(θk, θˆ) and the statistical error
Eθ∗ [d(θˆ,θ∗)]:
Ck =
d(θk, θˆ)
Eθ∗ [d(θˆ,θ∗)]
. (38)
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By using a distance of the form d(x, y) = (x− y)TM(x− y) and taking M = G, it can be
shown that:
Ck ≃ m−1U(θk)TG(θk)−1U(θk). (39)
In practice, we use Ck < c, with c < 1 and as close as possible to 0 (taken if possible
equal to 0.1).
3.2.2.4 Prior distributions
Depending on the number and schedule of observations available, the number of sub-
jects in the study, the measurement precision and the observed components of the model,
estimation identifiability issues can arise [Guedj et al., 2007b]. One method to deal with
this problem is to reduce the number of parameters to be estimated by fixing some of
them, using values from previous studies. Another more flexible way to improve the ac-
curacy obtained on the estimation of parameters relies on bayesian approaches, which
help constraining the space of exploration of the algorithm. Bayesian inference is usually
implemented with Markov chain Monte-Carlo (MCMC) method, as in the Stan software
[Gelman et al., 2015]. However, these methods can be time-consuming in complex mod-
els. An alternative was implemented in NIMROD, by using a normal approximation of
the posterior distribution and estimating the Maximum A Posteriori (MAP) [Drylewicz
et al., 2012]. This method is easy to include in the model, with a faster computation time
than MCMC. This approach is justified by the fact that the posterior distribution can be
approximated. In particular, Bernstein-Von Mises theorem [Van der Vaart, 2000] states
than under weak conditions, the posterior distribution converges to a normal distribution.
Parameter θ is initially defined by a probability density π(θ). The posterior distribution
is obtained by accounting for the observations: π(θ|Y ). As shown in Drylewicz et al.
[2012], applying Bayes formula gives:
θˆMAP = argmax
θ∈Θ
LθMAP , (40)
with
LθMAP = L(θ) + log(π(θ)). (41)
Numerically, it corresponds to maximizing the penalized log-likelihood:
L(P )(θ) = L(θ)− J(θ), (42)
with J(θ) = − log(π(θ)). The same algorithm (RVS) can be used for likelihood maxi-
mization, but with a modified function G such that:
G(θk) =
n∑
i=1
Ui(θk)U
T
i (θk)− n−1U(θk)UT (θk)−
∂2J
∂θ2
(θk), (43)
70
MODELING THE IMMUNE RESPONSE TO EBOLA VACCINE
and G(θk) ≃ ∂
2L(P )
∂θ2
(θk) near the maximum [Prague et al., 2012]. In practice, J is easy
to compute as only normal priors are used on the biological parameters φ. In that case:
J(θ) =
∑
j
(φj − E(φj))2
2var(φj)
. (44)
It allows to determine an approximately normal posterior distribution on the biological
parameters.
3.2.2.5 Individual parameters
In addition to providing population estimation of the parameters, the method also
allows the computation of individual parameters. Using some individual data, parameters
of a given patient can be computed using parametric empirical bayes estimators (PEB)
[Morris, 1983; Kass and Steffey, 1989]. The individual estimator can be written as:
ξˆi|F ij
= ξˆ0 + βˆ
Tz(t)i + uˆi|F ij
, (45)
where ξˆ0 and βˆ are the MAP values obtained from the estimation on a dataset excluding
observations 1 to j of patient i (written as F ij ). Estimation of the individual random
effects uˆi
|F ij
can be computed by maximizing the individual likelihood of patient i, based
on observations Yi1, ..,Yij:
uˆi|F ij
= argmax
u∈Rq
{
log[p(Yi1, ..Yik|θˆ, zi,u)]− J(θˆ,u)
}
, (46)
with θˆ the MAP value. Similar to the likelihood maximization, computation of individual
random effects can be realized with different methods, but the one implemented in NIM-
ROD is a Newton-like algorithm. This allows to compute individual trajectories from the
population estimation.
3.2.2.6 Model selection
In practice, a number of statistical models are evaluated to fit the data, by testing
different combinations of random and fixed effects on several parameters. Models are
compared and selected using several criteria: first, quality of fit, which is a visual check-
ing that the trajectories correspond to the expected dynamics, regarding the data. For
example, the Visual Predictive Check (VPC) is a tool comparing the percentiles of the
real data to the percentiles of data simulated with the estimated parameters [Post et al.,
2008]. Moreover, the likelihood is used to compare models (a higher likelihood is expected
for better models). We also use an approximation of the leave-one-out cross-validation
criterion (LCVa), developed in Commenges et al. [2007], which is an extension of Akaike
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criterion (AIC), accounting for the number of parameters but also for the penalization
and the number of observations [Commenges et al., 2008, 2015]. The LCVa estimates a
risk, so better models are expected to obtain lower values of LCVa. It is defined as :
LCV a = −n−1[L(θˆ)− Tr(H−1
LP
(θˆ)HL(θˆ))
]
, (47)
where HLP and HL corresponds to the Hessians of minus the penalized log-likelihood and
the log-likelihood respectively.
Several methods of model selection can be used. Our method of selection can be
considered as a backward stepwise approach. The model is first estimated by considering
random effects on all parameters. Then, for each random effect, we can test if the variance
is significantly different from 0, using a Wald test. Non significant random effects can
be removed from the model, one by one, by starting by the less significant one and
estimating again the model at each removal. The same method can be applied to the
selection of fixed effects (covariates) on the parameters. Significance of the fixed effects
is also tested using a Wald test and by checking that the variance of random effect is
usually reduced. We can process with the same removing method with the covariates.
Each time a parameter is removed, the LCVa and likelihood of the models with and
without the parameter are checked to make sure the parameter can actually be removed
without reducing the performance of the model. In the end, we obtain a model with
selected random and fixed effects on the parameters. However, it should be underlined
that it can be computationally difficult to estimate a model including random effects on
all parameters, as the likelihood is integrated on each random effect and the integration
dramatically increases the computational time. It can then be more convenient to evaluate
combinations of random effects on several subsets of parameters to determine the best
fitting one. Also, it should be kept in mind that the method of model selection should
be adapted to the modeling question. Indeed, the method described here corresponds
more to an explanatory approach and a statistical selection. As we are using mechanistic
models, some mechanisms can already be known from previous work and some of the
effects (either random and/or fixed) can be applied to the model because it makes sense
in a biological point of view.
3.2.3 Estimation with other tools
In this work, parameters estimation was mainly realized using NIMROD, as de-
scribed in the previous sections. However, other algorithms proposed different approaches
for likelihood maximization. In particular, the Stochastic Approximation Expectation-
Maximization (SAEM) algorithm is widely used, especially in the pharmacokinetics/phar-
macodynamics (PK/PD) field, as implemented in NONMEM [Beal et al., 1992] and
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MONOLIX [Kuhn and Lavielle, 2005]. This algorithm is a stochastic version of the
EM algorithm developed by Dempster et al. [1977]: it is an iterative procedure, and each
iteration is composed of two steps. The first one simulate the random effects with the
conditional distribution using a MCMC procedure and the second one updates the values
of the parameters of the model. This method was shown to converge to the maximum
likelihood estimate and MONOLIX is used in a wide range of non linear mixed models
estimated with a population approach, in particular in the PK/PD field [Lavielle and
Mentré, 2007; Chan et al., 2011]. This software can also be used to perform statistical
tests used in model selection such as Wald test and likelihood ratio test [Samson et al.,
2007]. However, there is a risk of convergence to local maxima, because the number of
iterations is limited and the parameters distance between two iteration steps decreases.
As the convergence is ensured with more criteria in NIMROD, we have observed in our
general use of these softwares that convergence was more robust in NIMROD in the con-
text of our applications. Yet, it should be underlined here that MONOLIX has been used
punctually during my PhD, to explore the space of estimated values, choose well initial
values to be tested in NIMROD, or to compare estimations obtained with NIMROD.
3.3 Application of the mechanistic modeling to Ebola
vaccine trial data: "Dynamics of the humoral im-
mune response to a prime-boost Ebola vaccine: quan-
tification and sources of variation"
The following paper is under preparation for submission.
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ABSTRACT The Ebola vaccine based on Ad26.ZEBOV/MVA-BN-Filo prime-boost immunizations is being evaluated9
in multiple clinical trials. The long-term immune response to the vaccine is unknown, including factors associated10
with the response and variability around the response. We analyzed data from three phase I trials performed by11
the EBOVAC1 consortium in four countries - UK, Kenya, Tanzania and Uganda. Participants were randomized in12
four groups according to the interval between prime and boost immunization (28 or 56 days) and the sequence13
in which Ad26.ZEBOV and MVA-BN-Filo were administered. Consecutive ELISA measurements of the IgG binding14
antibody concentrations against the Kikwit glycoprotein (GP) were available in 177 participants to assess the15
humoral immune response up to 1 year post prime. Using a mathematical model for the dynamics of the humoral16
response, from 7 days after the boost immunization up to 1 year after the prime immunization, we estimated the17
durability of the antibody response and the inﬂuence of diﬀerent factors on the dynamics of the humoral response.18
Ordinary diﬀerential equations (ODEs) described the dynamics of antibody response and two populations of19
antibody-secreting cells (ASC), short-lived (SL) and long-lived (LL). Parameters of the ODEs were estimated using a20
population approach. It has been estimated that half of the LL ASCs could persist at least ﬁve years. The vaccine21
regimen signiﬁcantly aﬀected the SL ASCs and the antibody peak but not the long-term response. The LL ASCs22
compartment dynamics diﬀered signiﬁcantly by geographic regions analyzed, with a higher long-term antibody23
persistence in European subjects. These diﬀerences could not be explained by the observed diﬀerences in cellular24
immune response.25
IMPORTANCE The Ebola virus disease epidemic of 2014-2016 has caused 11 310 deaths in Guinea, Sierra Leone26
and Liberia. As prevention measures did not completely control the disease and no treatment is available yet,27
research has focused on accelerating the development of preventive vaccines. Combining diﬀerent vector-based28
vaccines in prime-boost immunizations could induce a long-term response, assessed through binding antibody29
concentrations to Ebola virus GP. Using data from phase I trials in East African and European subjects, the dynamics30
of the humoral immune response following a boost immunization were modeled. We found that half of the LL31
plasma cells, which are responsible for the persistence of antibodies, could sustain at least ﬁve years after the32
boost immunization. Moreover, the vaccine regimens aﬀect only the early humoral immune response after the33
boost immunization, while long-term antibody concentrations are signiﬁcantly higher in European subjects than in34
East African ones.35
KEYWORDS: Ebola, vaccine, mechanistic modeling, antibody response36
Following the recent outbreak of Ebola virus disease (EVD) in West Africa that caused 28 616 cases and 1137 310 fatalities (1), the clinical development of several Ebola vaccine candidates has been accelerated. Among38
the vaccine candidates, a heterologous prime-boost strategy combining immunizations with adenovirus type 2639
(Ad26.ZEBOV, Janssen Vaccines and Prevention) and modiﬁed vaccinia Ankara (MVA-BN-Filo, Bavarian Nordic®) is40
being developed by Janssen. Prime-boost regimens are expected to be more immunogenic than prime-only vacci-41
nation strategies (2) (3) (4) (5). In the case of the heterologous Ad26.ZEBOV/MVA-BN-Filo prime-boost vaccination42
regimen, non-human primate studies have shown full protection in vaccinated animals following lethal Ebola virus43
challenge (6). Diﬀerent immunization regimens using Janssen’s vaccine candidate have been evaluated in phase 144
to 3 clinical trials. In particular, we will focus here on three phase 1 trials performed by the EBOVAC1 consortium45
on healthy adult volunteers in four countries - United Kingdom (7) (8), Kenya (9), Uganda and Tanzania (10). The46
consortium is part of the Innovative Medicines Initiative Ebola+ programme (11), which aims to assess a novel47
prime-boost preventive vaccine regimen against EVD. Results of the three phase 1 trials showed no vaccine-related48
serious adverse events and persistent levels of IgG binding antibodies in all vaccine recipients.49
One of the potential assets of the Ad26.ZEBOV/MVA-BN-Filo vaccine regimens is the establishment of a long-50
term immune response, which is in part characterized by the Ebola virus GP-speciﬁc binding antibody response after51
vaccination. Although no immune correlate of protection has been identiﬁed yet, preclinical studies have shown52
that the peak antibody concentrations post-vaccination are correlated with survival after intramuscular challenge53
in a non-human primate model, which is the closest model to humans (12) (13) (14). Whether circulating antibody54
concentrations also correlate with long term protection is not established, however it is of particular interest to55
quantify the dynamics of the humoral immune response and to estimate the durability of the antibody response.56
We proposed to use a mathematical model to address these questions. We had a unique opportunity to analyze57
the data from the three trials in the context of EBOVAC1, because they were conducted almost simultaneously58
with very similar study protocols. The uniqueness of the data also relied on the large number of consecutive59
immunogenicity measurements following the boost immunization.60
Most of the models that were already developed for the dynamics of the antibody response focused on61
the decline of the antibody concentrations after the peak response. Linear or piecewise-linear decreases of the62
antibody response were ﬁtted to data from a large number of vaccines, including Hepatitis B vaccine (15), combined63
diphteria, tetanus and pertussis vaccine (16) (17), Japanese encephalitis chimeric virus vaccine (18), Hepatitis64
A vaccine (19) (20) and human papillomavirus-16/18 vaccine (21) (22) (23). However, linear mixed models are65
limited in term of biological interpretation. The structure of mechanistic models is based on biology and is able to66
capture non-linear interactions. The estimation of the model parameters gives a quantiﬁcation of the biological67
phenomenon. Only a few within-host models were developed to describe the humoral immune response following68
vaccination. The dynamics of ASCs after vaccinia virus vaccination of human volunteers were described (24) by69
extending a widely known model for the CD8 T cell response (25) (26). However, this model did not account for70
the immunologic hypothesis that antibodies are produced by several populations of ASCs. Indeed, it has been71
suggested that the vast majority of plasma cells generated through immunization are SL cells (27) (28), peaking 772
days after the immunization and lasting very shortly in the organism (28) (29) (30) (31). However, the half-life of73
antibodies was estimated between 20 and 50 days in several studies (32) (33) (34) (35) (36) (37) (38). Therefore,74
the persistence of antibody response, observed to last for several years (39), is expected to be generated by LL75
plasma cells (28) (40) (41) (42) (43). Using long-term data following hepatitis A vaccination (up to 10 years after76
the boost immunization), an ODE-based mechanistic model helped quantifying 3 scales of the humoral response77
dynamics (44), corresponding to the life spans of antibodies (around 20-30 days), and two populations of ASCs (one78
living several months and the other one decades).79
Here, we used the same mechanistic model for the humoral immune response, with two populations of80
ASCs (SL and LL) and the antibody population. Parameters were estimated on data available from three trials81
of the EBOVAC1 consortium, with a 1 year follow-up for participants of the study including up to 9 consecutive82
measurements of antibody concentrations. This model allowed to quantify the dynamics of the humoral immune83
response following diﬀerent prime-boost vaccine regimens.84
RESULTS85
Mechanisticmodel of the immune response. A preliminary analysis was performed to estimate linear trends86
of the antibody concentrations decrease from 21 days after the boost immunization onwards. The method and87
results of this analysis are detailed in Appendix A3. This analysis showed in particular the need to model two88
phases of antibody decline. A mechanistic model was used to ﬁt these dynamics. Based on previous work in89
immunology (45) and modeling (24) (44), we made the hypothesis that antibodies are produced by two distinct90








Following this result, we explored if the estimated diﬀerence between East African and European subjects could188
be explained by the magnitude of the cellular CD4+ T cell response. It came from the hypothesis that diﬀerences in189
the pathogens to which individuals are exposed during everyday life could have an eﬀect on the cellular response190
(50). As CD4+ T cells are required for the humoral immune response, we made the hypothesis that the diﬀerence191
between East African and European subjects could be mediated by a diﬀerence in the T helper response early after192
the boost immunization. In the mechanistic model, the diﬀerence was estimated on parameter φL : the mean value193
over European subjects was higher than in East African subjects. As there was also a random eﬀect on φL , we were194
able to compute the individual estimated value of this parameter. We computed the correlation between the value195
of φL and the percentage of CD4
+ T cells producing at least one of the three cytokines IL2, IFNγ or TNFα at diﬀerent196
time points: after prime prior to boost immunization, 7 and 21 days after the boost immunization. Results are197
displayed in Fig 9. We did not observe any clear relationship between the CD4+ T cell percentages and φL values.198
Pearson correlation coeﬃcients were only signiﬁcantly diﬀerent from zero at 7 days after boost immunization, with199
a moderate value of 0.2. To further explore the hypothesis that the diﬀerence of value of φL could be mediated200
by the T helper response, we introduced the percentage of the CD4+ T cell producing cytokines 7 days after the201
boost immunization in the mechanistic model as a covariate on φL . Eﬀect of the covariate was added and tested202
separately on φL , with or without the geographic region variable, as shown in equation 6 from the materials and203
methods section. Without the geographic region variable, the estimated eﬀect of the CD4+ T cell was signiﬁcant204
(p-value = 0.03), but the likelihood of the model was much lower than for the model including the geographic region205
variable without the CD4 variable (136.34 versus 171.97). In a model including both geographic region and CD4206
variables, the estimated eﬀect of the CD4+ T cell response was not signiﬁcant (p-value 0.64). Overall, these results207
suggested that the diﬀerence of φL value between the geographic regions could not be explained by the measure208
of the percentage of CD4+ T cells producing at least one of the cytokines IL2, IFNγ or TNFα 7 days after the boost209
immunization.210
DISCUSSION211
The mechanistic model accounting for two populations of ASCs allowed to quantify the dynamics of the antibody212
response following diﬀerent prime-boost vaccine regimens. In particular, it allowed to estimate a lower bound213
of the durability of the antibody response through LL plasma cells. Moreover, we were able to identify several214
factors inﬂuencing the response to vaccine. We found that vaccine regimen impacts the magnitude of the early215
antibody response through the dynamics of the SL ASCs, but has no eﬀect on the LL ASCs and thus on the216
long-term persistence of antibodies. It suggests a minor impact of the interval between the prime and the boost217
immunizations on the long-term level of the binding antibodies.218
The dynamics of LL ASCs were estimated to diﬀer by geographic region, inducing a higher long-term level of219
antibodies in European subjects compared to East African ones. Several factors could contribute to the geographic220
eﬀect, such as HLA subtypes, nutritional status, co-infections or pre-existing immunity. Demographic factors could221
also play a role in this diﬀerence, although no signiﬁcative eﬀect of sex and age was found on the decrease of222
the antibody concentrations in the linear mixed model or on the parameter φL (see appendix A3 for details). The223
absence of association between this diﬀerence and circulating CD4+ T cells producing cytokines does not exclude224
alternative eﬀects of the CD4+ T cells on the humoral response, for example a link with plasma cells and antibody225
production at the level of the lymphoid organs. The diﬀerence of immune response between diﬀerent geographic226
regions has already been identiﬁed in some other vaccination studies, even if the vast majority of vaccination227
programs in Africa have had a tremendous positive public health impact. The eﬃcacy of Bacille Calmette-Guérin228
vaccination was observed to be lower in African infants compared to European ones (51). West Africans showed229
lower T-cell response following vaccination which an HIV vaccine candidate compared to South Africans and North230
Americans (5). The eﬃcacy of the licensed yellow fever vaccine 17D was also found to be lower in African population231
compared to European one; an activated immune environment prior to vaccination was hypothesized (49). In232
the case of Ebola vaccine, as the protective level has not been determined yet, we do not know if the diﬀerence233
in antibody concentrations has implications on the eﬃcacy of the vaccine. Yet, the observed diﬀerence in long-234
term antibody responses between East African sites and the UK site is an interesting outcome that would justify235

additional mechanistic studies to identify which factors contribute to these diﬀerences.236
The fact that immune memory is not considered in the model represents a limitation, especially in term of237
prediction of the response to exposure to wild type virus. However, the role of the memory response and the238
immune response levels required for protection are not known at the moment. Moreover, the main limitations for239
the estimation of the model are the low number of subjects as the data was generated in phase 1 trials, the lack240
of data on the number of plasmablasts, and the lack of measurements beyond 1 year. However, the statistical241
analysis using a population approach allowed to determine a lower bound of the long-term response.242
These results will beneﬁt from additional data coming from phase 2 studies to conﬁrm the robustness of the243
long-term response. Several studies showed that antibody responses in humans do not reach steady state levels244
until approximately 2-3 years after infection or vaccination (45). More data should also allow a better identiﬁcation245
of the half-life of the two ASC populations and will increase the statistical power of the analysis. Moreover, the246
diﬀerences between geographic regions will be reﬁned using data from West African subjects. Additional studies247
looking at the eﬀect of other factors on the immune response, such as malaria co-infection, will help explaining248
these potential diﬀerences.249
In conclusion, this ﬁrst modeling study estimates promising binding antibody responses to prime-boost250
regimens combining Ad26 and MVA in an Ebola vaccine. While the long-term antibody persistence is not found to251
be inﬂuenced by the vaccine regimen in the model, the geographic region could potentially impact the long-term252
dynamics by its eﬀect on dynamic parameters associated to the LL ASCs.253
MATERIALS AND METHODS254
Ethics statement. The UK trial protocol and study documents were approved by the UK National Research255
Ethics Service. The Kenya trial protocol and study documents were reviewed and approved by the local Ethics256
Committee, and the Kenyan regulatory authority. The Uganda/Tanzania trial protocol and study documents were257
reviewed and approved by the Tanzanian Medical Research Coordinating Committee of the National Institute for258
Medical Research; the Tanzania Food and Drugs Authority; the Uganda Virus Research Institute Research and259
Ethics Committee; the Uganda National Council for Science and Technology; the Uganda National Drug Regulatory260
Authority and the Ethics Committee of the London School of Hygiene and Tropical Medicine. These trials were261
conducted in accordance with the principles of Good Clinical Practice and the Declaration of Helsinki, and all262
participants gave formal, written consent before undergoing any trial-related procedure.263
Immunogenicitymeasurements. We analyzed data from three randomized, observer-blind, placebo-controlled,264
phase I trials in four countries on healthy volunteers aged 18 to 50. They aimed at assessing the safety and tol-265
erability of two novel candidate Ebola vectors combined in diﬀerent prime-boost regimens. The ﬁrst vector is a266
monovalent, recombinant, E1/E3-deleted, replication-defective, adenovirus type 26 vector vaccine encoding Ebola267
virus Mayinga variant GP (Ad26.ZEBOV). It was produced in PER.C6 human cells and injected in single dose at268
concentration of 1 × 1011 viral particles/mL. The second vector is a recombinant, replication-defective, modiﬁed269
vaccinia Ankara vector vaccine (MVA-BN-Filo) expressing Mayinga variant GP, Sudan virus Gulu variant GP, Marburg270
virus Musoke variant GP, and Tai Forest virus nucleoprotein. It was produced in chicken embryo ﬁbroblasts and271
injected at a concentration of 2 × 108 median tissue culture infective dose (TCID50)/mL.272
Trials were realized in UK, Kenya and Uganda/Tanzania. Results of the UK trial were described in (7) and (8).273
Within each trial, eligible participants were equally randomized into four vaccination regimens (within each they274
received active vaccine or placebo in a 5:1 ratio): two with MVA-BN-Filo as a prime vaccine on day 1 followed275
by Ad26.ZEBOV on day 29 or day 57 (MVA/Ad26 D29 and MVA/Ad26 D57) and two with a prime immunization276
of Ad26.ZEBOV at day 1 boosted by MVA-BN-Filo on day 29 or day 57 (Ad26/MVA D29 and Ad26/MVA D57). In277
UK, there was an additional open-label group receiving Ad26.ZEBOV on day 1 followed by MVA-BN-Filo on day278
15. This arm was not included in the analysis as this regimen was not realized in East African countries. We279
included in the analysis only subjects who received both prime and boost immunizations, which corresponded280
to a total of 177 subjects over all groups and countries. Subjects were followed up to 1 year after receiving281
the prime immunization, with consecutive immunogenicity assessments performed on blood samples. These282
samples were taken before prime and boost immunizations, 7 days after prime and boost immunizations and283
21 days after the boost immunization. Subjects allocated to groups receiving a boost immunization at day 57284

The corresponding ordinary diﬀerential equations are the following:308
dS
d t
= −δSS (1)309
dL
d t
= −δLL (2)310
dAb
d t
= θSS + θLL − δAbAb (3)311
with δ corresponding to decay rates and θ production rates. The equation for the antibodies dynamics can be312
written as:313
dAb
d t
= φSe
−δS t + φLe
−δL t − δAbAb (4)314
with φS = θSS0 and φL = θLL0, where S0 = S (t = 0) and L0 = L(t = 0) are the initial conditions at 7 days after the315
boost immunization. As SL and LL ASCs populations were not observed, θS and S0 could not be identiﬁed separately316
(and so were θL and L0). The initial condition Ab(t = 0) is given by the data (measure at 7 days after the boost317
immunization). Among the 177 subjects, only 1 did not have a measure of the antibody concentration 7 days after318
the boost immunization. The value was imputed by using the mean value of his/her group of vaccination in his/her319
trial, i.e., the mean value of Kenyan subjects in group MVA/Ad26 D29. Finally, we estimated the ﬁve following320
biological parameters: ξ = (φS , δS ,φL , δL , δAb ).321
For the statistical model, as described in (52), the parameters ξl , l = 1..5 are transformed using a logarithm322
transformation to ensure positivity of production and decay rates. Moreover, a mixed-eﬀect model was introduced323
on each parameter to account for between-subject variations and possible covariates. Value of parameter ξ˜l = l n(ξl )324
for each subject i can be written:325
ξ˜il (t ) = ξ˜l0 + β l z
i
l + u
i
l (5)326
where ξ˜l0 is the intercept and represents the mean ln-transformed value of parameter ξl across the population, β l327
is a vector of regression coeﬃcients, z i
l
is a vector of ne explanatory variables and u
i
l
is an individual random eﬀect,328
following a centered normal distribution with variance ω2
l
. Random eﬀects were independent from each other329
and applied on a subset of q biological parameters. In practice, after selection (see section Parameters estimation330
for the model selection method), we applied random eﬀects on the following parameters: φS , φL and δAb . We331
assessed the eﬀect of ne = 3 explanatory variables on all parameters except δAb : the order of immunization (binary332
variable equal to 0 when the subject receives a prime with MVA-BN-Filo boosted by Ad26.ZEBOV, 1 if the subject333
receives Ad26.ZEBOV then MVA-BN-Filo), the interval between the two immunizations (binary variable equal to 0334
when the subject receives a prime-boost regimen with an interval of 28 days, 1 when the interval is of 56 days), and335
the geographic region (binary variable equal to 0 in Europe and 1 in East Africa). Additionally, we also assessed336
the eﬀect of the cellular response as an explanatory variable. This was done by considering the percentage of337
CD4+ T cells producing cytokines 7 days after boost immunization. The variable CD4i (boost + 7day s) was added to338
the vector z l of explanatory variables, and its eﬀect was estimated on parameter φL . Values of βgr and βCD4 were339
estimated in :340
φ˜iL(t ) = φ˜L0 + βgr geog r aphi c_r eg i on
i
+ βCD4CD4
i (boost + 7day s) + u il (6)341
with CD4i (boost + 7day s) the percentage of CD4+ T cells producing cytokines 7 days after the boost immunization342
in participant i .343
For the observation model, we had access to immunological measurements of IgG binding antibodies concen-344
trations against the Kikwit GP in all studies. We assumed there was a measurement error normally distributed on345
the l og10 value of the antibody concentrations. In practice, we assumed we observe for patient i at discrete time j , :346
Y (t i j ) = l og10(Ab(t i j )) + ǫi j (7)347
with348
ǫi j ∼ N(0,σ
2
Ab ). (8)349
ǫ being an additive normally distributed measurement error.350
Parameters estimation With the three layers of the mechanistic model, the estimation problem corresponds351
to the determination of parameters intercepts, regression coeﬃcients, standard deviations of random eﬀects and352
standard deviations of measurement errors. The vector of parameters θ can be written as :353
θ = [(ξ˜l0 )l=1..nb , (β l )l=1..ne , (ωl )l=1..q , (σl )l=1..M ] (9)354
Estimation was made using NIMROD software, available at355
http://etudes.isped.u-bordeaux2.fr/BIOSTATISTIQUE/NIMROD/documentation/html/index.html. It uses a maximum-356
likelihood approach (53) with a Newton-like algorithm (54) which approximates the Hessian by using ﬁrst derivatives357
of the likelihood. Several criteria ensured the convergence of the algorithm. Moreover, we could account for358
information on parameters, obtained from biological knowledge and previous estimations in the literature, by359
adding a prior distribution on these parameters. This led to the determination of the Maximum a Posterior (MAP)360
estimator through the maximization of a penalized likelihood (55). In practice, we used a normal prior distribution361
on the ln-transformed population mean value of biological parameters ξ˜l0 . Some previous work showed that362
antibodies half-life could vary between a few weeks to a couple of months. Studies of intravenous IgG preparations363
reported half-life around 20 to 30 days (32) (33), while studies of passive immunity with maternal transmission364
of antibodies to infants have reported half-life varying from 20 days (34) to 35-50 days (35) (36) (37) (38). These365
studies also highlighted the inter-individual variability over the half-life of antibodies, as well as the possible366
eﬀect of geographic regions. We used an informative prior distribution on δ˜Ab0 such that mean antibody half-life367
would be 45.2 days, and the variance was chosen such that the 5-95 quantiles of the distribution were 6 days -368
9 months. Additional sensitivity analyses were performed with a much lower variance on the prior distribution369
implying 5-95 quantiles of the a priori distribution to be 34-51 days. We used non informative prior distributions370
on parameters φ˜S0 and φ˜L0 as we did not have any information on their possible value: mean value of the ln-371
transformed parameters is taken equal to 0, with standard deviation equal to 10. We used prior distributions372
on δ˜S0 and δ˜L0 . It helped constraining the estimation such that δS0 > δL0 as expected by the deﬁnition of the SL373
and LL populations. We used a large prior distribution on δ˜S0 as we did not know exactly the time scale of their374
half-lives. Mean value corresponded to a half-life of 1.88 days, with 5 - 95 quantiles equal to 0.0005 day and375
7000 days. Parameter δL was expected to be close to 0, but as data were collected up to 1 year after the prime376
immunization, we did not expect the model to be able to distinguish a half-life of more than a few years. To account377
for this constraint, we used a prior distribution with a mean value corresponding to a half-life of 1.2 year, and 5 - 95378
quantiles corresponding to half-lives of 40 days and 14 years. Table in Appendix A2 sums up the information on379
the prior normal distributions.380
Selection of the model random eﬀects and covariates was realized by performing estimation on several models381
that were compared according to two criteria: log-likelihood (to be maximized) and approximation of the likelihood382
based cross-validation criterion (LCVa) (48) (to be minimized). We proceeded in the following way: we ﬁrst estimated383
the model parameters using several combinations of 2 random eﬀects (one on the SL compartment, i.e., either on384
φS or δS and one on the LL compartment). We selected the best combination and then added a random eﬀect385
on δAb , which considerably improved the model. The variability on parameter δL was complicated to capture:386
δL has an eﬀect mainly on the late dynamics of the antibodies and data is not available beyond 1 year after387
the prime immunization. It brought us to compare only two combinations of three random eﬀects: on φS , φL388
and δAb and on δS , φL and δAb . Using model criteria, we kept the combination corresponding to the best model,389
namely the one with random eﬀects on φS , φL and δAb . For the covariate selection, we proceeded with a backward390
stepwise approach. First, the model was estimated with all covariates (order, interval and geographic region) on all391
parameters except δAb . Covariates were removed one by one: in particular, at each iteration i , the less signiﬁcant392
covariate Zk was determined using the p-value of the Wald test and removed. Model criteria ensured that the393
model was not worse without the covariate Zk compared to the model including Zk . At the next iteration, the394
model did not contain covariate Zk . The least signiﬁcant covariate Zk+1 was removed in a similar way. These steps395
were repeated until only signiﬁcant covariates that could not be removed without altering the performance of396
the model were kept. Sensitivity analyses were realized: in particular, we estimated ﬁrst the model with only the397
geographic region covariate on all parameters and applied the backward stepwise approach. Then we added the398

immunization: this time point was redeﬁned as the origin of time. More precisely, for groups receiving boost at day414
29, data were rescaled from day 50 and available measurements were then at day 0, 130, 190 and 310. For groups415
receiving boost at day 57, data were rescaled from day 78 with available measurements at day 0, 102, 162, 282.416
As two observation points (at least) were needed before and after the value of τ to estimate the two slopes in all417
groups, we chose τ = 150 days on the rescaled time. Covariates such as age and BMI were centered around the418
mean value of the study population. We also used the variable relative to vaccine regimens (order and interval) and419
geographic settings. This last categorical variable was either the geographic region (=0 for Europe and 1 for East420
Africa) or the trial (=0 for UK, 1 for Kenya, 2 for Uganda/Tanzania). Finally, the vector of covariates was :421
Z = (age, sex ,BMI , or der , i nt erv al , geog r aphi c_set t i ng , or der ∗ i nt erv al ) (10)422
We estimated the eﬀect of covariates Z on the peak value of antibodies (intercept) and on the decreasing slopes of423
antibody concentrations. For individual i at rescaled time j, we write the corresponding antibody concentration Abi j .424
Linear mixed models can be written as :425
(SS ) : l og10(Abi j ) = β0 + γ0i + β1t i j + β
T
covZi + β
T
covt
Zi t i j + ǫi j (11)426
(CS ) : l og10(Abi j ) = β0 + γ0i + β
T
covZi + βb t i j 1{t i j <τ } + β
T
covb
Zi t i j 1{t i j <τ } (12)427
+βa t i j 1{t i j ≥τ } + β
T
cova
Zi t i j 1{t i j ≥τ } + ǫi j428
where 1{t<τ } and 1{t ≥τ } are equal to 1 when t < τ and t ≥ τ respectively, 0 otherwise. In both cases, ǫi j ∼ N(0,σ
2).429
We ﬁrst realized backward selection on SS model using the geographic region variable. At each step, covariate with430
the highest p-value of Student test for β (> 0.05) was removed from the model. Performance of the models was431
assessed with Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). At the end of this ﬁrst432
selection, CS model was estimated, using only selected variables. At this point, no additional selection was needed.433
In the ﬁnal selected model, we also evaluated the trial variable instead of the geographic region.434
After selection process, the best SS model was the following:435
l og10(Abi j ) = β0 + γ0i + βage age i + βor der or deri (13)436
+ βi nt erv al i nt erv al i + βgr geog r aphi c_r eg i on i437
+ β1t i j + βi nt erv al t i nt erv al i t i j438
+ βgrt geog r aphi c_r eg i on i t i j + ǫi j439
Variables age, order, interval and geographic region have a statistically signiﬁcant eﬀect on the value of antibody440
concentration 21 days post boost, and only variables interval and geographic region have a signiﬁcant eﬀect on the441
decreasing slope of antibody concentration. Using a CS model signiﬁcantly improved the BIC criterium (BIC of SS442
model = 660.5, BIC of CS model = 532.7). However, using the trial variable instead of the geographic region variable443
improved the AIC criterium but not the BIC one (AIC/BIC of CS model with geographic region variable = 473.8/532.7,444
AIC/BIC of CS model with trial variable = 463.6/536.0). Table 3 shows the results of the CS linear mixed model445
using the trial variable. The biphasic decay is well captured by this model, as it can be seen that the decrease is446
estimated to be stronger before 150 days post boost than after, for all groups in all trials. Overall, we see that447
antibody concentrations have similar values 21 days after boost immunization across countries, with higher values448
when subjects are boosted at day 57. The decrease is lower in European subjects compared to East African ones,449
both before and after 150 days after boost immunization. It can be noted that subject characteristics BMI and sex450
were not statistically associated to antibody concentrations, and age was only associated to the concentration451
21 days after boost immunization but not the decrease. Adjusted on other covariates, an increase of 10 years in452
age induces a reduction of 0.10 log10 of antibody concentration at 21 days after boost immunization (conﬁdence453
interval -0.17;-0.038), and in the trials population, 50% of the subjects were aged 22-35 years. It is clinically less454
important than the order of vaccine immunizations, as the MVA/Ad26 regimen compared to the Ad26/MVA induces455
higher concentrations at 21 days after boost immunization of 0.18 log10 (conﬁdence interval 0.086;0.28) and a456
boost at day 57 compared to boost at day 29 induces higher concentrations at 21 days after boost immunization of457
0.27 log10 (conﬁdence interval 0.15;0.38).458
TABLE 3 Results of the CS linear mixed model
Europe East Africa
UK Kenya Uganda/Tanzania
Antibody concentrations 21 days post boost
(in log10 ELISA units/mL)
Group MVA/Ad26 D29 3.94 [3.81;4.07] 3.80 [3.67;3.93] 3.69 [3.67;3.93]
Group MVA/Ad26 D57 4.21 [4.08;4.34] 4.07 [3.94;4.20] 3.96 [3.94;4.20]
Group Ad26/MVA D29 3.76 [3.63;3.89] 3.62 [3.49;3.75] 3.51 [3.49;3.75]
Group Ad26/MVA D57 4.03 [3.90;4.16] 3.89 [3.76;4.01] 3.78 [3.76;4.01]
Slope value before 150 days post boost
(in log10 ELISA Units/mL per 30 days)
Group MVA/Ad26 D29 -0.075 [-0.10;-0.048] -0.20 [-0.23;-0.17] -0.17 [-0.19;-0.14]
Group MVA/Ad26 D57 -0.15 [-0.18;-0.12] -0.28 [-0.31;-0.25] -0.24 [-0.27;-0.21]
Group Ad26/MVA D29 -0.075 [-0.10;-0.048] -0.20 [-0.23;-0.17] -0.17 [-0.19;-0.14]
Group Ad26/MVA D57 -0.15 [-0.18;-0.12] -0.28 [-0.31;-0.25] -0.24 [-0.27;-0.21]
Slope value after 150 days post boost
(in log10 ELISA Units/mL per 30 days)
Group MVA/Ad26 D29 -0.038 [-0.049;-0.027] -0.12 [-0.13;-0.11] -0.089 [-0.10;-0.078]
Group MVA/Ad26 D57 -0.086 [-0.098;-0.074] -0.16 [-0.18;-0.15] -0.14 [-0.15;-0.12]
Group Ad26/MVA D29 -0.038 [-0.049;-0.027] -0.12 [-0.13;-0.11] -0.089 [-0.10;-0.078]
Group Ad26/MVA D57 -0.086 [-0.098;-0.074] -0.16 [-0.18;-0.15] -0.14 [-0.15;-0.12]
This preliminary analysis showed the importance of modeling the biphasic decay of antibody concentrations,459
as a CS model was better than a SS one. Moreover, it highlighted the diﬀerences in immune response between460
East African and European subjects, especially on the decreasing slope of antibody concentrations. Finally, no461
subject-speciﬁc factors had an eﬀect on the dynamics of antibody concentrations except for age, but with a lower462
impact than geographic region and vaccine-related factors. Only these last factors were considered to potentially463
aﬀect the dynamics of the humoral immune response in the mechanistic model.464
A ﬁnal check was realized after parameter φL of the mechanistic model was estimated to be signiﬁcantly465
diﬀerent between East African and European subjects. As the proportion of women included in the UK trial is466
higher than the one in East Africa (64% versus 29% and 20%) and the average age is 10 years higher in the UK trial,467
as seen in Table 1, the variables age and sex were tested separately as additional covariates on the parameter φL ,468
with or without the geographic region variable. Without the geographic region variable, the estimated eﬀect of469
age and sex was not signiﬁcant (p-value = 0.54 and 0.23 respectively). With the geographic variable, the estimated470
eﬀect of sex was not signiﬁcant either (p-value = 0.46) and the eﬀect of age was signiﬁcant (p-value = 0.045) but471
with a low magnitude compared to the eﬀect of geographic region (β = 0.024 for a 10-years diﬀerence versus a472
diﬀerence of β = 1.36 between European and East African subjects). These results suggested that the diﬀerence of473
φL value between the geographic regions could not be explained by potential confounding demographic factors.474
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3.4 Discussion
3.4.1 Additional insights
We have shown that a simple model of the humoral immune response is able to capture
the dynamics of the antibody concentrations and some of the factors associated with
their variability. The obtained results could be strengthened in several ways. Additional
measurements with a longer follow-up could help refining the estimation of the LL ASCs
half-life. This could also help confirming the different levels at which antibodies are
sustained in European and African participants. This estimation refinement should be
made possible by a follow-up of 4 years on subjects enrolled in the EBOVAC1 Sierra
Leona trial and some of the African subjects enrolled in EBOVAC2.
Moreover, it would be interesting to apply the same model to data collected in the
consortium (to maintain consistency between the clinical protocols), but on other subjects.
In particular, the Ad26/MVA was tested on a number of subjects enrolled in phase 2 trials
in Europe and Africa. Using the antibody concentrations data from all these subjects will
help refining the estimation of the parameters of the model and the effect of the factors
on the variability of the response. Also, a clinical trial was conducted in Sierra Leone
under the EBOVAC1 consortium. As we found differences of dynamics between European
and East African subjects, it would be beneficial to check if West African subjects also
have different antibodies dynamics induced by the parameters values by using the data
generated in both the EBOVAC1 Sierra Leone and the EBOVAC2 trials. It would help
determining if the observed dissimilarities in antibody concentrations after one year of
follow-up are mainly between European and African subjects, or reveal differences at
a more regional level. This could be explained by other region-specific environmental
factors, and/or genetic and/or co-infection parameters. To assess the effect of co-infection,
it would be useful to work on the sub-study of the Sierra Leone measuring the presence
of malaria infection at baseline. This could be added as a covariate which effect can be
tested on parameters of the mechanistic model. The effect of HIV infection could also
be assessed by using data generated in the EBOVAC2 clinical trial, as an HIV+ cohort
has been recruited. Moreover, children have been recruited in both the EBOVAC1 Sierra
Leone clinical trial and EBOVAC2 in West Africa. Using these data would help estimating
the effect of age on the immune response to immunizations. Finally, some participants
enrolled in the phase 2 trials in Africa received their boost immunizations at different
times than the one initially planned by the original clinical design; this heterogeneity
could be useful in the modeling approach to understand more deeply the impact of the
delay between immunizations on the immune response.
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3.4.2 Through more complete models of the humoral immune
response
The modeling work of the immune response to Ebola vaccine was initiated by using
a mechanistic model with only 3 compartments (two compartments of ASCs and a com-
partment of antibodies). Although simple, this model induced good fit of the antibody
concentrations data, helped quantifying the dynamics of the humoral response and gave
insights into the potential variability factors. However, we are aiming for a more com-
plete model of the immune response. This would help refining the quantification of the
dynamics of the response and understanding the role of the different populations of B lym-
phocytes in the establishment and maintenance of the response. In particular, it would
be interesting to capture the proliferation phase of the B lymphocytes following a vac-
cine immunization and their differentiation into memory cells. Overall, a more complete
model would give better understanding of the mechanisms of action of the immunological
memory and the impact of the different vaccine regimens on the immune response: this
could help determining optimized vaccine regimens and predicting the effect of a third
injection/a natural infection by EBOV, especially in African populations.
Investigation of more complete models of the humoral immune response has been re-
alized with Irene Balelli, during her post-doc project. First, due to its role in secondary
responses, immunological memory should be included in the model. Moreover, heterol-
ogous prime-boost regimens rely on the use of different vaccine platforms, which could
induce different reactions of the immune system; antigen should also be included in the
model. Finally, as ASCs are produced by differentiation of the naive B cells, these should
be added to the model as well. A graphic representation of a more complete model of the
humoral immune response is shown in figure 3.2A. This model is however very complex
due to its large number of compartments and parameters. A simplified version without
the naive compartment was considered (see figure 3.2B): this model was shown to induce
similar dynamics with less parameters, so it can improve the initial model without adding
too much complexity in it. The corresponding equations are the following:
dA
dt
= −δAA,
dM
dt
= ρAA− (µMS + µML)AM − δMM,
dS
dt
= µMSAM − δSS,
dL
dt
= µMLAM − δLL,
dAb
dt
= θSS + θLL− δAbAb.
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A: Complete mechanistic model of the humoral immune response
B: Simplified mechanistic model of the humoral immune response
Figure 3.2 – Models of the humoral immune response. A: antigen, N: naive B cells, M:
memory B cells, S: short-lived ASCs, L: long-lived ASCs, Ab: antibodies.
Courtesy of I. Balelli.
In this model, as the vaccine platforms are not recombinant, antigen decrease expo-
nentially. The presence of antigen (A) artificially triggers the generation of memory cells
(M). This compartment contains actually both activated B cells specializing against the
antigen and memory B cells when the reaction is over. Under the presence of the antigen,
memory B cells differentiate into either short-lived ASCs or long-lived ones (L). The com-
partments of short and long-lived ASCs are not renewed. These cells produce antibodies
and die at different rates, in the same way as in the model presented in the article section
3.3.
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Initial analyses of this model included identifiability investigation, sensitivity analysis
and calibration of the model using the antibody concentrations data from EBOVAC1
clinical trials conducted in UK, Kenya and Uganda/Tanzania. The next step is the
estimation of the parameters using additional data to quantify the dynamics of the model.
In short, structural identifiability analysis showed that we can reach local identifiability
by observing compartments M, S+L and Ab. It means that the antibody concentrations
data only is not sufficient to correctly estimate the parameters of the model. However,
this identifiability analysis makes the hypothesis that we wish to estimate the values
of all parameters using "perfect" data (observable at every time with no measurement
error). This is obviously not the case in real data, available at sparse time points with a
measurement error. Moreover, a population approach aims at estimating distributions of
parameters, which is different from a patient-by-patient approach where trajectories are
estimated one-by-one. Sensitivity analysis has allowed to determine the relative variation
of the antibody concentrations trajectory with respect to the parameters of the model
during time. It helps understanding which parameters have more impact on the variation
of the antibody concentrations, and at which moment of the time frame.
Finally, calibration was realized under consideration of previous knowledge on some
parameters and additional hypothesis. Indeed, parameters δS, δL and δAb were already es-
timated. Moreover, some biodistribution information were used for calibrating parameter
δA [Sheets et al., 2008; Hanke et al., 2005]. Parameters ρA, µMS and µML were expected
to be platform-dependent. In particular, calibrated values are such that µMS and µML
are lower with MVA than with Ad26. It can explain why after a single injection of MVA,
antibodies are not detectable, as there are not enough memory cells who differentiate into
ASCs. This calibrated model was also used to predict the effect of a third immunization
one year after the boost immunization and showed for example that in any case the an-
tibody concentrations were increased compared to the second immunization, due to the
presence of LL plasma cells and memory cells, and that the MVA/Ad26/Ad26 regimen
could induce a higher antibody peak than the Ad26/MVA/Ad26 (see figure 3.3). This
work should definitely be confirmed by parameters estimation using additional data gen-
erated in EBOVAC1 and EBOVAC2 consortium, in particular some B cells data generated
from the EBOVAC2 UK subjects.
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A: MVA/Ad26/Ad26 regimen B: Ad26/MVA/Ad26 regimen
Figure 3.3 – Prediction from the calibrated model of the antibody concentrations under
two regimens of vaccination consisting of 3 immunizations at 56 then 365 days
of delay. In the plot, time starts from the second immunization. Courtesy of
I. Balelli.
3.4.3 Through a systems vaccinology approach
The development of vaccine has mainly been empirical until now and there is a consen-
sus on the need for a better understanding of the mechanisms involved in the establishment
of the immune response to drive a more rationale vaccine development. Systems biology is
a promising approach to improve this field of research and has broadly emerged in the last
years [Pulendran et al., 2010; Germain, 2010; Hagan et al., 2015]. It aims at understand-
ing the immune system as a whole entity by accounting for a large number of its actors
and integrating all the newly available data generated thanks to biotechnology progress
(genomic, expression profiling, proteomic, RNA sequencing, ..). Moreover, this approach
is supposed to be quantitative and to be able to assess the respective contributions of
the compartments of the immune response [Germain, 2017]. This kind of approach raises
many challenges, including both the methods for data collection and for the computa-
tional analysis of the complex data sets to identify relationships between the numerous
markers involved.
In vaccine development, aiming for a so-called systems vaccinology approach involves
the inclusion of the information from genes, the microbiome and the environment: as
shown in figure 3.4 and discussed in section 2.2.2.3, they are determinants of the human
physiology, inducing different response to immunizations. In particular, we have shown in
our modeling work how environment variables could be included in a mechanistic model of
the immune response using covariates on the parameters. This approach should also aim
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Figure 3.4 – Systems vaccinology approach. Figure taken from Pulendran [2014]
at including the early immune response following vaccination, for two main reasons. First,
there has been increasing interest in understanding how the innate immune response can
be modified by repeated immunizations and its role in the immune response. The review
of Adams et al. [2016] shows that secondary NK cell responses, which are antigen-specific
and produce more IFNγ, are very likely to happen and affect the immunity. Moreover,
Palgen et al. [2018] have shown that prime and boost vaccine immunizations induced
different phenotypic profiles of innate responses. Also, even though there is still work
to do to understand the mechanisms by which innate immunity affects the generation of
both memory T and B cells, there is evidence that the innate immune system can modify
the protective immunity [Pulendran and Ahmed, 2006]. In addition, there is growing
evidence on the fact that early markers of the immune response can be predictive of
the efficacy of vaccines, or at least of the levels of biomarkers of interest. Only a few
studies identified early innate immune signatures to predict the antibody response, in the
case of yellow fever vaccine [Querec et al., 2009] and influenza vaccine [Nakaya et al.,
2011]. More specifically on Ebola, a study on the rVSV-ZEBOV vaccine showed that 5
early innate markers were correlated with antibody concentrations at day 28 and after
[Rechtien et al., 2017]. These markers included cytokines levels and specific cluster of
innate cells (identified with phenotypic markers). These early signatures identifications
could help rapid screening of vaccines with a quick determination of non responders and
acceleration of the vaccine development pipelines. However, these identifications do not
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necessary explain the mechanisms of immunity establishment.
In an effort of integrative analyses and quantification of the mechanisms of the immune
response, it would be interesting to include the information provided by early markers in
mechanistic models. Several methods could help the integration of this information: a
simple way would be to add covariates on the parameters of the model, as done with the
CD4+ data on the antibody response in the article presented in section 3.3. For example,
after identifying that a cytokine’s concentration, a gene expression level, or a specific
cell type’s percentage at a given time point is associated to the antibody response, we
could use this value as a covariate and test its effect on the parameters of the model.
Let us imagine that the effect is significant on the half-life of the ASCs, but not on
the antibody production rate, then it would mean that the presence cytokine or the
innate cell population in question is associated to a better survival and/or proliferation
of the ASCs, but not to their ability to generate antibodies. This method does not add
complexity to the model itself, but makes a linear hypothesis regarding the association
between the innate response marker levels and the parameters affecting the dynamics
of the adaptive immune response, which could be a limitation of the modeling method.
Another possibility is to model the dynamics of the innate marker and its underlying
mechanisms of the effect on the compartments of the adaptive immune response: this
can be realized by adding an equation to the ODE system, corresponding to the innate
marker compartment, and accounting for its interactions with the other compartments
of the system in the equations. It could eventually lead to a large system of ODEs for
the dynamics of the immune response. However, this option has several drawbacks: the
processes at different levels (genes, molecules, cell populations...) occur at different time
scales. It could induce numerical issues. Moreover, there is some intrinsic stochasticity at
the single-level that cannot be neglected and would not be accounted for in a deterministic
ODE-based model. Finally, this option adds complexity to the model and can induce
identifiability issues, if the data available is not rich enough compared to number of
parameters added to the initial ODE model. Another way to use the gene expression
data would be to obtain information on some unmeasured cell populations: if some genes
are known to be expressed in majority by a population of cell X, their observed expression
Y could be written as in equation (17), by:
Y i(tij) = f(X
i(tij)) + ǫij. (48)
However, this method would request additional estimation techniques to determine func-
tion f and this adds a challenge to the parameters estimation method.
The transcriptomic data could be included by modeling the dynamics of gene expres-
sion after immunizations. Indeed, gene expression happens in two steps: first DNA is
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transcribed into mRNA, then protein production is induced by the translation of the
mRNA. The transcription of the gene DNA can be inhibited or activated by regulatory
proteins (called transcription factors). Gene regulatory networks (GRN) have been widely
used to capture these dynamics and interactions: their structure is constituted of nodes
(genes, proteins) and edges (molecular interactions and relationships). This tool could
be used to analyze the transcriptomic data. However, this kind of analysis raises several
challenges. First, there is some large variability in gene expression, and it cannot be
accounted simply by a perturbation around a population mean. There is a first difficulty
in modeling this system with embedded stochasticity, and several methods have been
developed, including bayesian networks, boolean networks, information theory, ODEs
and piecewise deterministic Markov processes with deterministic trajectories defined with
ODEs [de Jong, 2002; Hecker et al., 2009; Wu et al., 2014]. A major additional difficulty
resides in estimating and inferring the model, both in statistical and computational terms.
Indeed, there has been some work on how to infer GRN [Yu et al., 2004; Herbach et al.,
2017] but it still represents a challenge [Marbach et al., 2010]. Moreover, even if a method
is able to infer the gene network, the information provided should then be included in
a mechanistic model of the biomarkers of interest. This question is far from trivial, and
even if there has been some growing interest on methods for developing models integrating
several types of data [Joyce and Palsson, 2006] there is still no general method and poor
literature on how to integrate GRN modeling into a large-scale mechanistic model of the
immune response.
In any case, the choice of the methodological tools for developing integrative models is
directly related to the data available for the study. In the specific case of Ebola vaccine and
more particularly the EBOVAC consortium, several datasets could provide information
that would feed this kind of integrative model. In particular, NK cells subsets have been
measured in the UK subjects of EBOVAC1 trial. Moreover, omic data will be obtained
from European subjects included in EBOVAC2 trials.
Overall, our computation and modeling tools should be constantly improved to tackle
this effort on integrating the different types of data generated during clinical trials. How-
ever, it should be kept in mind that in humans, the data is collected from blood samples
and corresponds to circulating actors of the immune response. We know that major
aspects of the immune response occur in lymphoid organs [Rappuoli et al., 2017]: for ex-
ample, the differentiation of activated B cells into memory cells happens in the germinal
centers and long-lived plasma cells are believed to migrate quickly to the bone marrow
where they reside. Also, a study in nonhuman primates showed that most of the protec-
tive CD8+ T cells were present in the liver compared to blood [Ishizuka et al., 2016]. This
induces limitations in our understanding of some key mechanisms of the immune response
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in humans. It could be included in the model, by modeling both circulating and tissue-
residing cells in the ODE system, and accounting only for the circulating compartments in
the observation part of the statistical model, but would induces parameters identifiability
issues. Challenges remain in identifying blood signatures which are good predictors of the
immune response occurring in other spatial compartments of the organism [Hagan and
Pulendran, 2017].
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4 Optimizing immune therapies in HIV-
infected patients
Abstract: In this chapter, we explain why immunotherapy is considered for some HIV-
infected patients. In particular, we focus on interventions based on interleukin 7 (IL-7)
injections to help patients recovering acceptable levels of CD4+ T lymphocytes when
antiretroviral therapy is not sufficient. We recall the previous modeling work that was
realized for quantifying the dynamics of CD4+ T lymphocytes following IL-7 injections.
As the mechanistic model has good ability to fit the data and predict the dynamics for
new included patients, tools can be developed for optimizing and adapting the schedules
of injections. In particular, we show that the process can be modeled using a piecewise
deterministic Markov process (PDMP) and the control problem can be reduced to an
impulse problem at the boundary of the state space. Based on theoretical results, this
problem can be solved numerically using the dynamic programming approach by iterating
an integro-differential operator, the so-called Bellman operator, leading to a sequence of
functions converging to the value function. We show how our numerical method can
help determining an optimal protocol of injections which allows administering fewer IL-7
injections than other naive clinical protocols but still maintains the patient at acceptable
levels of CD4+ T lymphocytes.
Key Words: Human Immunodeficiency Virus; immunotherapy; interleukin-7; immune
reconstitution; repeated injections; piecewise deterministic Markov process; impulse con-
trol; dynamic programming; optimal protocols.
4.1 Biological and clinical context
4.1.1 General introduction on HIV
4.1.1.1 HIV epidemic
Since the start of the HIV epidemic more than 30 years ago, there has been 76.1 million
of infections of people worldwide and 35 million of deaths related to AIDS [UNAIDS,
2017]. Prevention and treatment measures have allowed reducing by 16% the number
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of transmission events between 2010 and 2016 and by 48% the number of deaths from
AIDS-related causes between 2005 and 2016. However, HIV/AIDS still represent a major
public health concern. At the end of 2016, approximately 36.7 million people were living
with HIV; during that year, 1.8 million people were newly infected and 1.0 million people
died of AIDS-related causes.
4.1.1.2 HIV infection
HIV is a retrovirus, characterized by a long period between the time of infection and
the development of AIDS during which the immune system fails and eventually allows
opportunistic infections to occur in the organism. Two types of HIV were identified, them-
selves containing several groups. The classification is mainly based on genetic differences.
HIV-1 is present all over the world while HIV-2 is mainly present in West Africa. HIV-1
is related to SIV, which was transmitted either by chimpanzees (groups M, N and O)
or gorillas (group P), probably first to bush meat hunters. Globally, most of the cases
of HIV/AIDS are due to group M virus, which can itself be divided in nine subtypes or
clades, from A to K.
HIV has a spherical structure. The viral envelope is composed by the glycoproteins
gp120 and gp41. It contains a capsid with two single strands of RNA and enzymes
allowing the replication of the virus. This replication requires human cells. In particular,
HIV targets cells from the immune system, especially CD4+ T lymphocytes but also
macrophages and dendritic cells. HIV binds to receptors on the surface of the target cell
through the CD4 receptor, and enters the cell after fusion of the envelope of the virus with
the membrane of the cell. Reverse transcription allows then the conversion of the genetic
material contained in HIV RNA into HIV DNA, which enters the cell nucleus. This viral
DNA is integrated into the DNA of the cell. It allows the virus to use the cell system to
generate HIV proteins. These proteins are assembled with HIV RNA at the surface of the
cell to form new immature HIV. When out of the cell, protease release allows maturation
to a new infectious virus. The whole cycle of replication of HIV is represented in figure
4.1.
Both humoral and cellular responses play their role in the attempt to eradicate HIV,
thanks to antibody production and cytotoxic lymphocytes action. However, the immune
system itself is weakened by the virus, as activated CD4+ T lymphocytes are the most
likely to be infected by HIV. After proliferation, some of these infected cells migrate to
secondary lymphoid organs and can live there for several years. It creates the so-called
HIV reservoirs. As HIV is integrated to their nucleus, it is impossible for the immune
system to detect and eliminate the virus unless it starts to replicate.
The dynamics of the interaction between HIV and the immune system follow three
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Figure 4.1 – HIV replication cycle and type of therapies targeting different steps of this
cycle (AIDS info - NIH, 2017).
clinical phases: a primary infection phase lasting a few weeks after the infection, fol-
lowed by an asymptomatic phase that can last several years and finally the AIDS phase.
Primary infection is characterized by an initial burst of viremia and a fall of the CD4+
T lymphocyte counts. During the asymptotic phase, viral load remains stable and the
number of CD4+ T lymphocytes is small but still acceptable (generally around 500-600
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cells per µL of blood). Without any treatment, patients evolve to the AIDS phase after
an average of 10 years. During this final phase, the immune system collapses, with a
particular drop of the CD4 counts, and the viral load sharply increases. Patients usually
die from opportunistic infections.
4.1.1.3 Combination Antiretroviral Therapy
Since the approval of the first antiretroviral molecule in 1987 by the FDA, a large num-
ber of treatments with different mechanisms of action have been introduced, now offering
many possibilities to clinicians for treating HIV-infected patients. The first treatments
were monotherapies based on Nucleotide Reverse Transcriptase Inhibitors (NRTI), a class
of molecules interrupting HIV replication cycle via competitive inhibition of HIV reverse
transcriptase and termination of the DNA chain (step 3 of figure 4.1) [Fischl et al., 1987].
They were shown to help decreasing the rate of progression to AIDS and increasing the
CD4 counts in asymptomatic adults [Volberding et al., 1990] but drug resistances were
also observed in early and late stages patients [Larder et al., 1989; Kozal et al., 1994].
Later, two new classes of antiretroviral molecules were introduced: the Protease Inhibitors
(PI) which prevent viral formation after viral budding from infected cells (step 7 of figure
4.1), and the Non-Nucleotide Reverse Transcriptase Inhibitors (NNRTI), blocking step
3 of figure 4.1 as NRTIs. This significantly improved treatment strategies against HIV
thanks to combination Antiretroviral Therapy (cART), which uses a minimum of two
drugs from different classes and can help reducing the risk of mutations. More recently,
two other types of molecules were made available: the Fusion Inhibitors (FI), in 2003,
which prevent the entry of the virus in the target cell (step 2 of figure 4.1) and the Inte-
grase Inhibitors (INI), in 2007, preventing viral DNA to integrate the host DNA (step 4
of figure 4.1). Several clinical trials have shown the increased efficacy of cART compared
to monotherapies [Hammer et al., 1996; Delfraissy et al., 2008; Bierman et al., 2009]. The
choice of the combination has evolved with time, and recommendations are currently pub-
lished annually by health institutions, giving guidelines for clinical practice. In France,
tritherapy is recommended to contain 2 NRTIs and a third agent, either a NNRTI, an INI,
a PI alone or combined with ritonavir to improve pharmacokinetics properties [Morlat,
2017]. These regimens are preferred because of their efficacy, tolerability and they are
easy to use.
Overall, cART have improved life expectancy [Hammer et al., 1996; Autran et al.,
1997; Palella Jr et al., 1998] and a large number of the patients who benefit from cART
manage to control the virus and reconstitute their immune system [Battegay et al., 2006].
This has led to major improvement in reducing morbidity and mortality in HIV-infected
patients [Young et al., 2012]. However, in some cases, we can observe either a virological
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failure or an immunological failure. The virological failure is defined as the inability of
the patient to control the virus and to reduce the viral load. In that case, the treatment
should be modified, depending on some other parameters, such as the value of given
biomarkers, the presence of other co-morbidities or the patient’s habits. The reason for
this failure should also be investigated: it could be due to non-adherence of the patient,
meaning that medicine and doses prescriptions are not respected. Adherence constitutes
a real challenge in the treatment of HIV-infected patients, but will not be developed in
this thesis. We will focus here on the immunological failure: some patients are able to
control the virus replication but cannot recover normal levels of CD4+ T cells [Lange
and Lederman, 2003]. Even if the percentage varies between studies, a significant subset
of HIV-infected patients under treatment do not reach normal levels of CD4+ T cells
[Julg and Walker, 2009] – which lie between 500 and 1500 cells/µL in healthy individuals.
In several European studies, this percentage was found to vary between 16 and 33%
[Thiébaut et al., 2005]. In a study on 366 HIV-infected patients from cohorts in the
USA, 44% of patients starting cART with CD4 counts below 100 cells/µL and 25% of
the patients starting cART with CD4 counts between 100 and 200 cells/µL were found
to have CD4 count below 500 cells/µL even after 7 years of cART [Kelley et al., 2009].
Among 400 patients from the UK Collaborative HIV Cohort Study, 7%, 33% and 65%
of the participants were found to present CD4 counts below 200, 350 and 500 cells/µL
respectively, after at least 2 years of treatment [O’Connor et al., 2014]. To evaluate the
CD4+ T cell response after treatment initiation, some studies have focused on providing
curves of the evolution of the CD4+ T cell response in large cohorts in Europe [Bouteloup
et al., 2017] and South Africa [Yotebieng et al., 2015]. They showed that the median
CD4 number after 12 months of cART was below 500 cells/µL and this number depends
on the CD4 number at treatment initiation. A low CD4 gain was also found associated
to an increased risk of death, consistent with other studies showing that low CD4+ T
cell numbers are associated with higher mortality, opportunistic infections or AIDS event
[Thiébaut et al., 2005; Kitahata et al., 2009; Opportunistic Infections Project Team Of
The Collaboration Of Observational HIV Epidemiological Research In Europe (COHERE)
In EuroCoord et al., 2012]. It has also been shown that in HIV-infected patients, CD4+ T
cell counts above 500 cell/µL are associated with a nearly healthy clinical status [Lewden
et al., 2007]. Immunological failure is then a major concern in HIV-infected patients. In
that case, the treatment is not necessarily modified but co-infections are investigated and
immunotherapies are considered to complement the cART. In the following section, we
will introduce in particular the immune therapy with the cytokine interleukin-7 (IL-7).
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4.1.1.4 Immune therapy with interleukin-7
IL-7 is a cytokine produced by non-marrow-derived stromal and epithelial cells. It
has been considered as a good candidate for intervention in HIV-infected patients with
immunological failure because it may improve thymic production [Mackall et al., 2001;
Okamoto et al., 2002] and cell survival, as shown in vivo [Tan et al., 2001; Vella et al., 1998;
Leone et al., 2010]. A review showed that IL-7 has a role in thymic T cell development
as well as survival, proliferation and maturation outside of the thymus [Beq et al., 2004].
Moreover, IL-7 was shown to regulate proliferation and survival of antiviral CD4+ T
cells [Lenz et al., 2004]. The safety and beneficial effect of injections of exogenous IL-
7 was first established in an observational study [Camargo et al., 2009] and a phase I
trial [Sereti et al., 2009]. Following encouraging results, the safety and immunogenicity
of repeated administrations of recombinant human IL-7 were assessed in a prospective
open-label phase 1/2a trial [Levy et al., 2009]. 14 HIV-infected patients under cART
with CD4+ counts between 100 and 400 cells/µL received 8 injections every two days in
a 16 days period at dose 3µg/kg (6 patients) or 10µg/kg (8 patients) and were followed
up to 48 weeks after the first injection. IL-7 was well tolerated and a significant dose-
dependent increase of naive and central memory CD4+ and CD8+ T cells was observed,
even at long term. Proliferation was also enhanced after injections, as observed thanks
to increased expression of the Ki67 marker. These results suggested that IL-7 could have
an effect on T cell cycling, thymic output and/or T cell survival. Then, a dose escalation
study of repeated administration of a glycosylated rhIL7 (CYT107 - equivalent to IL-7)
was realized in a multicenter phase 1/2a placebo controlled trial (INSPIRE study) [Levy
et al., 2012]. Patients were divided in 3 groups receiving three weekly injections of IL-7,
at day 0, 7 and 14 at doses 10µg/kg (7 patients + 2 placebos), 20µg/kg (8 patients +
2 placebos) or 30µg/kg (6 patients + 2 placebos). They were followed up to 52 weeks
after the first injection. This trial confirmed the tolerability of IL-7 injections, as well
as the dose-dependent increase of CD4 levels, up to 52 weeks after the first injection,
as seen in figure 4.2A. In parallel with this increase, the measurements of Ki67 marker
showed it underwent a peak of expression during IL-7 administration, with an observed
maximum 7 days after the first injection (first available measurement) and a return to
baseline expression between 7 and 14 days after the last injection of the cycle, as seen
in figure 4.2B. It means that IL-7 stimulate cellular proliferation, which induces a peak
of CD4+ T cells shortly after the injections. Other potential effects on thymic output
and cell survival are suggested by additional biomarkers measurements, but will not be
developed here. Details can be found in Levy et al. [2012] and Thiébaut et al. [2014].
From tolerance and biologic activity, the dose of 20µg/kg was selected to be the most
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written as: 
dR
dt
= λ+ 2ρP − µRR− πR
dP
dt
= πR− ρP − µPP
(49)
The initial condition is taken at t = 0, before any injection and it was assumed that both
R P
λ
µR µP
π
ρ
Figure 4.3 – Simple model of the CD4+ dynamics. P=proliferating cells. R=resting cells.
populations were at equilibrium, meaning that dR/dt = 0 and dP/dt = 0. Estimation of
parameters (λ, π, ρ, µR, µP ) was realized using a population approach on INSPIRE data,
using the estimation method described in section 3.2.2 and the discrete observations of
both CD4+ T cell counts and Ki67+ percentages. A statistical model of the form:
ξ˜il (t) = ξ˜l0 + β
T
l z
i
l(t) + u
i
l (50)
was used on every log-transformed parameter ξl for each individual i. In particular, the
covariates vector z included the treatment effect (=0 if the patient received placebo or
1 if the patient received IL-7 injections) and the dose effect, assumed to be linear. For
example, parameter π was written as:
π˜ =

π˜0 if t = 0,
π˜0 + β0trt+ β1dose if 0 < t ≤ τ,
π˜0 if t > τ.
(51)
The time τ of IL-7 effect on proliferation rate was fixed to 16 days after sensitivity analyses.
Several models were tested and compared :
— model 1 with only an effect of IL-7 on proliferation (π)
— model 2 with an effect of IL-7 on proliferation (π) and resting cells survival (µR),
during or after IL-7 administration
— model 3 with an effect of IL-7 on proliferation (π) and thymic output (λ), during
or after IL-7 administration
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The potential additional effects of IL-7 on survival and thymic output were tested sepa-
rately as a model including both effects and the effect on proliferation was not identifiable.
After model selection, random effects were estimated on both λ and ρ rates and a sta-
tistically significant effect of dose was estimated on the proliferation rate. Model 1 was
found to be worse than both models 2 and 3, indicating that proliferation is not the only
effect induced by IL-7 on CD4+ T cells. Model 2 was found slightly better than model 3
in terms of statistical criterion but the difference was not striking in term of patient fits.
Using these estimation results, simulations suggested that strategies including repeated
cycles of IL-7 injections could be used to maintain CD4 levels above 500 cells/µL and
helped designing the clinical trial INSPIRE 3.
4.1.2.2 Effect of repeated cycles of IL-7 injections on CD4+ T cell dynamics
Repeated cycles of IL-7 injections at dose 20µg/kg were assessed in two multicenter
phase II trials. INSPIRE 2 was a single-arm trial including 23 patients and INSPIRE 3 was
a 2 arms trial with a 3:1 randomization to IL-7 versus placebo, with a total of 84 patients
treated and included in the analysis. Results of both studies were presented in Thiébaut
et al. [2016]. HIV-infected patients were included if they were under cART, had low
CD4+ T cell counts (between 100 and 400 cells per µL of blood) and controlled the virus
(undetectable viral load for at least 6 months). The design of INSPIRE 3 study (treatment
group only) is represented in figure 4.4. A first cycle of injections was administered at the
beginning of the study, then patients were followed up to 2 years. Repeated visits were
made every 3 months, and if the CD4 T cell counts were measured < 550 cells/µL at the
visit, a new cycle was administered to the patient. Patient in placebo group received no
treatment until 1 year after enrollment and started the same design after. These trials
showed that repeated cycles of IL-7 were well tolerated and allowed the maintenance of
CD4+ T cell counts above 500/µL in most of the study participants.
The modeling work was continued, in particular to quantify the effect of different in-
jections in a cycle, the effect of repeated cycles on the CD4+ T cell dynamics and the
long-term efficacy of the therapy in maintaining CD4+ T counts above 500 cells/µL. Sev-
eral models, including more compartments or other processes such as feedback terms, were
developed and tested on INSPIRE data in Jarne Munoz [2015], but will not be detailed
here. However, we will summarize the results obtained in Jarne et al. [2017], using the
same mathematical model as described in figure 4.3 with some statistical improvements.
The parameters of the model were estimated on grouped data from all INSPIRE studies,
including a total of 128 patients (21 from INSPIRE, 23 from INSPIRE 2 and 84 from IN-
SPIRE 3), using the same population approach as presented in sections 3.2.2 and 4.1.2.1.
All patients had repeated measurements of total CD4+ T cell counts during the follow-up
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µR is assumed to be constant from 2 days after the first injection, to last 12 months and
to linearly decreases to 0 during the following 12 months. Random effects were estimated
on production rate λ and reversion rate ρ, meaning that these two parameters induce the
observed inter-individual variations. The effect of IL-7 was found to be dose-dependent
and to increase the value of the proliferation rate π during 7 days (the duration of the
effect was determined by profile likelihood). Moreover, within a cycle, the quantitative
effect of the injections on proliferation rate π value differs: in particular βpi1 ≥ βpi2 > βpi3
with the first and second injections having a similar effect, but the third injection has a
much weaker effect than the previous ones. The effect of all cycles on the proliferation rate
π were found to be lower than the effect of the first cycle. That could be either due to the
fact that the immune system reacts to IL-7 by generating antibodies against the cytokine
or simply because of homeostatic regulation, as the number of CD4+ T cells is lower at
the moment of the first cycle compared to the other ones. However, we were not able to
distinguish these effects by modeling the available data. The model induced good fits of
the data as shown in figure 4.5. The mechanistic modeling and parameters estimation in
Figure 4.5 – Fits of some patients from INSPIRE studies. Time is in days. Red points
correspond to the data and blue line corresponds to the fit obtained through
the estimation of the mechanistic model.
the population approach allowed then the quantification of the effect of repeated cycles
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of IL-7 on the dynamics of CD4+ T cells. A major interest in the modeling approach is
that the model can be used to simulate other potential designs of clinical trials and help
determining better protocols of injections.
4.1.2.3 Simulation and comparison of clinical protocols
From the estimation of a good predictive model, simulations were realized in Jarne
et al. [2017] to evaluate the possibility to reduce the number of injections in protocols.
Four protocols were compared, all based on the same original design: visits are realized
every 3 months and a new cycle is administered if the CD4+ T cell counts is measured
below 550 cells/µL. The variation between the protocols is due to the number of injections
realized in each cycle. Protocol A corresponds to the original one, with cycles of 3 injec-
tions. Protocol B contains a first cycle of 3 injections, followed by cycles of 2 injections,
while in protocol C it is followed by cycles of 1 injection. Finally, protocol D contains
cycles of 2 injections only. The comparison of these four protocols was based on three
criteria of clinical interest: the number of injections received, the mean CD4+T cell counts
and the time spent below 500 cells /µL. These protocols were applied to pseudo-patients,
generated using the (normally approximated) posterior distribution of parameters esti-
mated on INSPIRE data with the final model. The whole target population is considered
as "low" responders to cART and have their CD4+ T cell counts below 400 cells/µL when
included in the trial. Two other sub-groups of interest were studied, in particular "very
low" responders with CD4+ T cell counts between 100 and 200 cells/µL, and "not too
low" responders with CD4+ T cell counts between 300 and 400 cells/µL. Protocols were
studied and compared on these pseudo-patients. Results are detailed in Jarne et al. [2017].
In short, protocols B and D allow to reduce the number of injections compared to protocol
A without significantly reducing the mean CD4 count or increasing the time spent under
500 cells/µL, for all patients. Protocol C could be used for "not too low" responders, as it
dramatically reduces the number of injections compared to the other protocols, without
reducing the mean CD4 count or increasing the time spent under 500 cells/µL. However,
this protocol is not convenient for "very low" responders, for which it increases very much
the time spent with low CD4 counts. These results are mainly due to the fact that the
effect of a third injection in a cycle on cells proliferation was estimated to be much lower
than the effect of the two previous injections.
This comparison of protocols suggested the possibility to reduce the number of injec-
tions in clinical trials, while still maintaining the patients’ CD4+ T cell count above 500
cells/µL. However, the simulation was still based on the criterion that all patient would
undergo follow-up visits every 3 months. This may not be clinically relevant for all pa-
tients. Indeed, as shown by the data and estimated by the model, there is inter-individual
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variability in the response to IL-7 injections: in particular, following the peak induced by
the repeated injections of a cycle, the CD4+ T cell counts decrease much faster in some
patients compared to others. For patients with a strong decrease, the limit of 500 cells/µL
could be reached quickly and before the following control visit at 3 months, whereas for
patients with slower decline, the control visit could be realized much later than 3 months
after the administration of the cycle of injections. Thus, it could be more efficient to adapt
visits and measurements of CD4+ T cell counts by patients or group of patients; this could
reduce the number of visits and injections for patients while making sure that CD4+ T
cell levels are maintained over time. This question led us to develop methodological tools
to optimize the response to immune interventions such as IL-7 injections. The pipeline is
the following: when a new patient is included in a study, its individual parameters could
be estimated using population distributions previously estimated in INSPIRE (or other)
data. Then, optimization methods could be used on this patient. Figure 4.6 shows the
possible pipeline for optimizing and adapting injections protocols. In particular, we will
mention a Bayesian approach (3’) and develop more precisely an approach based on the
optimal control theory (3). However, as our main goal was to assess the feasibility of these
approaches, step 2 was replaced by the generation of pseudo-patients using the posterior
distribution estimated on the population of INSPIRE. These simulated data were used in
the evaluation of the optimal control method.
4.2 Method: optimal control
4.2.1 Optimizing clinical protocols
4.2.1.1 Possible approaches
In control theory, two main methods have been developed separately to solve op-
timization problems: Pontryagin’s maximum principle [Pontryagin, 1987] and Bellman’s
dynamic programming [Bellman, 1957]. Both methods can be applied to deterministic and
stochastic processes. Pontryagin’s maximum principle provides, under suitable assump-
tions, a set of necessary conditions that should be satisfied by an optimal control. The
problem is reduced to solving a so-called Hamiltonian system including the maximum con-
dition equation. In the dynamic programming method, the optimal control problem can
be solved using an integro-differential equation, known as the Hamilton-Jacobi-Bellman
equation.
A large number of biological applications have been modeled using an ODE system of
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2) Inclusion of a new patient
Estimation of its individual parameters using the first
observations.
1) Parameters estimation
Estimation of the ODE parameters θ using INSPIRE
data =⇒ determination of a posterior distribution.
3) Optimal control approach
• Use of optimal control theory to
determine an optimal strategy of
injections from minimizing a cost
function.
• Stochasticity attributed to the
biological process.
• Global optimization until a given
horizon
3’) Bayesian approach
• Adaptive treatment decision at each
new observation, by updating indi-
vidual parameters’ estimation with
MCMC algorithm.
• Stochasticity attributed to the
uncertainty on the parameters
estimation.
• Local adaptation of decision
Figure 4.6 – Pipeline for optimizing schedule of IL-7 injections in a new patient
the form:
dx(t)
dt
= f(x(t),u(t)), (53)
where the solution of the ODE system depends on the dynamics of the control function
u(t). The problem corresponds to minimizing a cost function depending on the control u.
In most of the cases Pontryagin’s maximum principle was used to address this question.
In the HIV field, Stengel [2008] and Yang et al. [2013] were interested in determining an
optimal HIV treatment to minimize the viral load and maximize the number of uninfected
CD4+ T cells taking into account the occurrence of viral mutations. Solving this issue
relied on using a model for the dynamics of viral infection and adding a control repre-
senting the effect of treatment. In Stengel [2008] the treatment was represented by terms
corresponding to the mechanisms of the different possible treatments, e.g., the protease
inhibitor reduces the rate of infection of CD4+ T cells by the virus. In Yang et al. [2013],
the control corresponded to the increase of number of CD8+ T cells. Pontryagin’s prin-
ciple was used and adapted in both works. A similar method was used for determining
optimal therapeutic protocols in cancer immunotherapy [Castiglione and Piccoli, 2006;
Cappuccio et al., 2007; Castiglione and Piccoli, 2007; Pappalardo et al., 2010]. The first
intervention corresponds to the injection of tumor specific DCs which allows activation of
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helper and cytotoxic cells targeting the cancer cells. Other therapeutic scenarios, includ-
ing CD8+ T lymphocytes therapy and immunotherapy with cytokines were also explored.
The cost function that should be minimized combines the size of tumor at the end of
experiment and the potential toxicity of repeated treatment injections. Even if this tool
has been widely used in biological applications, Pontryagin’s maximum principle only
provides necessary conditions and may only help to explicitly determine an optimal con-
trol strategy. Moreover, it can be applied to models including either ODEs or stochastic
differential equations (SDEs), for which the theory is well developed [Yong and Zhou,
1999]. However, to the best of our knowledge, no maximum principle exists for PDMPs
which are very well adapted for modeling most of the dynamical systems undergoing
stochasticity, as will be described in section 4.2.2.1. In biology, stochasticity is difficult to
account for, especially in inference. However, it is inherent to many processes and cannot
be neglected at some levels of precision, for example in single-cell analysis where processes
such as gene activation and protein production are modeled [Herbach et al., 2017; Cloez
et al., 2017; Puszynski et al., 2016]. Markov Decision Processes, a subclass of constant
piecewise PDMPs, have also been developed in the special case of a countable space and
punctual observations [Winkelmann et al., 2014] to determine optimal treatment strate-
gies in HIV by accounting for the potential mutation of the virus and the emergence of
resistant strains to some treatments [Duwal et al., 2015]. The stochasticity can also be
due to the variability between individuals, with a population distribution of some values
of the key parameters affecting the biological process and inducing heterogeneity in the
population. Theses sources of stochasticity were not accounted for in the previous cited
examples using Pontryagin’s maximum principle. Also, the dynamic of the control is not
always known and cannot always be explicitly included in the ODE system as in equation
(53). It is especially the case in immunology, as highlighted by Eftimie et al. [2016] in
their review on mathematical modeling for immunology. In this paper, authors underline
the crucial need for developing complex optimal control approaches in parallel to im-
munology experiments to improve clinical interventions. As part of this effort, we aimed
at developing a tool based on optimal control theory and using dynamic programing for
optimizing schedules of IL-7 injections in HIV-infected patients by accounting for some
stochasticity in the biological process. This work was published [Pasin et al., 2018] and
will be presented in section 4.2.2.
4.2.1.2 Bayesian approach for adapting protocols
In this section, we will present a Bayesian approach for adapting protocols of IL-
7 injection in a succinct way. This approach was developed in parallel to the optimal
control work by Laura Villain during her PhD, supervised by Daniel Commenges and
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Rodolphe Thiébaut. For more details, the interested reader can refer to the manuscript of
the article Adaptive protocols based on predictions from a mechanistic model
of the effect of IL7 on CD4 counts, L. Villain, D. Commenges, C. Pasin, M. Prague,
R. Thiébaut, accepted in Statistics in Medicine and presented in Appendix B. The general
idea of this method relies on the fact that the model used for the dynamics of the CD4+
T lymphocytes, as detailed in section 4.1.2 and Thiébaut et al. [2014], Thiébaut et al.
[2016], Jarne et al. [2017] is deterministic; when a distribution of the parameters of a given
patient is known, the corresponding trajectory of the CD4+ T cells can be computed, as
well as the distribution of any related quantity. Decisions to adapt the treatment can be
taken using these predicted quantities. Moreover, each time a measurement is made on a
patient, more data is available and the parameter estimation can be updated, with more
precision. In practice, the individual parameters are estimated with an MCMC algorithm.
Two strategies were evaluated: one, the adaptive criterion of injection (ACI) is based on
the predicted risk to have CD4 counts below 500 cells/µL before the next visit (at 3
months). The other one, the adaptive time of injection (ATI) is based on the predicted
time at which CD4 counts will reach 500 cells/µL. Within both criteria, the possibility to
administer less than 3 injections per cycle was also assessed. It should be underlined that
here, both criteria are computed from the estimation of individual parameters, obtained
thanks to the observations, but not from the observations themselves as in the original
protocol. In short, the results showed that all adaptive protocols had the ability to reduce
the time spent with CD4 levels below 500 cells/µL without increasing much the number
of injections for each protocol. The protocols based on the ATI criterion actually helped
in reducing the number of visits of the patient. All protocols maintained the CD4 counts
at higher numbers than the original protocol. This approach offers clinical prospects, as
it could be applied in a larger trial to evaluate the impact of adaptive strategies on other
clinical outcomes. Its feasibility relies on the good capacity of the deterministic model to
capture the biological process and to be estimated using a limited number of markers and
measurements. In parallel on this work, we developed the optimal control approach, as
described in the following sections.
4.2.2 Optimal control on piecewise deterministic Markov pro-
cesses
In this section, we will introduce the notations and definitions related to uncontrolled
and controlled PDMPs. We will also remind the main results from Costa et al. [2016]
and adapt them to our particular context. The terminology will be mostly taken from
this article. From now, we will use the term of "impulse control" problem to refer to an
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optimal control problem with a possibility of punctual actions but only on the boundaries
of the system.
4.2.2.1 Uncontrolled PDMPs
In his paper, Davis [1984] observed that almost all continuous stochastic models could
be defined as combination of diffusion, deterministic motion, and/or random jumps. Diffu-
sions correspond to continuous time stochastic processes and include stochastic differential
equations, which are ordinary differential equations with a white noise perturbation. The
theory of control was well developed in this framework [Bensoussan, 1982; Peng, 1990] and
numerical tools were then developed to solve the control problems. However, the number
of applications was limited, because SDEs are not adapted for modeling a large number
of physical and biological processes. Now, control of SDEs is particularly developed in
finance [Framstad et al., 2004; Shen et al., 2014]. By developing PDMPs, Davis [1984]
proposed a general framework for modeling and eventually optimizing continuous-time
dynamical systems including uncertainty due to random occurrences, but without diffu-
sion. Since this paper, PDMPs have been used to model processes in many applications
including questions in biology such as neuronal membranes [Buckwar and Riedler, 2011]
or gene expression [Bobrowski et al., 2007] or in physics such as maintenance of metallic
structures [de Saporta et al., 2012].
A PDMP is characterized by local characteristics defined in a given state space X:
the flow φ, the jump rate η and the transition measure Q. The trajectory of a PDMP
can be described by iteration: starting from a point x0 ∈ X, the process follows the flow
φ(x0, t) until a jump occurs at time T1. This jump can either be spontaneous, following
a Poisson-like law defined by rate η or deterministic when the flows hits the boundary of
the state space. In both cases, the process starts again from a point determined by the
transition measure Q(.|φ(x0, T1)) and follows the flow until a new jump occurs. A graphic
representation of a PDMP is shown in figure 4.7. In a more formal way, the state space X
is an open subset of Rd, d ∈ N; ∂X corresponds to its boundary. The flow associated with
the process φ(x, t) : Rd × R 7→ Rd is a Lipschitz continuous vector field in Rd, meaning
that φ(x, t + s) = φ(φ(x, s), t) for all x ∈ Rd and (t, s) ∈ R2. The active boundary is
defined as Ξ = {x ∈ ∂X : x = φ(y, t)} for some y ∈ X and t ∈ R∗+. We will then denote
X = X∪Ξ and for x ∈ X, we can define t∗(x) = inf{t ∈ R+ : φ(x, t) ∈ Ξ}. The definition
of the flow φ outside the space X can be arbitrary, as it has no impact on the definition
of the process. The controlled jump intensity η is a R+-valued measurable function and
determines the law of the stochastic jumps. The transition measure Q(.|x) corresponds
to the distribution of the state after a natural jump occurring at x ∈ X.
A PDMP can be constructed using the flow, the jump intensity rate and the transition
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X
x0×
φ(x0, θ1)×
x2×
φ(x1, θ2)×
x1×
random jump (η)
transition measure (Q)
deterministic jump (Ξ)
Figure 4.7 – Graphic representation of a PDMP, starting from x0, with a random jump
at time τ1 = θ1, then starting again from x1 and undergoing a deterministic
jump at time τ2 = θ1 + θ2 when reaching the boundary of state space X,
before starting again from x2.
measure. We will not focus on technical details here, but roughly speaking, a canonical
space of trajectories Ω can be defined. A trajectory in this space can be written as
ω = (x0, θ1, x1, θ2, x2, ..) ∈ Ω, with initial state x0 ∈ X. Written this way, θi corresponds
to the time interval between two consecutive jumps and xi the value of the process right
after the jump. Note that the θs depend on the jump intensity rate as well as the flow and
the boundary of the state space, and the xs are determined by the transition measure.
We note hn = (x0, θ1, x1, θ2, x2, .., θn, xn) the path up to n ∈ N and Hn the set of all such
paths. The process has only n jumps when θn <∞ and θn+1 =∞. In that case, we can
fix θm = ∞ and xm = x∞ for every m ≥ n + 1, with x∞ corresponding the an isolated
artificial point after which no jump occurs. We note X∞ = X ∪ {x∞} and then we can
define mappings Xn : Ω → X∞ such that Xn(ω) = xn, corresponding to the post-jump
locations and Θn : Ω → R∗+ by Θ0(ω) = 0, Θn(ω) = θn corresponding to the sojourn
time (in a deterministic regime). We can also define the sequence of R
∗
+-valued mappings
(Tn)n∈N∗ corresponding to the time at which jump occurs, with Tn(ω) =
∑n
i=1Θi(ω) and
T∞(ω) = limn→∞Tn(ω). From Xn and Θn, we can determine Hn = (X0,Θ1, X1.., Xn).
Finally we can define the PDMP {ξt}t∈R+ such that:
ξt(ω) =
{
φ(Xn, t− Tn) if Tn ≤ t < Tn+1 for n ∈ N,
x∞ if T∞ ≤ t.
(54)
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4.2.2.2 Impulse control of PDMPs
In this section, we will remind the theoretical results presented in Costa et al. [2016]
and adapt them to a particular context which will constitutes our framework in the
case of protocols of IL-7 injections: here, we will be interested in an impulse control
problem where the decision maker can modify the measure of transition Q, but only on
the boundary of the system. The process is not controlled inside of the state space. It
means that punctual decisions can be taken to modify from where the process starts again
when a boundary is reached.
The action space is denoted A. For a particular point z ∈ Ξ at the boundary of the
system, the set of possible actions at this point is written A(z). We can then define the
state K = {(z, a) ∈ Ξ × A : a ∈ A(z)} of pairs containing all the elements of the active
boundary and their corresponding possible actions. The stochastic kernel Q on X givenK
determines the state of the process after any jump. For any (z, a) ∈ K, Q(.|z, a) describes
the distribution of the state after the jump induced by the impulsive action a from point z
on the active boundary. If a natural jump occurs in state x ∈ X, the measure of transition
does not depend on any action, as the process is uncontrolled inside of the state space.
We can write Q(.|x, a) = Q(.|x) the distribution of the state after the jump as well. In
the case of a stochastic jump, the signed kernel computes the difference between the state
before and after the jump:
q(dy|x) = η(x)[Q(dy|x)− δx(dy)]. (55)
For any function V : X→ R, we can define for (z, a) ∈ K:
QV (z, a) =
∫
V (y)Q(dy|z, a), (56)
and for x ∈ X:
qV (x) =
∫
V (y)q(dy|x). (57)
The set of all actions realized by the decision-maker constitutes a control strategy. For-
mally, an admissible control strategy is a sequence u = (χn)n∈N with, for any n ∈ N,
χn a stochastic kernel on A given Hn. When the process hits the boundary from xn,
the decision maker chooses randomly an action according to the distribution χn(.|Hn),
satisfying χn
(
A(φ(xn), t
∗(xn))|hn
)
= 1, for hn = (x0, θ1, x1, θ2, x2, .., θn, xn) ∈ Hn, with
xn 6= x∞ and t∗(xn) <∞. The set of all admissible control strategies is denoted by U .
The optimization problem corresponds to determining a strategy in U which minimizes
a performance criterion. This criterion is defined from a cost function, itself divided in
two parts: the gradual cost Cg, penalizing continuously the trajectory of the process, and
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the cost C i associated to an impulsive action. The associated performance criterion for
strategy u ∈ U starting from state x0 ∈ X is:
V(u, x0) = Eux0
[∫
]0,+∞[
e−αsCg(ξs)ds
]
+Eux0
[
+∞∑
n=1
e−αTn1{
ξTn−∈Ξ
} ∫
A
(
ξTn−
)C i(ξTn−, a)χn(da|Hn)
]
,
(58)
where α is a discount factor ensuring the convergence of the integral when the process is
defined on an infinite horizon. However, when working on a finite horizon Th, it is possible
to define a boundary of the process when t ≥ Th at which the process enters a so-called
absorbing state ∆, where nothing happens, φ(∆, t) = ∆ and Cg(∆) = C i(∆) = 0. In
that case, equation (58) can be computed with integrals on ]0, Th] instead of ]0,+∞[. The
optimization problem aims at finding an optimal strategy uˆ ∈ U such that:
V(uˆ, x0) = inf
u∈U
V(u, x0). (59)
Below are a list of assumptions that should be verified to solve the optimization problem,
as defined in section 3.2 of Costa et al. [2016]. They mainly ensure the ability to compute
values of the performance criterion and the existence of an optimal solution to the problem.
Assumption A. There are constants K ≥ 0, ε1 > 0 and ε2 ∈ [0, 1[ such that
(A1) For any x ∈ X, η(x) ≤ K.
(A2) For any (z, a) ∈ K, Q(Aε1 |z, a) ≥ 1− ε2, where
Aε1 = {x ∈ X : t∗(x) > ε1}.
Assumption B.
(B1) The set A(y) is compact for every y ∈ X.
(B2) The kernel Q is weakly continuous.
(B3) The function η is continuous on X.
(B4) The flow φ is continuous on Rd × R+.
(B5) The function t∗ is continuous on X.
Assumption C.
(C1) The multifunction Ψ from Ξ to A defined by Ψ(z) = A(z) is upper semicontinous.
(C2) The cost function Cg (respectively, C i) is bounded and lower semicontinuous on X
(respectively, K).
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When assumptions (A1) and (A2) hold, constants KA and KB can be defined as in section
5 from Costa et al. [2016]:
KB ≥ K
1− ε2 ,
KA ≥ K(1 +KB)(1− e
−(K+α)ε1) + (K + α)(K +KBε2)e
−(K+α)ε1
α(1− e−(K+α)ε1) .
(60)
The theorem allowing to determine the optimal cost and providing an optimal strategy
is adapted from theorem 5.5 in Costa et al. [2016]. It is stated as follows:
Theorem 1. Suppose assumptions A, B and C are verified. We define the sequence of
functions {Wm}m∈N for any x ∈ X as follows:{
Wm+1(x) = BWm(x) for m ∈ N,
W0(x) = −KA1Aε1 (x)− (KA +KB)1Acε1 (x),
(61)
with constants KA and KB defined as in equation (60), Aε1 = {x ∈ X : t∗(x) > ε1} and
BV (y) =
∫
[0,t∗(y)[
e−(K+α)tRV (φ(y, t))dt+ e−(K+α)t∗(y)T V (φ(y, t∗(y))), (62)
with real-value functions RV and T V defined for any V respectively on X and Ξ :
RV (x) = Cg(x) + qV (x) + ηV (x),
T V (z) = inf
a∈A(z)
{
C i(z, d) +QV (z, a)
}
,
with qV and QV defined as in equations (57) and (56) respectively.
The sequence of functions {Wm}m∈N converges to a function W defined on the state space
and such that :
i) W (x0) = infu∈U V(u, x0)
ii) there is a measurable mapping ϕ̂ : Ξ → A such that ϕ̂(z) ∈ A(z) for any z ∈ Ξ and
satisfying
C i(z, ϕ̂(z)) +QW (z, ϕ̂(z)) = inf
a∈A(z)
{
C i(z, a) +QW (z, a)
}
. (63)
The value function W as previously defined verifies W (x) = BW (x) for any x ∈ X,
which is an integral form of the Hamilton-Jacobi-Bellman equation. This theorem shows
that the optimal cost can be obtained by computing the value function W in x0. Note
that, due to the definition of W as the convergence of sequence {Wm}, its value should be
computed on the state space X in order to obtain the specific valueW (x0). Moreover, the
optimal strategy is obtained by choosing the optimal action ϕ̂(z) for every point z ∈ Ξ
reached on the trajectory of the process. The optimal strategy is simulated as follows:
we start with the trajectory from x0, then when a boundary is reached, the chosen action
corresponds to the one minimizing the criterion C i(z, a)+QW (z, a), as given by equation
(63).
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4.2.2.3 Numerical aspects
The theory of impulse control on PDMPs, as developed in previous sections 4.2.2.1 and
4.2.2.2, can be applied to biological or physical questions by using a two-steps method:
first, the PDMP associated to the process should be developed, then the impulse control
problem can be solved using theorem 1.
The defined PDMP can be simulated using a numerical software. Simulations consti-
tute a way to check if the PDMP is able to reproduce the biological process. Moreover,
simulations of the PDMP allow to generate and compare the effect of several injections
strategies on the process. It helps getting a first evaluation of the ability of the cost func-
tion to distinguish between the different strategies. It also gives a basis of comparison to
the optimal strategy, after it is determined.
Then, the impulse control problem should be solved numerically, but at the moment
there is no general computation method [de Saporta et al., 2015]. Some methods have
been developed in de Saporta and Dufour [2012], and they have also shown that some
tools are still under development. Results from Costa et al. [2016], and in particular
theorem 1 gives a natural method to solve the problem. Indeed, the value function W is
obtained by iteration of a sequence {Wm}m∈N. This sequence is defined by equation (61),
with Wm+1(x) = BWm(x). An approximation of the operator B defined in equation (62)
can be realized on a grid of the state space and it will allow to compute an approximation
of all functions Wm on the grid. This grid, written Γ, must be chosen to be stable by
transformation with BWm, for all m ∈ N: it can be ensured by approximating BWm(x)
on Γ, for every x ∈ Γ. Finally, it will give an approximation of the function W on Γ,
and in particular of W (x0), corresponding to the optimal cost. Our main contribution in
this work was to determine the PDMP associated to the context of IL-7 and to develop a
numerical method able to solve the optimal control problem for some given patients. The
challenge comes with finding a right way to organize the grid Γ to ensure good computation
of the sequence {Wm}m∈N on every point of the grid. Moreover, a computational challenge
is induced by the size of the grid, as a large number of elements is easily reached, which
can dramatically increases the time of computation.
In the next section, we include the article corresponding to the application of the theory
of optimal control on PDMPs to the IL-7 question. Details of the two steps of the method
are given: first the PDMP is described and the algorithm for computing the sequence of
functions is explained. We decided to focus on a biological process slightly simpler than
the one described by the ODE models on INSPIRE data and focused only on the effect of
IL-7 on the proliferation of cells. This is partly due to the fact that our work was more a
"proof-of-concept" and mainly aimed at showing that the theory of optimal control could
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be used in a context of optimization of schedules of injections. It was then natural to
choose a simple biological model, but still realistic and good enough to fit the data from
INSPIRE studies. The numerical method was applied to 50 pseudo-patients that were
generated using the posterior distributions previously estimated on the parameters using
INSPIRE data. All codes (both simulation of the PDMP and computation of the iterative
sequence for solving the optimal problem) were written in Matlab version R2016b (The
MathWorks, Inc., Natick MA, USA, 1984).
4.3 Application of the optimal control to the IL-7 con-
text: "Controlling IL-7 injections in HIV-infected
patients"
The following paper was published in Bulletin of Mathematical Biology (2018), volume
80, issue 9, pp 2349-2377.
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Abstract
Immune interventions consisting in repeated injections are broadly used as they are
thought to improve the quantity and the quality of the immune response. However,
they also raise several questions that remain unanswered, in particular the number
of injections to make or the delay to respect between different injections to achieve
this goal. Practical and financial considerations add constraints to these questions,
especially in the framework of human studies. We specifically focus here on the use of
interleukin-7 (IL-7) injections in HIV-infected patients under antiretroviral treatment,
but still unable to restore normal levels of CD4+ T lymphocytes. Clinical trials have
already shown that repeated cycles of injections of IL-7 could help maintaining CD4+
T lymphocytes levels over the limit of 500 cells/µL, by affecting proliferation and
survival of CD4+ T cells. We then aim at answering the question: how to maintain
a patients level of CD4+ T lymphocytes by using a minimum number of injections
(i.e., optimizing the strategy of injections)? Based on mechanistic models that were
previously developed for the dynamics of CD4+ T lymphocytes in this context, we
model the process by a piecewise deterministic Markov model. We then address the
question by using some recently established theory on impulse control problem in order
to develop a numerical tool determining the optimal strategy. Results are obtained on a
reduced model, as a proof of concept: the method allows to define an optimal strategy
for a given patient. This method could be applied to optimize injections schedules in
clinical trials.
Keywords Optimal control · Immune therapy · Dynamic programming
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1 Introduction
The infection by the Human Immunodeficiency Virus (HIV) compromises the immune
system functions, mainly because of the depletion of CD4+ T lymphocytes. Combined
antiretroviral (cART) therapy has led to a spectacular improvement of patients’ sur-
vival by controlling virus replication and consequently restoring the immune system
functions. However, some patients fail at reconstituting their immune system and
recovering normal CD4+ T cell levels, especially when they start antiretroviral treat-
ment late (Lange and Lederman 2003). Immune therapy has been considered as a
complement to cART to help immune restoration. In particular, interleukin-7 (IL-7),
a cytokine produced by non-marrow-derived stromal and epithelial cells, is thought to
improve thymic production (Mackall et al. 2001; Okamoto et al. 2002) and cell sur-
vival (Tan et al. 2001; Vella et al. 1998; Leone et al. 2010). The safety and beneficial
effect of injections of exogenous IL-7 was first shown in phase I trials (Sereti et al.
2009; Levy et al. 2009) and observational studies (Camargo et al. 2009). Then, phase
I/II human clinical trials (INSPIRE 1, 2 and 3 studies) have evaluated the effect of
repeated cycles of three IL-7 injections and showed that this therapy helped maintain-
ing HIV-infected patients with CD4+ T cells levels above 500 cells/µL (Levy et al.
2012), a level associated with a nearly healthy clinical status (Lewden et al. 2007).
The dynamics of CD4+ T lymphocytes following IL-7 injections can be fitted by
mechanistic models based on ordinary differential equations (ODEs). These models
contain compartments corresponding to different populations of CD4+ T lymphocytes
and biological parameters characterizing these populations. Hence, it was possible to
quantify the effect of repeated cycles of IL-7 on CD4+ T lymphocytes on specific
parameters. Previous work using data from clinical trials (INSPIRE studies) has shown
that IL-7 enhances both proliferation and survival of CD4+ T lymphocytes (Thiebaut
et al. 2014). Moreover, a differential effect of the injections within a given cycle
has been found, the third injection of a cycle appearing to have a weaker effect on
proliferation than the first ones (Jarne et al. 2017).
In addition to providing insight into the most important mechanism of the effect
of exogenous IL-7, the models have shown a very good predictive capacity (Thiebaut
et al. 2014; Jarne et al. 2017). Hence, the next step was the determination of the best
protocol of injections. A first approach, realized in Jarne et al. (2017), consisted in
simulating and comparing the regular protocol to three other protocols with different
numbers of injections by cycle. In all four protocols, CD4 counts were measured every
3 months, and a new cycle was administered when the CD4 numbers were below 550
cells/µL. Comparison was based on three criteria: number of injections received, mean
CD4 count and time spent below 500 cells/µL over a 4-years period. Results showed
that cycles of two injections could be sufficient to maintain CD4 levels, while using
less injections than in the clinical protocol. These results suggest the possibility to
reduce the number of injections in clinical protocols. However, the 3 months delay
between visits is independent of the patient and constrains the protocol. While some
patients with “not too low” baseline CD4 levels could afford coming back later than
3 months after the last visit, some patients with “low” baseline CD4 levels would
need more repeated cycles or more injections by cycle. Individualized protocols could
help in achieving the maintenance of the patient’s CD4+ T lymphocytes levels over a
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given threshold by using different patient-dependent timing of injections and doses.
The possibility of conducting the lightest intervention for every patient could be very
important for the development of IL-7 in HIV-infected patients especially for further
large clinical trials.
Optimization of schedule and doses is an up-to-date question when working on
protocol of injections. In their review on mathematical modeling for immunology,
Eftimie et al. (2016) emphasize the need for complex optimal control approaches
coupled with immunology experiments, in order to improve clinical interventions.
Basically, there are two kinds of techniques that can be used to solve optimal control
problems: methods involving Pontryagin’s maximum principle and dynamic program-
ming approaches. Pontryagin’s maximum principle has been applied to a number of
biological problems of the form dx(t)dt = f (x(t), u(t)), where the solution to the
ordinary differential equation depends on the dynamics of the control function u(t).
For example, it was applied to the determination of the optimal schedule of dendritic
cells vaccine injection in cancer immunotherapy by Castiglione and Piccoli (2006),
Cappuccio et al. (2007), Castiglione and Piccoli (2007) and Pappalardo et al. (2010).
However, in our case, the model is a piecewise deterministic Markov model (PDMP),
where dynamics of IL-7 are unknown and not modeled. Addressing the objective of
spending the least time possible under the threshold of 500 cells/µL by using repeated
injections of IL-7 corresponds in a more formal way to determining actions (injec-
tion or not and choice of dose) at given time points over a horizon of time: this can
be treated as a problem of impulse control in the optimal control theory. To the best
of our knowledge, there is no maximum principle solving this kind of problem. We
will focus on a dynamic programming method, as developed in Costa et al. (2016).
In a formal mathematical framework, we addressed the question of optimizing the
schedule of IL-7 injections for a given patient by a two-steps method: determining an
adapted mathematical model for the process, and developing a numerical method to
determine an optimal strategy of IL-7 injections for a given patient.
As described in Davis (1984), most of the continuous-time stochastic problems of
applied probability (including those modeling biological processes) consist of some
combination of diffusion, deterministic motion and/or random jumps. Ordinary dif-
ferential equations can be included in the class of deterministic motion with random
jumps. In our particular framework of modeling cell dynamics after IL-7 injections,
jumps correspond to the change of some parameters value. This can be easily and
naturally modeled by the largely studied class of Piecewise Deterministic Markov
Processes (PDMPs). A non-controlled version of this model can be described by iter-
ation as follows: from a point in the state space, the process follows a deterministic
trajectory determined by the flow, until a jump occurs. This jump happens either spon-
taneously in a random manner, or when the flow hits the boundary of the state space.
After the jump, the system restarts from a new point determined by the transition
measure of the process. We will show in this article how to model the dynamics of the
CD4+ T cells in HIV-infected patients following IL-7 injections using a PDMP.
According to the problem studied in Costa et al. (2016), impulse control consists
in possible actions only when the process reaches its boundary. This will constitute
our framework: the decision-maker has the possibility to inject IL-7 when the number
of CD4+ T lymphocytes reaches a given level or when a certain amount of time has
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passed since the last injection. Each action has a cost, and a strategy is defined as
the set of all realized actions over a given horizon. The impulse problem consists in
determining a strategy of injections minimizing the optimality criterion induced by
the cost function. In our case, the cost function depends on the number of injection
realized and the time spent with the CD4+ T lymphocytes levels under the threshold
of 500 cells/µL, as both quantities should be minimized.
As emphasized by the authors of Dufour and Zhang (2015), the development of
computational methods for the control of PDMPs has been limited, and at the moment,
there is no general method allowing the numerical resolution of optimal control on
PDMPs (and in particular impulse control). This constitutes a real challenge. We
propose in this work a numerical method based on the results developed in Costa et al.
(2016). In this paper, the authors studied the existence of a solution of the Bellman–
Hamilton–Jacobi equation by showing that the value function is the limit of a sequence
of functions given by iteration of an integro-differential operator. This construction
leads to a natural method for the computation of the optimal cost and the determination
of an optimal strategy of injections. In particular, we have developed an algorithm for
the iteration of the operator and applied our numerical tool to the case of the biological
model. This provides a proof of concept as it succeeded in determining an optimal
strategy for a number of pseudo-patients simulated using previous estimations. The
paper is organized as follows: Sect. 2 presents the mathematical modeling of the
process, including data and design of INSPIRE studies, as well as mechanistic model
and finally the associated PDMP. Section 3 focuses on the optimal control problem, by
reminding the main theoretical results from Costa et al. (2016) and adapting them to the
IL-7 study. Section 4 presents some numerical aspects of the dynamic programming
work, necessary to determine the optimal cost function and strategy for a given patient.
Results are presented in Sect. 5, and discussion is done in Sect. 6.
2 Mathematical Modeling
2.1 Material
Our work is based on three phase I/II multicenter studies assessing the effect of a
purified glycosylated recombinant human Interleukin 7 (IL-7) treatment for immune
restoration in HIV-infected patients under treatment: INSPIRE (Levy et al. 2012),
INSPIRE 2 and INSPIRE 3 (Thiébaut et al. 2016). A total of 128 HIV-infected patients
under antiretroviral therapy with CD4+ T cell count between 100 and 400 cells/µL and
undetectable viral load for at least 6 months were included among the three studies from
the time of the first injection. IL-7 was administered in cycles of weekly injections,
with a “complete cycle” defined as three weekly injections. In INSPIRE, all 21 patients
received complete cycles of IL-7 at different weight-dependent doses: 10, 20 and 30
µg/kg. In INSPIRE 2 and INSPIRE 3, 23 and 84 patients (respectively) received
repeated (and sometimes incomplete) cycles of IL-7 at dose 20 µg/kg. Repeated visits
and follow-up once every 3 months after the first cycle allowed to measure biomarkers
levels in patients, in particular total CD4+ T cell counts and number of proliferating
CD4+ T cells through Ki67 marker. At every visit, a new cycle of injections was
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administered if the patient’s CD4+ T cell level was under 550/µL, in order to globally
maintain the levels above 500 cells/µL. The total duration of the studies was 12, 24
and 21 months for INSPIRE, INSPIRE 2 and INSPIRE 3, respectively.
2.2 Mechanistic Model
The dynamics of CD4+ T lymphocytes were largely described in Thiebaut et al.
(2014) and Jarne et al. (2017) by using several mechanistic models. We focus here
on the following model, described in Fig. 1: it includes two populations of cells, non-
proliferating (or resting, R) and proliferating (P). Resting cells are produced by thymic
output at rate λ, become proliferating cells at rate π and die at rate μR . Proliferating
cells die at rate μP and can also divide and produce two non-proliferating cells at rate
ρ. The system of differential equations is written as follows:
⎧⎪⎨
⎪⎩
dR
dt
= λ− μR R − πR + 2ρP
dP
dt
= −μP P − ρP + πR
(1)
We assume the system is at equilibrium at t = 0, before the study begins and any
injection is administered. IL-7 injections are realized through cycles containing up
to three injections with 7 days elapsed between each injection. Parameters estimation
was performed using a population approach. Mixed-effect models including intercept,
random and fixed effects, were used on log-transformed parameters, in order to both
obtain an estimation across population and account for between-individuals variability.
In the controlled framework, the decision-maker can decide to inject IL-7 to a patient at
a given dose d, and this will affect the value of the proliferation rate π . Each injection
denoted by n ∈ {1, 2, 3} of a cycle has a different effect on the value of π for patient
i , defined as follows:
π˜ i = π˜0 + β
(n)
π d0.25i 1{t∈[t iinj,t iinj+τ i ]} (2)
with π˜ = log(π); βπ = [β(1)π , β(2)π , β(3)π ] is the vector of effect of each injection of a
single cycle; d is the injected dose; tinj is the time (in days) at which IL-7 is injected,
Fig. 1 Mechanistic model for
the dynamics of CD4+ T
lymphocytes
R P
λ
µR µP
π
ρ
123
2354 C. Pasin et al.
and τ is the length of effect of the injection (in number of days), considered equal
to 7 in previous models (Jarne et al. 2017). Estimation of parameters showed that
effect of successive injections on the proliferation rate decreases within a cycle, and
in particular, the third injection seems to have a much weaker effect (as β(3)π < β(2)π <
β
(1)
π ) (Jarne et al. 2017).
2.3 Mathematical Model: Piecewise Deterministic Markov Process
As described in the introduction, ODEs-based mechanistic models can be included
into the broader class of PDMPs. A PDMP is characterized by a state space in which
it evolves, a flow, a jump intensity and a measure of transition. From a mathematical
point of view, we note X the state space, an open subset of Rd , d ∈ N, and ∂X its
boundary. The flow associated with the process is φ(x, t) : Rd × R → Rd . The
active boundary is defined as Ξ = {x ∈ ∂X : x = φ(y, t)} for some y ∈ X
and t ∈ R∗+. We will then denote X = X ∪ Ξ and for x ∈ X , we can define
t∗(x) = inf{t ∈ R+ : φ(x, t) ∈ Ξ}. The controlled jump intensity η is a R+-valued
measurable function and determines the law of the stochastic jumps. When the process,
i.e., the trajectory of CD4+ T lymphocytes, reaches Ξ , the decision-maker can act
by injecting IL-7 to the patient. The action varies according to the dose injected. This
leads to a jump in some parameters value, and the process restarts from a new point
defined by the transition measure Q(.|φ(x0, τ ), d), depending on the dose and the
position of the state before the jump φ(x0, τ ).
In this section, we present the PDMP associated with the biological process
described in Sect. 2.2. Here, the PDMP is patient-dependent. As we focus on the
control question (and not the estimation one), we suppose that parameters values
of the studied patient are known. Previous work has shown that estimation of ODE’s
parameters based on population approaches can be reliable (Lavielle and Mentré 2007;
Prague et al. 2013). Moreover, the model developed in our particular framework for
the CD4 dynamics has shown good predictive abilities (Jarne et al. 2017). Therefore,
we make the assumption that we determine the strategy for a patient who is already
included in a clinical study and for which we had enough observations to estimate its
parameters (by running a first cycle of injection for example). As developed in this
part, the stochasticity is supposed to be induced by the biological model but not by the
uncertainty on the parameters estimation. Sensitivity analysis of the method regarding
the estimation uncertainty is provided in “Appendix C”.
The PDMP modeling the dynamics of CD4+ T lymphocytes of a given patient is
defined using six variables: the state vector is denoted by x = (γ, n, σ, θ, p, r). γ
determines the value of parameter π when combined with n, the number of injections
realized in the ongoing cycle. If d = [d0, d1, .., dmd ] is the vector of all possible doses
(with d0 = 0), then γ ∈ {1..md + 1}. Injecting dose dk at the n-th injection of a cycle
gives the following: γ (dk) = k + 1 and π = π0 + β(n)π d(γ )0.25. The two variables σ
and θ are time variables, discretized with steps of 1 day. In particular, σ corresponds to
the number of days since the last injection and θ to the running time (θ = 1 at the first
injection of the first cycle). Finally, variables p and r are values of compartments P
and R solutions of system 1 with parameter π defined by γ and n and other parameters
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are supposed to have been previously estimated. We suppose the patient is followed
until a horizon of time Th , then the state space is X = X˜ ∪Δ with
X˜ = {1..md + 1} × {1..ninj} × {0..Th − 7(ninj − 1)} × {0..Th}
×{pmin..pmax } × {rmin..rmax }
and Δ is an absorbing state representing the end of the study, at t = Th : Δ =
(0, 0, 0, Th, 0, 0). For x = (γ, n, σ, θ, p, r) ∈ X , the flow is defined as:
– φ(x, t) = (γ, n, σ + t, θ + t, p, r) if θ ≤ 1
– φ(x, t) = (γ, n, σ + t, θ + t, P(t, γ, n), R(t, γ, n)) if θ ∈ [1, Th − 1], with
P(t, γ, n) and R(t, γ, n) solutions of system 1 with initial conditions p and r and
π determined with γ and n
– φ(Δ, t) = Δ
Moreover, even if the deterministic mechanistic model allowed good fits for the data,
we make the hypothesis that the process undergoes some stochasticity: in particular,
as the value of parameter π is modified by an injection of IL-7 during some days,
we suppose that this modification can last randomly up to 7 days after the injection.
Stochastic jumps can then occur with intensity η such that for x ∈ X˜ , η(x) = η1{γ>1}
with η a given value and η(Δ) = 0. It means that if we consider the modification of π
value after an IL-7 injection through Eq. 2, τ follows there a random exponential law
of parameter η. We define the constant K = η such that η(x) ≤ K for every x ∈ X˜ .
IL-7 injections aim at maintaining the CD4+ T cell level over 500 cells/µL. When
this value is reached, we consider that the system has reached a deterministic boundary
of the state space. A new injection of IL-7 injection is possible at that moment and gives
the possibility to increase CD4+ T cell counts. To account for clinical constraints, we
assume a minimum time σmin is observed between the beginning of two consecutive
cycles, even if the number of CD4 falls below the threshold of 500. During cycles, the
deterministic boundary corresponds to the 7 days delay between injections. In a more
formal way, the boundary can actually be reached in five different situations described
in the following:
– for a technical reason due to the mathematical modeling which cannot account for
an impulse action at t = 0, we define a first artificial boundary when the study
begins, at θ = 1: Ξ1 = {x : θ = 1}. This allows a cycle of injections to begin at
θ = 1. We suppose the studied patient is already included in the clinical study: it
means that its biological parameters are known, and her/his CD4+ T cell count at
t = 0 as well (either because she/he is at equilibrium, and the values are known
from biological parameters, or because some measures have been realized at this
time).
– we also define a time corresponding to the end of the study and a boundary when
the time reaches the horizon Th :Ξ2 = {x : θ ≥ Th}
– another boundary is reached when the patient is undergoing a cycle of injections
and 7 days have passed since the last injection:Ξ3 = {x : n < ninj, σ = 7, θ < Th}
– we also consider a boundary when at least one cycle was already achieved and the
count of cells is equal to or below the threshold of 500 cells/µL . We also assume a
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minimum time σmin is observed between the beginning of two consecutive cycles:
Ξ4 = {x : p + r ≤ 500, n = ninj, σ ≥ σmin, θ < Th}
– finally, an artificial boundary is created when π has not returned to its baseline
value 7 days after the last injection of a cycle: Ξ5 = {x : γ > 1, n = ninj, σ =
7, θ < Th}
We define the active boundary asΞ = 1∪Ξ2∪Ξ3∪Ξ4∪Ξ5. In this process, actions
(IL-7 injections) can only be realized when the process hits the active boundary. We
model the possibility of not doing an injection in a given cycle by using a fictive dose
d0 equal to zero. When beginning a new cycle of injections, the first injection needs to
be positive though. The possible action made by the decision-maker depends on the
boundary reached. Therefore, for every x ∈ Ξ :
A(x) =
⎧⎨
⎩
{d1, ..dmd } if x ∈ Ξ1 ∪Ξ4
{0, d1, ..dmd } if x ∈ Ξ3
∅ if x ∈ Ξ2 ∪Ξ5
We also define the transition measure (or Kernel): it determines the new point from
which the process restarts after a jump. It depends on the injected dose only when the
boundary of the process is reached. All possible situations are the following:
– when the flow hitsΞ1, the study begins with administration of a cycle of injections.
γ takes the value corresponding to the chosen dose. (p, r) = (Pc, Rc), known
values from either equilibrium or biological measures made on the patient before
the beginning of the study
– when the flow hits Ξ2, the study is over and nothing happens from absorbing state
Δ
– when the flow hits Ξ3, a new injection is administered to the patient. γ takes the
value corresponding to the chosen dose γ (d), n increases by one, σ goes back to
0
– when the flow hits Ξ4, a new cycle of injections begins. γ takes the value corre-
sponding to the chosen dose, n goes back to 1, σ goes back to 0
– when the flow hits Ξ5, there is no injection. γ goes back to 1
– in case of spontaneous jump, there is no injection and γ goes back to 1
In a formal way, the Kernel Q is written:
Q(dy|x, d) = δ(γ (d),1,0,1,Pc,Rc)(dy)1{x∈Ξ1} + δΔ(dy)1{x∈Ξ2}
+ δ(γ (d),n+1,0,θ,p,r)(dy)1{x∈Ξ3} + δ(γ (d),1,0,θ,p,r)(dy)1{x∈Ξ4}
+ δ(1,n,σ,θ,p,r)(dy)1{x∈Ξ5} + δ(1,n,σ,θ,p,r)(dy)1{x∈X˜}
The impulse control problem consists in determining the optimal scheme of injec-
tions and their associated dose according to a given optimality criterion, based on the
cost function C: in our case, this cost function depends on the number of injections
realized and the time spent with the CD4+ T lymphocytes levels under the threshold
of 500 cells/µL. Both quantities need to be minimized, in order to maintain the patient
in good health by injecting the least possible. The cost can be divided in two parts.
First, the gradual cost penalizes the trajectory of the process through the time spent
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under the threshold after the beginning of the first cycle. This time is considered in
months, approximately, as it is computed as the number of days divided by 30. For
x = (γ, n, σ, θ, p, r) ∈ X˜ :
Cg(x) =
1
30
1{p+r<500}1{θ≥1}
Then, the cost associated with an impulsive action penalizes the fact of injecting IL-7
to the patient:
C i (x, d) = 1{x∈Ξ1∪Ξ4} + 1{d 
=0}1{x∈Ξ3}
After the horizon, the cost is null, as C i (Δ) = Cg(Δ) = 0.
3 Optimal Control
In this section, we will first remind the main theoretical results obtained in Costa et al.
(2016), then we will transpose these results to our particular context.
3.1 Main Theoretical Results
The objective of this section is to adapt some results obtained in Costa et al. (2016) to
our specific context. We follow closely their notation. The set of all realized injections
over a given horizon constitutes the strategy of injections. In a more formal way, a
strategy u of the decision-maker is a sequence u = {un}n∈N of functions un : X → A
giving the action to realize at punctual time points tn ≥ 0 when the system is in state
x ∈ X . The set of all admissible strategies is noted U . According to section 2.2 in
Costa et al. (2016), there exists a continuous-time stochastic process ξ defined on
probabilistic space using characteristics φ, η and Q depending on the action given
by u, such that ξt , t ∈ R+ corresponds to the state of the variables at time t . To
each admissible strategy u ∈ U , we associate a discounted cost optimality criterion
depending on the gradual cost on the trajectory of the process ξ , Cg , and the cost
related to an injection, C i , as defined in Sect. 2.3:
V(u, x0) = Eux0
[ ∫
]0,+∞[
e−αsCg(s)ds
]
+Eux0
[ ∫
]0,+∞[
e−αs I{ξs−∈}
∫
A(ξs−)
C i (ξs−, a)u(da|s)μ(ds)
] (3)
with α > 0 the discount factor and where μ is a measure that counts the number
of jumps in the process. The impulse control problem aims at finding a strategy u
minimizing the discounted cost optimality criterion. Here we want to determine the
patient-specific schedule of injections and their dose to optimize the patient’s CD4+ T
lymphocyte numbers by using a minimum number of injections. The theorem allow-
ing to determine the optimal cost and providing an optimal strategy is adapted from
Theorem 5.5 in Costa et al. (2016). It is stated as followed:
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Theorem 1 Suppose assumptions A, B and C from section 3.2 in Costa et al. (2016)
are verified. We define the sequence of functions {Wq}q∈N for any x ∈ X as follows:{
Wq+1(x) = BWq(x) for q ∈ N
W0(x) = −K A1Aε1 (x)− (K A + K B)1Acε1 (x)
(4)
with constants K A and K B defined as in section 5 of Costa et al. (2016), Aε1 = {x ∈
X : t∗(x) > ε1} and
BV (y) =
∫
[0,t∗(y)[
e−(K+α)tRV (φ(y, t))dt + e−(K+α)t∗(y)TV (φ(y, t∗(y))) (5)
with real-value functions RV and TV defined for any V , respectively, on X and Ξ :
RV (x) = Cg(x)+ qV (x)+ ηV (x)
TV (z) = inf
d∈A(z)
{
C i (z, d)+ QV (z, d)
}
q being the signed kernel, which computes the difference between the states before
and after the spontaneous jump. For x ∈ X, it is defined with:
q(dy|x) = η(x)[Q(dy|x)− δx (dy)]
The sequence of functions {Wq}q∈N converges to a function W defined on the state
space and such that:
(i) W (x0) = infu∈U V(u, x0), with V defined as in Eq. 3
(ii) there is a measurable mapping ϕ̂ : Ξ → A such that ϕ̂(z) ∈ A(z) for any z ∈ Ξ
and satisfying
C i (z, ϕ̂(z))+ QW (z, ϕ̂(z)) = inf
d∈A(z)
{
C i (z, d)+ QW (z, d)
}
. (6)
This theorem allows to determine the optimal cost and an optimal injection strategy,
consisting in choosing the optimal action ϕ̂(z) for every point z ∈ Ξ reached on
the trajectory of the process. Indeed, the iteration of the sequence {Wq}q∈N defined
by Eq. 4 can be realized by numerically approximating the operator B defined in
Eq. 5. This will give an approximation of the function W , and in particular of W (x0),
corresponding to the optimal cost. Moreover, to obtain an optimal strategy, the process
is the following: we simulate a trajectory from x0, then when a boundary is reached, the
chosen action corresponds to the one minimizing the criterion C i (z, d)+ QW (z, d),
as given by Eq. 6.
3.2 Application
The process describing the effect of IL-7 on CD4+ T lymphocytes dynamics is now
well defined by its characteristics φ, η and Q, boundaries and possible actions in
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Sect. 2.3. Moreover, both gradual cost on the trajectory and impulse cost were defined
in that section. We will quickly describe in this part how to apply the results from
Theorem 1 for our specific problem, i.e., determining the function B needed for the
computation of the optimal strategy. For a more detailed and formal computation, we
refer the reader to “Appendix A”. We need to compute:
BV (y) =
∫
[0,t∗(y)[
e−(K+α)tRV (φ(y, t))dt + e−(K+α)t∗(y)TV (φ(y, t∗(y)))
We define
G(V , y) =
∫
[0,t∗(y)[
e−(K+α)tRV (φ(y, t))dt (7)
and
H(V , y) = e−(K+α)t
∗(y)
TV (φ(y, t∗(y)) (8)
We define a time interval Δt (in practice equal to 1 day) and for every y =
(γ, n, σ, θ, p, r) ∈ X˜ , we note
n∗(y) =
⌊
t∗(y)
Δt
⌋
For every j ∈ {0..n∗(y) − 1}, we denote φ j (y, t) = φ(y, jΔt) and φ(y, t∗(y)) =
(γ, n, σ+t∗(y), θ+t∗(y), p∗(y), r∗(y)). The integral defined in Eq. 7 is computed by
approximation using the classic trapezoidal rule using the jΔt nodes. Thus, G(V , y)
can be approximated by a linear combination of {V (y j )} j∈{0..n∗(y)−1}, with y j depend-
ing on φ j (y, t). Moreover, H(V , y) is proportional to V (y), with y depending on the
boundary reached in φ(y, t∗(y)). Finally, for every point y ∈ X˜ , if we note y = yn∗(y),
BV (y) can be computed as a linear combination of {V (y j )} j∈{0..n∗(y)}.
4 Numerical Aspects of the Dynamic ProgrammingMethod
From Theorem 1, we know that we need to compute the sequence {Wq}q∈N such that
for y ∈ X, W0(y) = −K A1Aε1 (y) − (K A + K B)1Acε1 (y) and Wq+1(y) = BWq(y)
for q ∈ N. The sequence converges to a function W defined on X that allows the
determination of the optimal cost and the optimal protocol of injections achieving
that cost. This computation is realized on a grid of the state space: at each iteration
q, a new matrix is computed, each element on line v and column s corresponding to
BWq(xvs), with xvs element of the grid Γ of the state space. The implementation of
our algorithm was realized in Matlab version R2016b (The MathWorks, Inc., Natick
MA, USA, 1984). In this section, we give elements to understand how the method is
implemented. The structure of the code is detailed in “Appendix B”.
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4.1 Discretization of the State Space
The grid Γ contains points of the form (γ, n, σ, θ, p, r). γ and n are discrete variables
with γ ∈ {1 . . .md + 1}, n ∈ {1..ninj}. σ and θ are discretized with a time step of
1 day, with σ ∈ {0..σmax} and θ ∈ {0..Th}. Solutions p and r of the ODE system are
continuous and are discretized in a regular grid, with p ∈ {pmin..pmax} with regular
step h p and r ∈ {rmin..rmax} with regular step hr . We then obtain:
n p =
pmax − pmin
h p
+ 1
nr =
rmax − rmin
hr
+ 1
hr and h p are chosen such that both n p, nr ∈ N count the number of values of p and
r on the grid, respectively.
4.2 Organization of the Grid
We arrange all points of the grid Γ in a matrix M of size Nsum × Npr , with Nsum
corresponding to the number of possible (γ, n, σ, θ) combinations and Npr = n pnr
number of possible (p, r) combinations. Each element M(v, s)v∈{1..Nsum}
s∈{1..Npr }
corresponds
to a given combination (γ, n, σ, θ, p, r) of Γ , through the following bijection:
χ : Γ → {1..Nsum} × {1..Npr }
xvs = (γ, n, σ, θ, p, r) → (v, s) =
(
χl(γ, n, σ, θ), χc(p, r)
)
χl is defined in the following way: v corresponds to a given value of (γ, n, σ, θ).
Possible combinations of (σ, θ) depend on the value of (γ, n): for example, during
the first cycle, when n = 1, σ = 0 is associated with θ = 1, while when n = 2, σ = 0
is associated with θ = 8. We divide the lines of matrix M by defining then Nγ n =
(md+1)ninj blocks, corresponding to the possible combinations of (γ, n). Each block is
indexed by i = f (γ, n) = γ +(md+1)(n−1) ∈ {1..Nγ n} and contains combinations
of (σ, θ), indexed by j = gi (σ, θ) ∈ {1..Nbi }within the i-th block. The total number of
lines of matrix M is the sum of the number of lines in each block: Nsum =
∑Nγ n
i=1 Nbi .
We can define a vector lblock = (1, 1 + Nb1 , .., 1 +
∑k
i=1 Nbi , ..,
∑Nγ n−1
i=1 Nbi ) of
length Nγ n , that determines the index of the first line of each block. Finally:
v = χl(γ, n, σ, θ) = lblock(i)+ j − 1
with i = f (γ, n) and j = gi (σ, θ). χc is defined in the following way:
s = χc(p, r) =
p − pmin
h p
+ 1 + n p
r − rmin
hr
such that s = 1 when (p, r) = (pmin, rmin) and s = n pnr when (p, r) = (pmax, rmax).
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4.3 Iteration of the Algorithm
Each iteration of the algorithm computes then a matrix Mq such that
Mq(v, s) = Wq
(
M(v, s)
)
= Wq(xvs)
For every x = (γ, n, σ, θ, p, r) ∈ Γ , Wq(x) is a linear combination of some Wq(xm),
m ∈ {1..Mx }, as shown in Eq. 12 from “Appendix A”. Values of Wq(xm) are given by
Mq(χ(xm)); they are linearly combined and implemented in Mq+1(χ(x)).
4.4 Convergence Criterium
We assume that the sequence converges when ‖Wq+1 − Wq‖∞ < ǫ. In practice, we
compute maxv,s |Mq+1(v, s)−Mq(v, s)| and we consider that the sequence converges
with ǫ = 0.001. It usually occurs after 35 to 45 iterations.
5 Results
We applied the previously described method to the model detailed in Sect. 2.3, with a
choice of md = 2 possible doses: d = [0, 10, 20] (unit = µg/kg), cycles of 3 injections:
ninj = 3 and a reduced horizon Th = 365 days. We also assumed a minimum time
of σmin = 30 days between the end of a cycle and the beginning of a new one. For a
given patient with fixed biological parameters, we can approximate the function W in
a grid of the state space through convergence of the sequence {Wq}: this determines
the optimal cost over all strategies. Moreover, using Eq. 6 from Theorem 1, we can
simulate the strategy choosing the optimal action to realize when reaching the boundary
of the state space and compute the cost of the obtained strategy. As some randomness
is included in the model by the time of effect of an injection of parameter π , we
simulate N = 5000 realizations of a protocol on a given patient with a Monte Carlo
method and compute the expectation of its cost. From that, we check the numeric
performance of our method by first comparing the cost of the optimal strategy to the
computation of the optimal cost from the value function W . Moreover, we wish to
compare the optimal strategy to other “naive” protocols. For each protocol, including
the optimal one, we compute by Monte Carlo the mean cost, the standard deviation and
the minimum cost achievable. This is usually reached when the patient responds well
to all injections, i.e., the effect of the injection on parameter π lasts 7 days after every
injection. In order to compare protocols based on clinical criteria, we also computed
by Monte Carlo the mean number of CD4+ T cells count until horizon, the mean
time spent under 500 cells/µL (in days) and the mean number of injections over all
simulations. These comparisons were realized with 50 pseudo-patients. Parameters
values were generated from the posterior law estimated on real data from INSPIRE
trials in Thiébaut et al. (2016). Patients are divided in three categories according to
their initial levels of CD4+ T cells: “very low” baseline (100−200 cells/µL), “low”
baseline (200−300 cells/µL) and “not too low” baseline (300−400 cells/µL). Table 1
sums up the characteristics of the pseudo-patients population.
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Table 1 Characteristics of the
pseudo-patients population Parameter Mean (SD)
λ (cells/day) 2.24 (0.39)
ρ (/day) 1.96 (0.84)
π0 (/day) 0.0461 (0.0035)
μR (/day) 0.0503 (0.0033)
μP (/day) 0.0717 (0.014)
βπ1 0.958
βπ2 0.752
βπ3 0.143
Category Number of patients (%)
Very low 4 (8%)
Low 24 (48%)
Not too low 22 (44%)
Table 2 Comparison of cost
values from value function and
Monte Carlo simulation
Patient A Patient B Patient C
very low low not too low
Optimal cost W (x0) 9.47 6.11 2.87
Cost of optimal strategy:
mean (SD) (obtained by
Monte Carlo)
9.53 (0.85) 6.20 (0.56) 2.90 (0.36)
We first compare the value of the optimal function obtained from the numerical
computation of W with the cost of the optimal strategy. For a sake of clarity, we show
detailed results in Table 2 only for three chosen patients. Patient A is in category “very
low”, patient B in category “low” and patient C in category “very low”. We note that
for these three patients the two cost values are very similar, meaning that we make
a good approximation of the value function with our numerical method. We make
the same observation on the 47 other patients (data not shown). Also of note is the
hierarchy of the cost between the categories of patients. Very low patients have higher
optimal costs (between 8.4 and 12) than low (between 3.9 and 9.4) and not too low
(between 2.1 and 4.2). This is consistent with the fact that the lower baseline CD4
levels the patient has, the more time will be spent under 500 cells/µL and the more
injections are needed, which both increase the cost of the strategy of injections.
We also realized comparisons of several protocols. We simulated five “naive” proto-
cols: P1 with 3-injections cycles, P2 with a first cycle of 3 injections then 2-injections
cycles, P3 with 2-injections cycles, P4 with a first cycle of 2 injections then 1-injection
cycles and P5 with 1-injection cycles, all protocols with dose 20. Assessing the cost
of these protocols is interesting as they imply variable trajectories within the same
patient as well as different values for clinical criteria. Moreover, they would be clini-
cally feasible and represent a good basis for comparison for our optimal strategy. For
every protocol k, we note P+k the space of patients such that cost of optimal strategy
is lower than cost of protocol k and n+k its size. We have computed the mean relative
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Table 3 Computation of the mean relative variation of cost value (MRC) for every protocol allows
determining the mean percentage of gain in term of cost function when using the optimal strategy over
protocol k
Protocol P1 P2 P3 P4 P5
n+ 50 50 50 49 50
MRC (%) 43 31 20 5.7 8.8
P1 Cycles of 3 injections. P2 First cycle of 3 injections then cycles of 2 injections. P3 Cycles of 2 injections.
P4 First cycle of 2 injections then cycles of 1 injection. P5 Cycles of 1 injection
positive variation of cost value (MRC), as shown in Table 3. We note Copti the mean
cost of optimal strategy for patient i and CPki the mean cost of protocol k for patient
i . The MRC allows computing the mean percentage of gain in term of cost function
when using the optimal strategy over protocol k:
MRCk =
1
n+k
∑
i∈P+k
(CPki − Copti )
CPki
(9)
Results show that mean cost of the optimal strategy is always lower than all other
simulated strategies (except one patient for protocol 4, but this is due to numerical
approximation, as for this patient W (x0)=4.0, Copt = 4.1 and CP4 =4.0). The percent-
age of cost reduction of the optimal strategy compared to the other protocols in the
simulated population of pseudo-patients varies from 5.7 to 43%. It confirms that our
numerical method allows optimizing the cost function.
In addition to comparing the cost value of all five protocols to the optimal strategy,
we have also compared clinical criteria such as the mean number of CD4+ T cells count
until horizon, the mean time spent under 500 cells/µL (in days) and the mean number
of injections over all simulations. Results of these comparisons are shown in Fig. 2,
where each point corresponds to the value of the criterion for one pseudo-patient, and
each color corresponds to the category of the patients (“very low”, “low” and “not
too low” baseline). We observe that mean cost of the optimal strategy is lower than
other simulated protocols and the optimal strategy achieves a good balance between all
clinical criteria. Even if CD4+ T cells levels are not as high as for protocols P1, P2 and
P3, the optimal strategy allows to spend as much time with levels over 500 cells/µL
as these protocols by using less injections. Protocol P5 has the same performance as
the optimal strategy for “not too low” patients, as these strategies are very often the
same on these patients. The same observation is made on protocol P4 and the “low”
patients. Overall, Fig. 2 shows that the determined strategy allows optimization of
the cost function through the chosen criteria (time spent under 500 and number of
injections).
More detailed results of comparison of cost function and clinical criteria between
optimal strategy and protocols Pk are displayed in Table 4 for patients A, B and C.
For these three patients, we observe again that mean cost of the optimal strategy is
lower than all other simulated strategies. For patient A, the optimal strategy is achieved
by two first cycles of two injections then cycles of one injection. For patient B, the
optimal strategy consists in a first cycle of 2 injections followed by 1-injection cycles.
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Fig. 2 (Color figure online) Comparison of cost (a) and clinical criteria (b mean number of CD4+ T cells count until horizon, c mean time spent under 500 cells/µL in days, d
mean number of injections over all simulations) between the determined optimal strategy and the five other protocols. Each point corresponds to the value of a pseudo-patient,
with “very low” patients in yellow, “low” in purple and “not too low” in blue. Mean values within each category are represented by horizontal colored lines. P1: cycles of 3
injections. P2: first cycle of 3 injections then cycles of 2 injections. P3: cycles of 2 injections. P4: first cycle of 2 injections then cycles of 1 injection. P5: cycles of 1 injection
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Table 4 Comparison of protocols of injections for patients A, B and C
Protocol P1 P2 P3 P4 P5 Optimal
Patient A
Mean cost 14.8 11.6 10.7 10.4 11.1 9.53
Std 0.52 0.62 0.68 1.21 1.23 0.85
Min cost 14.6 11.4 10.4 9.56 10.1 8.82
CD4 mean 671 662 659 552 506 578
Days under 500 54.5 55.4 56.5 102 150 58.0
Number of injections 15.1 11.1 10.2 8.25 7.48 8.66
Patient B
Mean cost 9.35 7.62 6.91 6.26 6.63 6.20
Std 1.14 1.00 0.98 0.70 0.87 0.56
Min cost 8.62 6.91 6.14 5.91 6.12 5.91
CD4 mean 762 742 736 622 598 625
Days under 500 18.4 19.0 24.2 28.1 61.9 24.4
Number of injections 9.83 7.73 6.84 6.05 5.27 6.10
Patient C
Mean cost 5.54 4.75 3.80 3.08 2.93 2.90
Std 0.29 0.24 0.31 0.37 0.49 0.36
Min cost 5.46 4.70 3.73 2.95 2.79 2.79
CD4 mean 774 762 758 666 631 631
Days under 500 5.56 5.53 5.65 5.90 8.43 5.89
Number of injections 6.02 5.02 4.04 3.13 3.03 3.07
P1 Cycles of 3 injections. P2 First cycle of 3 injections then cycles of 2 injections. P3 Cycles of 2 injections.
P4 First cycle of 2 injections then cycles of 1 injection. P5 Cycles of 1 injection
We can see that the minimum cost is the same for the optimal strategy and protocol P3
(= 5.91): when the patient has a good response to all injections, these strategies are the
same. For patient C, the optimal strategy is obtained with 1-injection cycles. Similarly,
the minimum cost is the same for the optimal strategy and protocol P5 (= 2.79). For all
patients, the optimal strategy is very intuitive: the first complete cycles are needed to
raise the number of CD4 over 500 cells/µL; then, 1-injection cycles allow to sustain
the levels over 500 cells/µL. For “not too low” patients, CD4 levels are high enough to
use only one injection in the first cycle. This helps reducing the number of injections:
in patient A, the optimal strategy requires 2–7 less injections than P1, P2 and P3 but
allows to spend as much time over 500 cells/ µL. In patient C the optimal strategy
requires one less injection as P3 but allows to spend as much time over 500 cells/
µL. It can be noted that a third injection is never used, even for the first cycles of
very low patient. It is due to our choice of cost function: it balances the number of
injections and the number of months spent under 500 cells/µL. The effect of a third
injection is usually too low to allow increasing the time spent over 500 cells/µL by
1 month and is then not chosen as part of the optimal strategy. These results suggest
that our numerical method allows to determine an optimal strategy of injections, and
the clinical interpretation of the results are consistent with the mathematical method.
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Fig. 3 Dynamics of CD4+ T lymphocytes in patient A. Straight line corresponds to the “best” outcome, i.e.,
when the effect of all injections lasts 7 days. Dashed line corresponds to other possible trajectories, when this
effect can last less than 7 days. a Dynamics of CD4+ T lymphocytes in patient A under P3, a 2-injections
cycles protocol (dose 20). b Dynamics of CD4+ T lymphocytes in patient A under the determined optimal
strategy
In terms of trajectories of the process, Fig. 3a, b show some trajectories obtained
with, respectively, the 2-injection cycles protocol (P3) and the optimal strategy for
patient A. We can note that even if CD4+ levels are globally lower in the optimal
strategy compared to the two injections cycles at dose 20 µg/kg, it still allows a
maintenance over the threshold of 500 cells/µL by using less injections: indeed, in
the best case scenario, the 2-injections cycle strategy implies 5 cycles of 2 injections
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which is a total of 10 injections, while the optimal strategy induces 2 cycles of 2
injections and 4 single injections, which is a total of 8 injections. The trajectories for
patients B and C are provided in “Appendix D”. All together, our results support the
interest of determining the optimal strategy based on a criterion combining both the
number of injections and the time spent under 500.
6 Discussion
In this work, we have developed a numerical tool allowing to solve an impulse control
problem for a PDMP. The specificity of our work is in the development of a dynamic
programming method in the context of a specific biological framework. The objective
is to determine the optimal strategy of IL-7 injections for a given HIV-infected patient,
in order to maintain CD4+ T lymphocytes levels over the threshold of 500 cells/µL.
We first modeled the dynamics of CD4+ T lymphocytes during repeated cycles of
IL-7 injections by a PDMP. Then, we solved the impulse control problem by iterating
a sequence defined by an integro-differential operator. Theoretical results have shown
that this sequence converges to the value function, which allows to determine the
optimal action that should be realized at every point of the boundary. We proposed a
numerical tool approximating the sequence and the value function on a grid of the state
space and applied it to our clinical question. As our method relies on numerical approx-
imation, the obtained optimal strategy could be an approximation of the theoretical one.
However, the obtained results suggest that we managed to determine optimal strategies
for pseudo-patients and that our method allows improving the strategy of injections.
Although the horizon of study is only 1 year, these results are also consistent with a clin-
ical interpretation. The optimal strategy determined for different patients is indeed intu-
itive: the first cycles aim at increasing the CD4+ T lymphocytes levels and should con-
tain as many injections as possible until the levels are acceptable. Then, the following
cycles sustain the CD4 levels over the threshold, and punctual injections are sufficient
to reach this objective. The optimal strategy, determined with our method, has a lower
cost than other possible clinical strategies. Actually, the obtained optimal strategy
depends on the cost previously defined, and we could explore other optimal strategies
depending on other cost functions. For example, it could be interesting to use different
weights on the time spent under 500 cells /µL and the number of injections (depending
on the clinician priorities), or to account for the possible negative side effects due to
higher doses (this would need additional data on the question). Finally, the model could
be extended by studying the patient until a longer horizon (up to 2 years). This rises
the issue of the increase in computational time (by increasing the size of the grid of the
state space) and constitutes a new challenge in itself. In the end, we hope to use this tool
in future possible clinical trial investigating the effect of IL-7 injections with patients-
specific schedules of injections, personalized and optimized using this method.
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A Optimal Control: Application
We defined the process describing the effect of IL-7 on CD4+ T lymphocytes dynamics
by its characteristics φ, η and Q, boundaries and possible actions in Sect. 2.3. We also
defined both gradual cost on the trajectory and impulse cost in that section. As we aim
at applying the results from Theorem 1 to determine the optimal cost and an optimal
strategy by dynamic programming, we need to determine how to compute numerically
the function B to iterate the sequence {Wq}q∈N defined in Eq. 4. As a reminder, B is
defined in Costa et al. (2016) by:
BV (y) =
∫
[0,t∗(y)[
e−(K+α)tRV (φ(y, t))dt + e−(K+α)t∗(y)TV (φ(y, t∗(y)))
We will first detail the computation of R then T, and we will finally show how to
compute B.
Computation ofR
For x = (γ, n, σ, θ, p, r) ∈ X , and function V : X → R, R is defined as:
RV (x) = Cg(x)+ qV (x)+ ηV (x)
with q computing the difference between the states before and after the spontaneous
jump. As Q depends on the action only when the process hits the active boundary,
q(dy|x, d) = η(x)[Q(dy|x)− δx (dy)]
= 1{γ>1}η[δ(1,n,σ,θ,p,r)(dy)− δ(γ,n,σ,θ,p,r)(dy)]
then for every function V , and as K = η:
qV (x) =
∫
V (y)q(dy|x)
= 1{γ>1}K [V (1, n, σ, θ, p, r)− V (γ, n, σ, θ, p, r)]
Then
RV (x) =
1
30
1{p+r≤500} + qV (x)+ K V (x)
=
1
30
1{p+r≤500} + K V (1, n, σ, θ, p, r)1{γ>1} + K V (x)1{γ=1}
Finally,
RV (x) =
1
30
1{p+r≤500} + K V (1, n, σ, θ, p, r)
RV (Δ) = K V (Δ)
(10)
Computation ofT
For x ∈ Ξ , and function V : X → R, T is defined as:
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TV (x) = inf
d∈A(x)
{
C i (x, d)+ QV (x, d)
}
= inf
d∈A(x)
{
1x∈Ξ1∪Ξ4 + 1d 
=01x∈Ξ3 +
∫
V (y)
[
δ(γ (d),1,0,1,Pc,Rc)(dy)1{x∈Ξ1}
+ δΔ(dy)1{x∈Ξ2} + δ(γ (d),n+1,0,θ,p,r)(dy)1{x∈Ξ3}
+ δ(γ (d),1,0,θ,p,r)(dy)1{x∈Ξ4}
+ δ(1,n,σ,θ,p,r)(dy)1{x∈Ξ5}
]}
Finally,
TV (x) = inf
d∈A(x)
{
[1 + V (γ (d), 1, 0, 1, Pc, Rc)]1x∈Ξ1
+[1d 
=0 + V (γ (d), n + 1, 0, θ, p, r)]1x∈Ξ3
+[1 + V (γ (d), 1, 0, θ, p, r)]1x∈Ξ4
}
+ V (Δ)1x∈Ξ2
+ V (1, n, σ, θ, p, r)1x∈Ξ5
TV (Δ) = V (Δ)
(11)
Computation ofB
Now, for Y ∈ X , and function V : X → R, we need to compute:
BV (y) =
∫
[0,t∗(y)[
e−(K+α)tRV (φ(y, t))dt + e−(K+α)t∗(y)TV (φ(y, t∗(y)))
As we cannot make an exact computation of BV on X , we need to approximate this
computation on a grid of the state space. In order to detail the approximation of the
computation, we define
G(V , y) =
∫
[0,t∗(y)[
e−(K+α)tRV (φ(y, t))dt
and
H(V , y) = e−(K+α)t
∗(y)
TV (φ(y, t∗(y))
as in Eqs. 7 and 8. We define a time interval Δt (in practice equal to 1 day) and for
every y = (γ, n, σ, θ, p, r) ∈ X˜ , we note
n∗(y) =
⌊
t∗(y)
Δt
⌋
For every j ∈ {0..n∗(y) − 1}, we note φ j (y, t) = φ(y, jΔt) and φ(y, t∗(y)) =
(γ, n, σ + t∗(y), θ + t∗(y), p∗(y), r∗(y)). The integral defined in Eq. 7 is computed
by approximation using the classic trapezoidal rule using the jΔt nodes:
G(V , y) ≃
Δt
2
RV (y)+
Δt
2
e−(K+α)t
∗(y)
RV (φ(y, t∗(y)))
+
n∗(y)−2∑
j=1
Δte−(K+α) jΔtRV (φ j (y, t))
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with RV (x) =
1
30
1{p+r≤500} + K V (1, n, σ, θ, p, r), as computed in Eq. 10. Then
we obtain the following for every y = (γ, n, σ, θ, p, r) ∈ X˜ :
G(V , y) =
Δt
2
(
1
30
1{p+r<500} + K V (1, n, σ, θ, p, r)
)
+
Δt
2
e−(K+α)t
∗(y)
(
1
30
1{p∗+r∗<500}
+ K V (1, n, σ + t∗, θ + t∗, p∗(y), r∗(y))
)
+Δt
n∗(y)−2∑
j=1
e−(K+α) jΔt
(
1
30
1{p j+r j<500}
+ K V (1, n, σ + jΔt, θ + jΔt, p j , r j )
)
Now, we need to compute H as defined in Eq. 8: it depends onTV (φ(y, t∗(y))), which
takes different values according to the boundary reached in that point, as written in
Eq. 11. Moreover, as we know the flow, we can give conditions on y = (γ, n, σ, θ, p, r)
to reach a given boundary in φ(y, t∗(y)). Then:
– if φ(y, t∗(y)) ∈ Ξ1 (θ ≤ 1) then
H(V , y) = inf
d∈[d1,..dmd ]
{
e−(K+α)t
∗(y)
[
1 + V (γ (d), 1, 0, 1, Pc, Rc)
]}
– if φ(y, t∗(y)) ∈ Ξ2 (θ + t∗(y) ≥ Th) then
H(V , y) = e−(K+α)t
∗(y)V (Δ)
– if φ(y, t∗(y)) ∈ Ξ3 (n < ninj, θ + t∗(y) < Th) then
H(V , y) = infd∈[0,d1,..dmd ]
{
e−(K+α)t
∗(y)
[
1{d 
=0}
+ V (γ (d), n + 1, 0, θ + t∗(y), p∗(y), r∗(y))
]}
– if φ(y, t∗(y)) ∈ Ξ4 (n = ninj, γ = 1, θ + t∗(y) < Th) then
H(V , y) = inf
d∈[d1,..dmd ]
{
e−(K+α)t
∗(y)
[
1 + V (γ (d), 1, 0, θ
+ t∗(y), p∗(y), r∗(y))
]}
– if φ(y, t∗(y)) ∈ Ξ5 (n = ninj, γ > 1, θ + t∗(y) < Th) then
H(V , y) = e−(K+α)t
∗(y)V (1, n, σ + t∗(y), θ + t∗(y), p∗(y), r∗(y))
Finally, for every y = (γ, n, σ, θ, p, r) ∈ X˜ :
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BV (y) =
Δt
2
(
1
30
1{p+r<500} + K V (1, n, σ, θ, p, r)
)
+
Δt
2
e−(K+α)t
∗(y)
[ 1
30
1{p∗+r∗<500} + K V (1, n, σ
+ t∗, θ + t∗, p∗(y), r∗(y))
]
+Δt
n∗(y)−2∑
j=1
e−(K+α) jΔt
[ 1
30
1{p j+r j<500}
+ K V (1, n, σ + jΔt, θ + jΔt, p j , r j )
]
+ inf
d∈[d1,..dmd ]
{
e−(K+α)t
∗(y)
[
1 + V (γ (d), 1, 0, 1, Pc, Rc)
]}
1{θ≤1}
+ e−(K+α)t
∗(y)V (Δ)1{θ+t∗(y)≥Th}
+ inf
d∈[0,d1,..dmd ]
{
e−(K+α)t
∗(y)
[
1{d 
=0}
+ V (γ (d), n + 1, 0, θ + t∗(y), p∗(y), r∗(y))
]}
1{n<ninj,θ+t∗(y)<Th}
+ inf
d∈[d1,..dmd ]
{
e−(K+α)t
∗(y)
[
1 + V (γ (d), 1, 0, θ + t∗(y), p∗(y), r∗(y))
]}
×1{n=ninj,γ=1,θ+t∗(y)<Th}
+ e−(K+α)t
∗(y)V (1, n, σ + t∗(y), θ + t∗(y), p∗(y), r∗(y))
×1{n=ninj,γ>1,θ+t∗(y)<Th} (12)
and
BV (Δ) =
∫
[0,+∞)
e−(K+α)t K V (Δ)dt =
K
K + α
V (Δ)
B Structure of the Code
Structure of the code and its subroutines are shown in Fig. 4. Application in the results
section requires the following grid:
– γ ∈ {1..3}
– n ∈ {1..3}
– σ ∈ {0..351}
– θ ∈ {1..365}
– p ∈ {2..110} depending on the patient
– r ∈ {100..1500} depending on the patient
The grid of the state space created in Matlab contains 67,614 lines and 7755 columns.
For a given patient, the computation of 40 iterations of the sequence (convergence is
reached between 35 and 45 iterations) requires between 5 and 6 days.
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SequenceBW
Initiation W0 (from S3)
Iteration q+1 for every v ∈ {1..Nsum}, s ∈ {1..Npr}
Step 1:
Determine xvs = (γ, n, σ, θ, p, r) = χ
−1((v, s)) by identifying block i (γ,n),
line j (σ,θ) using S1, column s (p,r).
Step 2:
Get t∗(xvs) with S3 and the flow from xvs with S2 =⇒ define the elements
of the grid xm necessary for the computation of GWq(xvs).
Step 3:
Determine the positions χ(xm) of xm in the grid using S1.
Step 4:
From previous iteration, get Wq(xm) = Mq(χ(xm)) and use linear combina-
tion determined in Appendix A to compute GWq(xvs)
Step 5:
Determine boundary reached in t∗(xvs) and compute HWq(xvs) as in
Appendix A.
Step 6:
Compute Wq+1(xvs) = GWq(xvs) +HWq(xvs)
Outputs: at each iteation q, a matrix Mq of size Nsum × Npr with value of
Wq(xvs) in position (v, s).
Subroutine 1 (S1)
Creation of combinations (σ,θ)
Outputs: for every combina-
tion i of (γ,n), a matrix C(σ,θ),i of
size Nbi × 2 containing all possible
pairs (σ,θ) at line j = gi(σ, θ).
Subroutine 3 (S3)
Creation of t∗(x) and W0(x) for
every x of the grid, identified using
S1.
Outputs: a matrix of size
Nsum×Npr with value of t
∗(xvs) in
position (v, s) and a matrix of size
Nsum × Npr with value of W0(xvs)
in position (v, s).
Subroutine 2 (S2)
Creation of flows for every initial
possible (p, r) of the grid.
Outputs: for every combina-
tion i of (γ,n), a matrix Fi of size
np × nr such that F (k, l) is the
approximated flow on the grid from
initial point pk = pmin + (k − 1)hp
and rl = rmin + (l − 1)hr.
Fig. 4 Structure of the code and its subroutines
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C Sensitivity Analysis of theMethod
To evaluate how the uncertainty on individual parameters estimation could impact the
determination of the optimal strategy, we have realized a sensitivity analysis. For a
given patient, we suppose a normal distribution of parameters λ and ρ. We generate
L = 500 pairs of parameters (λ, ρ) from this joint distribution. Each pair corresponds
to an initial value of lymphocytes T CD40. We determine the empirical quartiles of
the distribution of the CD40 and focus on the pairs inducing values close the first and
the third quartiles. Then, for each pair, we simulate the five possible protocols P1 to
P5 and compare them to the optimal strategy determined on the mean value of (λ,ρ).
In practice, values of pairs and associated values of CD4 are displayed in Table 5. For
the mean value of (λ,ρ), we determined the optimal strategy to be a first cycle of 2
injections and then cycles of 1 injection, which corresponds to protocol P4. We show in
Table 5 the cost of each protocol for each pair of (λ,ρ), and we put in bold the minimum
cost over the five protocols. We can see that protocol P4 achieves the minimum cost for
all pairs inducing CD4 values at the first quartile. For pairs inducing CD4 values at the
third quartile, the protocol achieving the minimum cost is P5. However, the difference
of cost is not huge and P4 actually induces more time spent over the 500 threshold
and less than one more injection than P5 on average, which is still acceptable. Overall,
this shows that even with some error on the estimation on λ, ρ we would be able to
determine a strategy achieving a good balance between clinical criteria.
Table 5 Pairs of (λ,ρ), associated CD4 values and mean cost for protocols P1 to P5
Category λ ρ C D40 P1 P2 P3 P4 P5
Mean 2.065 2.022 289 6.55 5.54 5.54 4.16 4.95
Q1 1.506 2.305 224 8.59 6.94 6.03 5.20 5.67
Q1 2.062 1.180 223 11.6 9.19 8.52 7.28 8.02
Q1 1.701 1.747 224 8.94 7.31 6.50 5.60 6.40
Q1 2.163 1.078 222 11.9 9.50 8.82 8.04 8.39
Q1 1.737 1.371 224 9.06 7.39 6.64 5.71 6.48
Q1 1.689 1.758 223 8.92 7.31 6.52 5.62 6.40
Q1 1.728 1.689 224 9.00 7.35 6.63 5.71 6.45
Q1 1.426 2.599 222 8.54 6.90 5.98 5.14 5.62
Q1 2.493 0.838 222 13.3 11.0 10.3 8.85 9.76
Q1 1.805 1.542 223 9.23 7.59 6.94 6.36 6.66
Q3 2.160 2.594 337 5.62 4.81 3.88 3.15 3.04
Q3 2.424 1.956 336 5.83 4.99 4.10 3.81 3.21
Q3 2.638 1.625 335 6.10 5.22 4.30 3.93 3.31
Q3 2.219 2.429 337 5.68 4.85 3.93 3.21 3.11
Q3 2.477 1.879 337 5.87 5.04 4.12 3.83 3.21
Q3 2.466 1.896 337 5.86 5.01 4.09 3.82 3.22
P1 Cycles of 3 injections. P2 First cycle of 3 injections then cycles of 2 injections. P3 Cycles of 2 injections.
P4 First cycle of 2 injections then cycles of 1 injection. P5 Cycles of 1 injection. P4 Is the optimal protocol
for mean value of (λ,ρ)
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D Trajectories of Patients B and C
See Figs. 5, 6.
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Fig. 5 Dynamics of CD4+ T lymphocytes in patient B. Straight line corresponds to the “best” outcome, i.e.,
when the effect of all injections lasts 7 days. Dashed line corresponds to other possible trajectories, when
this effect can last less than 7 days. a Dynamics of CD4+ T lymphocytes in patient B under P3, a 2-injections
cycles protocol (dose 20). b Dynamics of CD4+ T lymphocytes in patient B under the determined optimal
strategy
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Fig. 6 Dynamics of CD4+ T lymphocytes in patient C. Straight line corresponds to the “best” outcome, i.e.,
when the effect of all injections lasts 7 days. Dashed line corresponds to other possible trajectories, when
this effect can last less than 7 days. a Dynamics of CD4+ T lymphocytes in patient C under P3, a 2-injections
cycles protocol (dose 20). b Dynamics of CD4+ T lymphocytes in patient C under the determined optimal
strategy
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4.4 Discussion
4.4.1 Numerical method: consistency with theoretical results,
calibration, performance
In order to ensure consistency with the theoretical results obtained in Costa et al.
[2016], assumptions A, B and C were verified during our work. However, we will not
develop these theoretical considerations, as the focus of our work was mainly on the
development of a numerical tool for solving the optimal control problem using dynamic
programming.
Part of the proof of theorem 1 in Costa et al. [2016] relies on the fact that the se-
quence {Wm}m∈N defined in equation (61) is increasing and uniformly bounded, and thus
converges. Actually, it can be shown that the sequence of function {Vm}m∈N similarly
defined, such that {
Vm+1(x) = BVm(x) for m ∈ N,
V0(x) = KA1Aε1 (x) + (KA +KB)1Acε1 (x),
(64)
is decreasing and uniformly bounded and converges to the same function as the sequence
{Wm}m∈N. This property was verified in the numerical method. As reminded in section 4
of the article from section 4.3, the numerical method computes at each iteration a matrix
containing the value of Wm at all the points of the grid of the state space. For each of
the first pseudo-patients studied, we have checked that Wm+1(x) −Wm(x) ≥ 0 for every
point of the grid until convergence. Moreover, we have run the sequence Vm with the
same criterion of convergence, namely ‖Vm+1−Vm‖∞ < ǫ with ǫ = 0.001 and checked first
that Vm+1(x)− Vm(x) ≤ 0 and that ‖W∞ − V∞‖∞ < ǫ˜ with a small ǫ˜. These verifications
ensured consistency of the numerical method with theoretical results.
As mentioned in the "Results" section of the article presented in section 4.3, we first
evaluated the performance of our optimization algorithm by comparing the approximated
value of the optimal function obtained from the numerical computation ofW with the cost
obtained from numerical approximation of the optimal strategy. The cost is estimated
with Monte Carlo method, by simulating the strategy and the corresponding trajectory
of the process a large number of times. In the article, results were only presented for 3
pseudo-patients among the 50 generated. We also computed a mean relative variation
between these two values on all pseudo-patients by defining:
MRV =
1
50
50∑
i=1
|W (x0)i − Copti |
Copti
, (65)
with W (x0)i given by the approximation of the value function for patient i and Copti the
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value obtained by simulating the trajectories associated to the numerical approximation
of the optimal strategy for patient i. We find a mean relative variation of 1.5%, showing
the consistency of our numerical results. However, the performance of the method could
depend on the precision of the grid of the state space. To evaluate the sensitivity of the
numerical approximation to the grid of the state space, we ran the sequencing algorithm
on the 3 patients A, B and C presented in the article with 3 other grids of the state space.
As mentioned in Appendix B of the article presented in section 4.3, the grid contains
vectors of six elements: (γ, n, σ, θ, p, r). Parameters γ and n only takes a few number of
values, and it makes sense to discretize the time in days, so we evaluated variations only
on the choice of step for the discretization on values of p and r. For all grids, we consider
pmin = 2, pmax = 142, rmin = 100, rmax = 1500 to include most of the patients’ values.
Note that the intervals [pmin; pmax] and [rmin; rmax] can be reduced and adapted to patients
if necessary. The program was run on each grid for the same patients A, B and C as those
presented in the results section of the article presented in section 4.3. Table 4.1 below
sums up the characteristics of the grids of computation, their size and the computation
time requested for each patient. For each patient and each grid, we computed the value
Grid hp hr Size of the Total size Computational time (n
†
it)
p× r grid of the grid Pat A Pat B Pat C
Γ∗1 2 10 10 011 676 883 754 5.5d (34) 7.2d (40) 7.6d (45)
Γ2 10 10 2 115 143 003 610 30h (36) 36h (41) 41h (45)
Γ3 2 50 2 059 139 217 226 28h (35) 36h (43) 37h (44)
Γ4 10 50 435 29 412 090 6.2h (35) 7.7h (41) 8.3h (45)
Table 4.1 – Characteristics of the different grids used for the numerical approximation.
Computational time is in days (d) or hours (h). Γ∗1 corresponds to the grid
used in the article presented in section 4.3. † nit: number of iterations of the
sequence until convergence.
W (x0) corresponding to the minimal cost that can be reached and we also simulated and
computed the cost of the associated optimal strategy. Table 4.2 shows the values and the
MRV computed on these 3 patients. We can see that all grids induce the same optimal
strategy (as simulated by choosing the optimal action when reaching the boundary), as
the value of the cost stays pretty much the same among the different grids. It should
be highlighted here that the strategy is simulated on continuous values of P and R, but
the action is determined by projecting their values on the grid of the state space. This
can explain the differences of values between the grids when simulations of the optimal
strategy are realized. However, we observe larger differences in the determination of the
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Pat A Pat B Pat C
Grid W (x0) Copt(sd) W (x0) Copt(sd) W (x0) Copt(sd) MRV
Γ∗1 2.87 2.90 (0.36) 6.11 6.20 (0.56) 9.44 9.54 (0.85) 1.2%
Γ2 2.91 2.90 (0.36) 6.06 6.21 (0.57) 9.46 9.54 (0.84) 1.2%
Γ3 2.28 2.91 (0.37) 6.51 6.18 (0.57) 8.97 9.80 (0.80) 12%
Γ4 2.45 2.91 (0.38) 5.65 6.21 (0.57) 9.45 9.79 (0.75) 10%
Table 4.2 – Comparison of cost value from value function and Monte Carlo simulations
(with the standard deviation sd) in patients A, B, C on the 4 different grids.
value function between the grids, meaning that the evaluation of the optimal strategy is
more robust that the computation of the value function. In particular, grids Γ3 and Γ4
induce a mean variation of 12 and 10% between the value W (x0) obtained from the value
function and cost function computed with Monte Carlo simulation. With grid Γ3 the
computation time is almost the same as for Γ2, but there is less variation between W (x0)
and the optimal cost obtained with simulations when using Γ2 (only 1.2%). Actually, grid
Γ2 seems to have similar estimations of the value function on these 3 patients as grid Γ1,
with a much lower computation time. If we had to consider increasing the time of the
grid but looking at a longer horizon of time, it could be interesting to investigate further
these considerations (on a larger number of patients) and the grid Γ2 could be a good
choice to reduce computation times.
4.4.2 Cost function
The numerical approximation of the optimal strategy is dependent on the definition
of the cost function. Indeed, the method allows to determine an approximation of the
strategy uˆ minimizing V(u, x0) as in equation (59) and the criterion V directly depends on
the cost function. In our particular framework, the criterion combines the time spent with
CD4 counts below 500 cells/µL and the number of injections realized. The combination
could be weighted to balance these two quantities. We chose to allocate the same cost
to an injection of IL-7 and to spending 30 days below 500 cells/µL. This choice is not
in favor of a third injection in cycle, as we have seen that the third injection has less
effect on the cells’ proliferation than the two previous ones. Most of the time, the third
injection does not allow any patient to increase the sustainability of CD4 levels above
500 cells/µL during more than a month. In order to illustrate the impact of the choice
of the cost function on the ranking of the strategies of injections, we have computed for
patients A, B and C of the article presented in section 4.3 the mean criterion of several
protocols, using either the cost counting the number of months spent below 500 cells/µL
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– used in the article (Cm) or the number of days (Cd). This computation was also realized
for an additional pseudo-patient (written Patient A’, with very low levels of CD4+ T cells
at baseline). Table 4.3 sums up the computed values obtained from protocols P1 to P5
as described in the article section 4.3 and the optimal strategy obtained using Cm (as in
the article), denoted optimalm. We note that for patient C, with not too low levels of
Patient
Protocol
P1 P2 P3 P4 P5 Optimalm
A (very low)
Cm 14.8 11.6 10.7 10.4 11.0 9.54
Cd 65.7 63.5 63.6 102 144 63.4
A’ (very low)
Cm 16.8 13.7 13.2 14.7 14.2 11.8
Cd 96.3 98 103 183 222 109
B (low)
Cm 9.41 7.62 6.91 6.25 6.63 6.21
Cd 27.5 25.3 29.7 32.2 64.2 29.3
C (not too low)
Cm 5.53 4.75 3.80 3.08 2.94 2.89
Cd 10.8 10.0 9.25 8.72 11.3 8.48
Table 4.3 – Comparison of mean criteria for protocols P1 to P5 and optimal strategy writ-
ten Optimalm because it was obtained using Cm, the cost computed from the
number of months spent below 500 cells/µL. Cm corresponds to the criterion
computed from the number of months spent below 500/µL and Cd from the
number of days. For each line, we have written in bold red the worst protocol
(highest cost) and in bold green the best one (lowest cost).
CD4+ T cells at baseline, the optimal strategy determined with Cm still has the lowest
cost among all other protocols P1 to P5. This is also the case for patient A, although
the difference between the optimalm and protocols P2 and P3 is less clear with cost Cd
(63.4, 63.5 and 63.6 respectively). For patients A’ and B, the optimalm strategy does not
have the lowest cost when computed with Cd, and in particular for patient A’ protocol
P1 was the worst using Cm and is the best choice with Cd. Overall, using Cd is not in
favor of protocol P5. This is easily explained by the fact that Cd counts all the days spent
with CD4+ levels below 500 days/µL, and each day has the same weight as one injection
with Cd. This cost function penalizes more the protocols inducing more days with low
CD4 levels (even if less injections are realized, as in P5). It is also the reason why Cd
is more in favor with protocols with a large number of injections for patients requesting
many injections to sustain their CD4 levels. As some subjects tend to spend many more
days with low CD4 levels if the number of injections is reduced compared to others, they
will be more sensitive to the choice of the balance between number of injections and time
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spent with low CD4 levels in the cost function.
We have shown that the choice of the cost function can be crucial for determining
the optimal strategy of injections, but the impact of this choice can also differ among all
participants of the study. The cost function could account for other parameters than the
ones studied. In particular when several doses of a given product are tested, side effects
due to higher doses could be included by accounting for a term dependent of the dose
in the cost function. Finally, these considerations emphasize the need to define the cost
function in agreement with clinicians and real expectations from the optimization of the
design.
4.4.3 Improving the biological model
Our main contribution is a "proof-of-concept", showing that the theory of optimal
control can be applied successfully to the question of optimizing schedule of injections.
As we focused mainly on this proof-of-concept, we chose to work on a simple, although still
realistic, mechanistic model of the effect of IL-7 on the CD4+ T cells dynamics. In order
to apply this method to actual clinical studies, we would need to consider an improved
biological/mechanistic model. This would require first to account for the additional effect
of IL-7 on survival, modeled by a modification of parameter µR after IL-7 injection and
depending on time [Thiébaut et al., 2014]. A cycle effect was also estimated [Jarne et al.,
2017]. It could simply be due to the fact that CD4 counts are higher during the repeated
cycles than at the beginning of the study and the homeostatic regulation of the immune
system limits the number of CD4+ T cells generated; but it could also mean that the
immune system is also responding to IL-7 by generating antibodies against it. Both the
effect of IL-7 on cell survival and the decreased effect of IL-7 on cells proliferation in
the repeated cycles compared to the first one should be accounted in a more biologically
plausible model. For example, the cycle effect could be added in the PDMP by adding a
state variable c counting the number of cycles realized so far. The value of the parameter
π would be different when c = 1 and c > 1.
In term of modeling, we also chose to introduce stochasticity in the PDMP through
the time of effect of an IL-7 injection, τ . Adding stochasticity to the model could be
discussed, as the deterministic model had good fitting and predictive abilities. However,
it makes biological sense to assume that there is some stochasticity in the mechanism of
action of IL-7 on the CD4+ T cells. This stochasticity could have been introduced in
other ways in the model: for example, the value of the effect of IL-7 on the proliferation
rate, βpi could be random. In term of trajectories, the impact of both hypothesis would be
difficult to assess on the available data. As a first way to account for stochasticity in the
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process, we decided to add randomness in the time of effect of an IL-7 injection because
it could easily be handled by the jump intensity η in the PDMP.
One limitation of the optimal control approach resides in the assumption that the
process is continuously observed which allows the action to be adapted when needed. In
the clinical context of treatment injections, the patient can only be observed at punctual
time points. To account for these constraints, we would need to model the process as
partially observable and time of observations should also be optimized in the problem, to
determine the best visit times to obtain information on the patient and adapt the decision
from this observation. This would lead to a more complex modeling and optimizing
problem.
Finally, another inconvenient of the optimal control approach is that the parameters of
the studied patient are assumed to be known. Although we are confident in the estimation
obtained from the population approach, uncertainty on the parameters could induce some
modifications in the determined optimal strategy. It makes this method less applicable
in the clinical context of IL-7 than the Bayesian approach mentioned in section 4.2.1.2.
This point constitutes one of the reason why we did not pursue in improving the biological
model by accounting for the previous points discussed in this section, but we rather focused
on understanding the gain from both approaches and trying to determine a framework
where the optimal control method would be beneficial. In particular, the optimal control
method could be more efficient when the model requires intrinsic stochasticity. This is
discussed in the next following sections.
4.4.4 The challenge of both estimation and optimization
The Bayesian approach presented in section 4.2.1.2 and the optimal control approach
were developed in parallel and it gave us a unique opportunity to discuss both methods
for optimizing and adapting schedule of IL-7 injections in HIV-infected patients. This
section does not aim at realizing a formal comparison between the two approaches but
constitutes more of a discussion on the interests of both approaches in this framework
and in prospects.
First, it should be reminded that both estimation and optimal control problems are
difficult to assess simultaneously. Indeed, it would correspond to a partially observed
optimal control problem and it represents a real challenge from both theoretical and
numerical point of views [Hernández-Lerma, 1989; Bäuerle and Rieder, 2011]. In our
particular case, we assumed that the principle of separation was valid, meaning that we
are able to separately estimate the parameters of the model and optimize its control. In
the optimal control approach presented in section 4.3, we assumed that the stochasticity
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was due to the biological process itself and not to the estimation of the parameters. The
pseudo-patient parameters are assumed to be determined before the optimization step. It
is a strong assumption, especially as the estimation is realized on a deterministic model
and not the stochastic model itself. Moreover, it should be underlined that the optimal
control method depends on the chosen model, by making the strong assumption that
the model is valid throughout the follow-up of the patient. In the previous section, we
mentioned possibilities to modify the biological model, by accounting for example for a
reduced effect of IL-7 on cell proliferation due to consecutive cycles. This could also
modify the final optimal strategy obtained with our method. In our work, we then based
the optimization method on two main assumptions: in term of parameters estimation,
the population approach was already shown to give good results in ODE-based models
[Lavielle and Mentré, 2007; Prague et al., 2013a]. In term of model choice, the previous
work on modeling the effect of IL-7 on CD4+ T cells dynamics and developed in section
4.1.2 ensured the model induced good fits of the data and had good prediction abilities.
In the Bayesian approach, the stochasticity was considered to arise from the uncer-
tainty on the estimation of a patient’s parameters, but the model for the CD4 dynamics
was still deterministic, as previously developed in 4.1.2. The advantage of this method is
that the parameters estimation can be updated each time new information is obtained.
Moreover, decisions allow to locally optimize some criteria and they are based on the
prediction from the model, not directly from the observation of a biological marker. It
was also showed that the algorithm only requested a short phase of learning before having
a reliable estimation of the parameters and a sequence of right decisions to take.
Overall, we have showed that both approaches could be used to adapt schedules of
injections while maintaining patients above 500 CD4+ T cells as long as possible. We
should underline here that the IL-7 question provided a specific context of work for several
reasons. First, the mechanistic model for the dynamics of the marker of interest (CD4+
T cells) is very simple with linear equations. Moreover, it can be estimated using only
two biomarkers (CD4 and Ki67), which makes the clinical context much easier. For other
questions, the marker of interest could depend from the dynamics of a large number of
markers and its dynamics could be less clear to describe. It would lead to a more complex
mathematical model, with more compartments and interactions between the agents of
the process and could request more measures for estimation. Moreover, the model is
deterministic and induces good fits and predictions, which makes the use of the Bayesian
approach easier. If the model needed stochasticity, the computation of the criteria of
decision would have much more variance and it would make it more difficult to take any
adaptive decision. We believe that in that case, the optimal control approach could be
more adapted and robust. This should not be neglected, as we know that most of the
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biological and physical processes actually undergo stochasticity, and if we aim at modeling
systems with more granularity, it could request accounting for more stochasticity.
Finally, in practice, due to the limitation in term of computation time and not account-
ing for the uncertainty on the patient’s estimation, the optimal control approach is harder
to apply directly in clinical studies. The Bayesian approach can be easily implemented
and at the moment it offers clinical perspectives, such as the evaluation of the adaptive
strategies on other clinical outcomes in larger trials. The optimal control approach offers
prospects in other applications where the stochasticity needs to be included and modeling
the process with a PDMP is more appropriate; we will discuss the particular case of gene
networks in the following section.
4.4.5 Prospects in vaccinology
One of the objectives of developing methods for optimizing schedules of injections is
also to be able to optimize prime-boost vaccination regimens, combining several products
in distinct immunizations. We have already mentioned in section 3.4.3 that systems vac-
cinology is a promising approach which consists in integrating data from different sources
and measurements techniques into a broader model of the immune response to immuniza-
tions. This already represents in itself a challenge: currently, there is no general method
for integrating information from the environment, the microbiome and the gene expres-
sion into mechanistic models of the biomarker(s) of interest (antibodies, cell populations,
or others, possibly acting as a surrogate of protection). In fact, modeling and infering
this information is still an open question, especially regarding the gene expression data.
We have seen that gene regulatory networks (GRN) have been widely used, but there is
no consensus on the best way to model and estimate these processes. In view of the work
realized in this thesis, an interesting way to model GRN is actually to use PDMPs: the
gene expression is determined by the state of the promoter of the gene, which randomly
shifts between active (on) or inactive (off) state. The state of the promoter depends
on transcription factors (proteins) that can bind to the DNA. The level of mRNA and
proteins can be considered as continuous quantities, and their dynamics are modeled by
ODEs. The mRNA is transcribed only during the active state. The PDMP related to
this kind of process was described in Zeiser et al. [2010] and Herbach et al. [2017]. In a
particular case of this model, the transcription occurs on very short periods which induce
a burst of mRNA and of the protein synthesis [Bokes et al., 2013]. In these models, the
flow is defined by the ordinary differential equations determining the dynamics of both the
mRNA and the protein concentrations; these equations depend on the state i ∈ {0, 1} of
the gene promoter, with 0 corresponding to inactive and 1 to active. The transition rates
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from state inactive to active and active to inactive can depend on protein concentrations,
generated by the gene itself and possibly other genes included in the model. This rate of
transition determine the random time at which the jumps occur. Vaccine immunizations
can modify the gene expression. This could be modeled in the PDMP by modifying some
transition rates following immunizations to induce higher or lower rates of activation, as
some gene are observed to be differentially expressed. Further investigations should be
realized to assess the possibility to infer complex GRN modeled this way: in Herbach
et al. [2017], the theory is not based on a limited number of genes but simulations were
conducted for networks with only 2 genes. Moreover, as we have developed in this thesis
work a numerical tool for solving impulse control problems, it could be interesting to in-
vestigate the possibility to control gene expression levels by vaccine immunizations using
a similar framework. This could be realized first on a calibrated GRN if inference is not
completely achieved. The decision-maker would have the choice to realize immunizations
at given time points, using one or several vaccine platforms. If some genes are related to
the dynamics of the biomarker(s) of interest, it could be useful to be able to have devel-
oped methodological tools to optimize their expression. In that case, further investigations
are also necessary to evaluate how the optimization performs regarding the complexity
of the GRN and the number of genes included. The optimization method could help a
rapid adaptation of the vaccine immunization regimen depending on the responder/non
responder profile of the recipient. A representation of this modeling/optimizing approach
in systems vaccinology is given in figure 4.8.
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Gene expression data
Model: GRN with PDMP
Challenge: inference
Biomarker / cell population data
Model: ODE-based, mechanistic
Challenge: integrating data
Environment
data
Microbiome
data
Optimal control on PDMP
Numerical method using dynamic
programming
Vaccine / Immune interventions
Figure 4.8 – Schematic representation of a modeling/optimizing approach in systems vac-
cinology
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5 General discussion
In this thesis, we have conducted some work combining mathematics, immunology
and biostatistics, as part of an effort to use models for understanding, quantifying and
optimizing the immune response to preventive and therapeutic interventions against in-
fectious diseases. This work is driven by concrete clinical questions, and sophisticated
methods are developed to analyze longitudinal data obtained in human clinical trials:
the challenge of parameter estimation in ODE-based models is handled by a population
approach based on likelihood maximization, and the optimization of a clinical protocol
of repeated injections is realized by developing a dynamic programing numerical method
based on recent theoretical results. The originality of this thesis resides in both the ana-
lyzed data, as no mechanistic model of the response to Ebola vaccine has been studied on
human data so far, and the application of complex optimal control theory on stochastic
processes to the specific biological framework of optimal administration of IL-7.
In particular, we have shown that a simple model of the humoral immune response,
including the dynamics of two populations of ASCs and of the antibodies, could fit well
the binding antibody concentration data measured on subjects receiving Ebola vaccine
candidates in phase 1 clinical trials. This model was based on ODEs and the parameters
were estimated in order to quantify the dynamics of the humoral immune response and to
determine factors involved in its variability. The advantage of the mechanistic model relies
in the fact that its structure is biologically justified, and not data-driven; in this way, it
can be applied in other contexts and could be estimated on other datasets generated in the
EBOVAC consortium or other clinical trials. Moreover, the findings from this modeling
work could have clinical implications, in particular in the adaptation of vaccine regimens
according to the targeted population. The predictions of the model could be checked
using longer follow-up measurements. The model would obviously benefit from additional
data measurements, whether it be other biomarker measurements (ASCs for example),
genomic, proteomic or microbiome measurements, or measurements from other subjects
enrolled in other clinical trials. However, this would raise additional methodological
challenges, especially regarding the integration of all necessary compartments in a large
model. All this additional information would help: i) refining the estimated durability
of the humoral immune response, ii) quantifying the effect of factors impacting on the
variability of the immune response, iii) understanding more deeply the mechanisms of the
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immune memory, iv) predicting the effect of additional interventions, such as additional
immunization or probiotic intervention, aiming at increasing the immunogenicity of the
vaccine, v) aiming at optimizing protocols of vaccine immunizations.
Regarding the optimization of vaccine regimens based on several immunizations, we
have developed in parallel to the modeling work a numerical tool based on optimal control
theory. This was applied to the context of immunotherapeutic interventions in HIV-
infected patients, as a proof-of-concept, showing that the theory could indeed be applied
in some specific biological framework. We have focused on using PDMPs for modeling the
biological process of interest, as this class of model corresponds to stochastic processes
where the system undergoes deterministic trajectories that are changed discretely after
some random time periods. The deterministic part can indeed be modeled by ODEs,
which is our preferential tool in mechanistic modeling. In particular, we have applied
some previously developed theory on the optimal control of PDMP to the particular
case of impulse control on the boundaries of the system. A numerical method based on
dynamic programming was developed and helped determining optimized immunotherapy
protocols for HIV-infected patients. This development opens the door to other biological
applications, especially in the field of vaccinology.
More generally, the work realized in this thesis highlights the availability of complex
methodological tools for analyzing data from clinical trials on preventive and therapeutic
interventions against infectious diseases. Of course, these tools should be constantly
improved and adapted to the availability and of the data, evolving with the development
of new technologies. However, mathematical tools can already be useful to accelerate
the clinical development thanks to in silico trials. This term corresponds to the use
of patient-specific computer simulations [Viceconti et al., 2016] for the development of
a product, the diagnosis of the disease or the design of a treatment. For that, all the
information regarding the characteristics of the patient and the mechanisms of effect of
the studied product should ideally be integrated in a multi-scale model, able to predict
the outcome of interest. As described in Viceconti et al. [2016] in silico trials could be
used in several ways, in particular to reduce the number of subjects enrolled in clinical
trials or the length of the study, to refine the efficacy of a product or replace some
animal and human studies. In the last few years, there has been growing interest in these
computation methods. Some examples of use of this approach cover the feedback control
of glucose concentration in diabetic patients [Magni et al., 2009], the development of drugs
accounting for variability due to several factors [Rostami-Hodjegan and Tucker, 2007] or
the simulation of immunotherapy to design optimized interventions: this is in particular
due to the non linearity of the process and the possibility to generate counter-intuitive
predictions of the immunotherapy effect with the model [Clermont et al., 2004]. An in
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silico phase 3 clinical trial was also implemented on 10000 pseudo-patients with Chron’s
Disease to evaluate the response to new treatments [Abedi et al., 2015]. It was also recently
suggested to regulatory agencies to account for modeling and simulations analyses in the
development process of biologic products, as explained in Pappalardo et al. [2018]. This
review also underlines the potential usefulness of in silico trials at all phases of the clinical
development of future vaccines. In the team, a classic in silico pipeline of analysis has
consisted in developing a deterministic, ODE-based mechanistic model and estimating
the distribution of the parameters in the population of the study. Two applications can
be considered, either at the individual or population level. Indeed, if a new subject is
included in the study, its individual parameters can be estimated based on the model and
the previous estimations. Simulations of the deterministic model by accounting for the
uncertainty around the individual parameters estimation can help adapting the treatment
of this subject. This type of approach was used for adapting the schedule of IL-7 injections
as already mentioned, and described in appendix B. On the other hand, a large number of
pseudo-patients can be generated from the posterior distribution of the parameters. This
population is supposed to be representative of the population studied in the clinical trials
used for the estimation of the model. In that case, the outcome of several interventions
can be simulated on all pseudo-patients. This can help determining the best intervention
to use in a target population, or for different classes of profiles of patients. For this type of
approach, a work in collaboration with Mélanie Prague aims at developing in silico trials
to evaluate therapeutic relief in HIV-infected patients [Prague et al., 2018]. In particular,
short-cycle therapies consisting of x days under treatment and 7-x days with no treatment,
are though to be promising and have been under clinical investigation for a few years.
By comparing the results obtained through the simulation approach with existing results
from current clinical trials, we have shown that the computer-based approach was a good
predictor of the effect of short-cycle therapies on HIV-infected patients, meaning that this
approach should be considered in the development of new treatments strategies based on
already existing antiretroviral therapies.
Following these results, a similar in silico pipeline could be considered in vaccinol-
ogy and especially in the development of prime-boost regimens. Several designs could
be tested, including different orders of immunizations, different intervals between the im-
munizations or hypothetical additional immunization and its timing. In the light of our
findings on Ebola vaccine, it could also be interesting to evaluate optimal vaccine strate-
gies according to the geographical location of the subject. The in silico method could
help determining optimized vaccine regimens that should be tested in new clinical trials.
The good results obtained from the methods used in the IL-7 and the ART frameworks
can mostly be attributed to the ability of the deterministic model to fit the data using a
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small number of biomarkers and the short phase of learning for estimating the parameters
of a new subject. However, we have mentioned the necessity to integrate more than just a
few biomarkers’ data in a model for the immune response: transcriptomic, proteomic and
microbiome data should also be included if possible. A step of selection of the necessary
information could be considered to reduce the complexity of such model. But accounting
for additional types of data could be crucial and induces other methodological challenges,
either in modeling the dynamics of the underlying processes and/or in integrating the
information in a large mechanistic model. Indeed, stochasticity cannot be ignored at
the single-cell level, but on the other hand, adding stochasticity in the model makes the
inference harder. The optimal control work realized in this thesis has highlighted the
availability of other tools for modeling and optimizing stochastic processes, in particular
by using PDMPs. The optimization is based on theoretical results and not on empiri-
cal methods. PDMPs could be used in a modeling strategy when stochasticity cannot
be ignored, as we have shown that optimization of this kind of process in a biological
framework could be realized. This type of modeling raises other challenges, especially in
the inference of the model. However, it could be interesting to investigate the possibility
to modify the in silico pipeline, by first calibrating the stochastic model on clinical data
and then applying the optimal control tools on the calibrated model: an application of
interest could be for example the modeling of the gene expression through GRN. Over-
all, a good balance should be found between the complexity of the model (including the
number of compartments, the stochasticity, the time scales...) and the availability of the
data. Here, the population approach is very much valuable, as specific measurements are
usually realized on sub-cohorts of clinical trials. The population approach allows to pool
the data from the principal study with ancillary studies, as having the same amount of
data for all subjects is not mandatory in this approach. In any cases of modeling and
optimizing methods, the in silico methods could help for a more rational development of
vaccines, based on the quantification of the immune response generated by the immuniza-
tions and the understanding of the underlying mechanisms, instead of the actual empirical
methods. It should be kept in mind that these methods are not supposed to replace the
experimental methods, as a model is always a simplification of the real biological process:
anything that will be predicted from in silico trials is related to the knowledge included
in the construction of the model and the data used for the inference/calibration of the
model. Experimentations should be combined to computation approaches as complemen-
tary roles in a collaborative effort between immunologists and mathematicians to further
improve the development of new preventive and therapeutic interventions against infec-
tious diseases. This would constitute a loop process, where generated data can be used
for the development of models, which themselves can generate new hypotheses and help
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designing future studies and determining additional data to be collected. These data can
then validate or not the hypotheses and refine the model [Vodovotz et al., 2017].
In conclusion, further work directions can be pursued: in terms of modeling, more
complex models of the immune response should be developed, including the immune
memory and integrating early signals of the response. Stochasticity should be considered,
especially at the single-cell levels, and in this prospect, inference of gene networks should
be investigated and possibly adapted depending on the data available. In term of clinical
interpretation, additional data (long term follow-up, sub-cohorts) will help refining the
quantification of the immune response to vaccine immunizations and the factors associated
to its variability. In terms of optimization, the numerical method based on dynamic
programming could be improved and applied to other frameworks, especially where the
modeling by a PDMP seems to be more adapted and necessary. All together, this will allow
for adopting a substantial system vaccinology approach for future clinical developments.
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A B S T R A C T
Objectives: For Ebola vaccine development, antibody response is a major endpoint although its
determinants are not well known. We aimed to review Ebola vaccine studies and to assess factors
associated with antibody response variability in humans.
Methods: We searched PubMed and Scopus for preventive Ebola vaccine studies in humans or non-
human primates (NHP), published up to February 2018. For each vaccination group with Ebola Zaire
antibody titre measurements after vaccination, data about antibody response and its potential
determinants were extracted. A random-effects meta-regression was conducted including human groups
with at least 8 individuals.
Results: We reviewed 49 studies (202 vaccination groups including 74 human groups) with various
vaccine platforms and antigen inserts. Mean antibody titre was slightly higher in NHP (3.10, 95%
conﬁdence interval [293; 327]) than in humans (2.75 [257; 293]). Vaccine platform (p < 0001) and viral
strain used for antibody detection (p < 0001) were associated with antibody response in humans, but
adjusted heterogeneity remained at 95%.
Conclusions: Various platforms have been evaluated in humans, including Ad26, Ad5, ChimpAd3, DNA,
MVA, and VSV. In addition to platforms, viral strain used for antibody detection inﬂuences antibody
response. However, variability remained mostly unexplained. Therefore, comparison of vaccine
immunogenicity needs randomised controlled trials.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Introduction
Following the deadly 2013-2016 epidemic in West Africa, there
has been an accelerated development of several candidates for an
Ebola preventive vaccine. Outbreaks of Ebola virus disease (EVD)
have occurred recurrently and unpredictably for the past 40 years
with a high lethality rate (Liu et al., 2015). The 2013-2015 outbreak
was unprecedented in scale, with over 28,000 cases and more than
11,000 deaths (Ebola Situation Report, 2016). Incidental cases are
still reported as recently in the Democratic Republic of Congo in
May 2017 (Dhama et al., 2015). In the absence of any speciﬁc
treatment, EVD prevention and control measures are primarily
based on case identiﬁcation and isolation, early non-speciﬁc
medical care, surveillance of suspect cases, and safe burial
practices (Henao-Restrepo et al., 2017). These measures are now
sometimes complemented by ring vaccination of contacts of cases,
based on the promising results of a phase III cluster-randomized
ring vaccination efﬁcacy trial conducted in Guinea in 2015
(Ohimain, 2016). However, the vaccine used for ring vaccination
(rVSV ZEBOV vaccine) is not yet licenced and conducting new
efﬁcacy trials for licencing is not feasible in the absence of a large
outbreak. Nevertheless, preparation for future outbreaks is
required and the licensing of one or several preventive vaccines
for stockpiling is a priority.
Several candidate vaccines strategies have been investigated
since the ﬁrst reported EVD outbreak in 1976. During and following
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the 2013-2015 epidemic, the process of vaccine development has
been substantially accelerated, and several strategies have been
moved into clinical phases. Despite the promising results of the
ring vaccination trial in Guinea (Ohimain, 2016), many questions,
such as durability of immune responses, and immune responses
and protection in speciﬁc sub-groups such as young children,
remain to be addressed and Ebola vaccine development continues
to be very active. Based on their delivery technologies, several
candidate vaccine platforms can be distinguished: whole-virus
vaccines, DNA vaccines, virus-like particles vaccines, and recom-
binant vaccines with different viral vectors (vesicular stomatitis
virus or VSV, modiﬁed vaccinia Ankara or MVA, human adenovirus
or Ad, and chimpanzee adenovirus or ChAd) (World Health
Organisation, 2013). Each platform may use speciﬁc dose levels
and Ebola antigen inserts.
Vaccine trials aim to assess vaccine safety and immunogenicity
in phase I and II trials in humans prior to testing for a protective
effect in phase III. Assessment of vaccine efﬁcacy during pre-
clinical and clinical studies is required to go through the vaccine
license steps. Clinical protection from EVD in human populations is
impossible to observe outside an epidemic period. In the non-
epidemic context, Ebola vaccines are thus currently evaluated by
using a main immunogenicity endpoint: the antibody response
after vaccination. There is no deﬁnite evidence that antibody
response is the correlate of protection or surrogate endpoint for
efﬁcacy in humans, that is a speciﬁc immune response to vaccine
associated with vaccine-induced protection (Sullivan et al., 2009)
and it may vary according to the vaccine platforms (Sullivan et al.,
2000a,b). However, we know that antibody response is correlated
with survival after challenge in nonhuman primate models, which
is the nearest model to humans for EVD and hence the animal gold
standard to test candidate Ebola vaccines; this association is found
consistently for different Ebola candidate vaccines (Wong et al.,
2012; Food and Drug Administration, 2015; Sridhar, 2015).
For these reasons, antibody response is used as the main
criterion to assess the Ebola candidate vaccines in phase I/II trials.
In the absence of the possibility to conduct additional phase III
trials, regulatory pathways not requiring such efﬁcacy results are
also under discussion (Food and Drug Administration, 2015).
Signiﬁcant variations in antibody responses are observable across
studies, which could be due to the different types of vaccines
evaluated, or not. Various factors are suspected to inﬂuence the
level of antibody response beyond the vaccine features (vaccine
platform, Ebola viral insert, dosage, single injection or boost, . . . )
such as the measurement techniques (time of measurement,
antigen used to detect antibody response, . . . ) or the population
type (human or nonhuman primates, age, sex, study site, . . . ).
There is a lack of quantiﬁcation of the contribution of each factor in
the observed variation of the reported antibody responses.
Although previous reviews exist on Ebola vaccines (Ohimain,
2016; Sridhar, 2015; Wu et al., 2015), the speciﬁc topic of antibody
response determinants has not yet been addressed by a systematic
review or meta-analysis. Yet, the identiﬁcation of factors poten-
tially associated with antibody response after Ebola vaccination
could provide relevant information for further vaccine trials and
for regulatory decision making.
By conducting this systematic review with a meta-analysis, we
aimed to determine whether the reported antibody response
variability in Ebola vaccine trials is not only determined by the
vaccine platform but also by other characteristics of vaccine and by
population and measurement characteristics and to quantify these
factors.
Methods
Search strategy and selection criteria
Studies were identiﬁed by searching electronic databases
PubMed and Scopus. Pubmed was searched using the following
terms: (« hemorrhagic fever, ebola » [MeSH Terms] OR « ebola » [All
ﬁelds] OR « ebolavirus » [MeSH Terms] OR « ebolavirus » [All ﬁelds])
AND (« vaccines » [MeSH Terms] OR « vaccines » [All ﬁelds] OR «
vaccine » [All Fields]). Scopus was searched using the following
terms TITLE-ABS-KEY (ebola) AND TITLE-ABS-KEY (vaccine).
Additionally, the Clinicaltrials.gov website was searched to identify
unpublished and ongoing studies. Several experts in the ﬁeld were
contacted to ﬁnd papers which could be not indexed in databases.
Reference lists of relevant papers and reviews were examined to
identify further articles.
The search was performed on March 23, 2016 and updated as of
February 24, 2018 with a publication date limit of the same date in
order to identify all published studies which met the inclusion
criteria and without restriction on language. All preventive Ebola
vaccine clinical trials conducted in humans or in nonhuman
primates and with a measure of Ebola Zaire antibody titre after
vaccination were included in our systematic review. Studies were
excluded in case of duplicate study, studies without original data,
preclinical studies conducted in animals other than nonhuman
primates or in vitro experimentation.
Data extraction
A ﬁrst step of selection was performed on the title and abstract,
and then a second step was performed after reading the full article.
Two authors independently assessed each full article to include
papers matching the review’s inclusion criteria. Disagreements
between reviewers were resolved by consensus.
Data were extracted by two independent reviewers, with
differences reconciled by consensus. The following variables were
extracted: paper identiﬁcation (title, ﬁrst author, publication year),
study design, inclusion and exclusion criteria, characteristics of the
population (number of subjects; human or nonhuman primates;
proportion of women, average age and study site for clinical trials;
and animal species for pre-clinical studies using nonhuman
primates), characteristics of vaccine (vaccine platform in terms
of delivery technology used, speciﬁc vector for recombinant
vaccines, Ebola viral insert, dosage, route of administration,
vaccination schedule), characteristics of measurement techniques
(time interval between last injection and measure, strain and
nature of antigen used to detect antibody response, measurement
method), antibody response after vaccination (geometric mean
titre and its variance). Regarding the antibody response after
vaccination, geometric mean titre was extracted from the text or
estimated from ﬁgures. If a single vaccination group had more than
one measure of antibody response, data from measurement after
each injection were extracted. Therefore, if available, measurement
post-prime and measurement post-boost from a same vaccination
group were both included in our meta-analysis. If several
measurements post-prime or if several measurements post-boost
were available, for each injection we extracted the one closest to
28 days after injection, which is a standard time point in Ebola
vaccine trials. Variance of titre (within-group variance) was
extracted directly from the text or calculated from conﬁdence
interval or from individual values. The present study was
registered in PROSPERO (no. 54303).
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Data analysis
For all analyses, the statistical unit used was the vaccination
group (one or several groups for a single study), i.e. a protocol-
deﬁned group undergoing the same intervention and follow-up
procedures (such as a randomized arm of a clinical trial or an
animal group in NHP studies).
First descriptive analyses were performed among all groups,
separately for nonhuman primates and for humans. Then, a
random-effect meta-regression analysis was performed including
only human groups with 8 individuals or more. This threshold
allowed both to have sufﬁcient inter-individual variability in each
group and to avoid excluding too many groups. Thus, it was not
possible to perform the regression analysis with NHP studies
because of the usual small sample size of the groups. The effect of
every potential determinant of antibody response was assessed
through ﬁxed effects. A random intercept was allowed to capture
between-group variability not explained by the ﬁxed effects. The
residual variance (within-group variance) was ﬁxed in the model
according to the values resulting from data extraction as described
by Van Houwelingen (Van Houwelingen et al., 2002).
Each potential determinant associated in unadjusted analyses
with a p-value <0.25 was included in the multivariable model
using forward step-wise selection. The heterogeneity was checked
visually with forest plots and quantiﬁed by using the Q test. The
proportion of total variation across groups due to heterogeneity
(I2) and the amount of variability explained by the factors included
in the random-effect model (R2) were estimated. Antibody titres
after vaccination were log transformed in the model.
For the meta-regression analysis, the dosage variable was
categorized into “low dose” or “high dose” per vaccine platform,
since units of measurement for dose level were platform-
dependent. For each unit of dose measurement and each vaccine
platform, the average dose level among the human groups
included in the meta-regression model was used as a classiﬁcation
threshold for this variable; if only one dose level was assessed for a
vaccine platform, the dosage variable was deﬁned as undifferenti-
ated. The absence of interaction between vaccine platform and
dosage was checked (likelihood ratio test: p = 0.223).
All analyses were performed using the metafor package of R
(i386 3.2.2 version, the R Foundation, Vienna, Austria).
Results
Study selection
The selection process of the studies and vaccination groups is
described in Figure 1.
The search yielded a total of 2166 studies. Of these, 49 met the
inclusion criteria to the research question corresponding to 202
vaccination groups. Unpublished clinical trials and one trial found
by contact with an expert were excluded since no results were
available. Studies not reporting any antibody measurements were
also excluded. This led to the exclusion of the “Ebola ça sufﬁt” ring
vaccination trial conducted in Guinea, the only trial that was able
to assess clinical efﬁcacy in humans so far (Ohimain et al., 2016).
This trial was conducted under emergency conditions and did not
collect blood samples for immunogenicity measurements.
Table 1 shows details of all trials included in the systematic
review: 32 studies were conducted in NHP, 13 trials in humans
were phase 1, two trials phase 1/2, and two phase 2. The number of
trials has increased signiﬁcantly since the last outbreak of EVD.
Clinical trials were conducted mostly in Europe and North America
(Figure 2).
Description of included vaccination groups
Among the 202 vaccination groups included in our systematic
review, 74 were human groups and 128 were non-human primate
groups. The distribution of the number of individuals by groups is
Figure 1. Flow chart for study/vaccination group selection.
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Table 1
Main characteristics of the preclinical studies and clinical trials included in the systematic review.
Title First author Year of
publication
Population and study
features
Vaccine(s) Measurement of
antibody response
Phase 1 Trials of rVSV Ebola Vaccine in Africa
and Europe (Agnandji et al., 2016)
Agnandji 2016 Humans (Germany,
Switzerland, Gabon,
Kenya), phase 1,
randomization and
placebo
Recombinant VSV-GP(Zaire), single injection,
IM, 300 000 to 50 million PFU
Antibodies anti GP
(Kikwit), D28 or
D180
Successful topical respiratory tract
immunization of primates against Ebola
virus (Bukreyev et al., 2007)
Bukreyev 2007 NHP: rhesus monkeys;
placebo
Recombinant HPIV3(+/ modiﬁed)-GP +/ NP
(Zaire Mayinga), single injection +/ boost
D28, IN + IT, 4 to 20 million TCID50
Antibodies anti
virion, D28 (or D39
after boost)
Mucosal parainﬂuenza virus-vectored vaccine
against Ebola virus replicates in the
respiratory tract of vector-immune
monkeys and is immunogenic (Bukreyev
et al., 2010)
Bukreyev 2010 NHP: rhesus monkeys
(+/ HPIV3
seropositive); placebo
Recombinant HPIV3-GP(Zaire Mayinga),
boost D28, IN + IT, 20 million PFU
Antibodies anti
virion, D28
Safety and immunogenicity of a chimpanzee
adenovirus-vectored Ebola vaccine in
healthy adults: a randomised, double-blind,
placebo-controlled, dose-ﬁnding, phase 1/
2a study (De Santis et al., 2016)
De Santis 2016 Humans (Switzerland),
phase 1/2,
randomization and
placebo
Recombinant ChAd3-GP(Zaire Mayinga),
single injection, IM, 25 to 50 billion VP
Antibodies anti GP
(Mayinga), D28,
results in EC90
Respiratory tract immunization of non-
human primates with a Newcastle disease
virus-vectored vaccine candidate against
Ebola virus elicits a neutralizing antibody
response (DiNapoli et al., 2010)
DiNapoli 2010 NHP: rhesus monkeys;
no placebo
Recombinant NDV-GP(Zaire Mayinga) or
HPIV3-GP(Zaire Mayinga), boost D28, IN + IT,
20 million PFU
Antibodies anti
virion (Mayinga),
D28
A Monovalent Chimpanzee Adenovirus Ebola
Vaccine Boosted with MVA (Ewer et al.,
2016)
Ewer 2016 Humans (United
Kingdom), phase 1, no
randomization, no
placebo
Recombinant ChAd3-GP(Zaire Mayinga) 10 to
50 billion VP, boost between D7 and D46 with
recombinant MVA-GP(Zaire Mayinga + Sudan
Gulu)/NP(Taï Forest) 150 to 300 millions PFU,
IM
Antibodies anti GP
(Mayinga) or anti
virion (Makona)
Vesicular stomatitis virus-based vaccines
protect nonhuman primates against aerosol
challenge with Ebola and Marburg viruses
(Geisbert et al., 2008a,b)
Geisbert 2008 NHP: cynomolgus
macaques; placebo
Recombinant VSV-GP(Zaire Kikwit), single
injection, 20 million PFU
Antibodies anti
virion (Kikwit), D14
or D27
Vesicular stomatitis virus-based ebola vaccine
is well-tolerated and protects
immunocompromised nonhuman primates
(Geisbert et al., 2008a,b)
Geisbert 2008 NHP: rhesus monkeys
(SHIV infected);
placebo
Recombinant VSV-GP(Zaire Mayinga), single
injection, IM, 10 million PFU
Antibodies anti
virion (Mayinga),
D14
Single-injection vaccine protects nonhuman
primates against infection with marburg
virus and three species of ebola virus
(Geisbert et al., 2009)
Geisbert 2009 NHP: cynomolgus
macaques and rhesus
monkeys; placebo
Recombinant VSV-GP(Zaire Mayinga and/or
Sudan Boniface +/ Marburg), single injection
+/ boost D14, IM, 10 to 20 million PFU
Antibodies anti
virion, between
D14 and D28
Recombinant adenovirus serotype 26 (Ad26)
and Ad35 vaccine vectors bypass immunity
to Ad5 and protect nonhuman primates
against ebolavirus challenge (Geisbert et al.,
2011)
Geisbert 2011 NHP: cynomolgus
macaques (+/ Ad5
seropositive); placebo
Recombinant Ad5, Ad26, or Ad35, or prime
Ad26 + boost Ad35 D28 - GP (Zaire + Sudan
Gulu), IM, 20 to 200 billion VP
Antibodies anti GP,
D21, results in EC90
Codon-optimized ﬁlovirus DNA vaccines
delivered by intramuscular electroporation
protect cynomolgus macaques from lethal
Ebola and Marburg virus challenges (Grant-
Klein et al., 2015)
Grant-Klein 2015 NHP: cynomolgus
macaques; placebo
Vaccin ADN-GP(Zaire +/ Sudan, Reston et
Marburg), 3 injections (28 jours apart),
electroporation IM, 500 mg to 2 mg
Antibodies anti GP
(Mayinga) DTM or
DMuc, D28
Demonstration of cross-protective vaccine
immunity against an emerging pathogenic
Ebolavirus Species (Hensley et al., 2010)
Hensley 2010 NHP: cynomolgus
macaques; placebo
Vaccin ADN-GP(Zaire Mayinga + Sudan Gulu),
4 injections IM, 4 mg (28 to 42 days apart +/
boost D371 recombinant Ad5-GP (Zaire
Mayinga) IM 100 billion VP
Antibodies anti GP,
D21 or D371,
results in EC90
Venezuelan equine encephalitis virus replicon
particle vaccine protects nonhuman
primates from intramuscular and aerosol
challenge with ebolavirus (Herbert et al.,
2013)
Herbert 2013 NHP: cynomolgus
macaques; placebo
VRP GP(Zaire Kikwit +/ Sudan Boniface),
single injection, IM, 10 to 20 billion FFU
Antibodies anti GP,
D28
The effect of dose on the safety and
immunogenicity of the VSV Ebola candidate
vaccine: a randomised double-blind,
placebo-controlled phase 1/2 trial (Huttner
et al., 2015)
Huttner 2015 Humans (Switzerland),
phase 1/2,
randomization and
placebo
Recombinant VSV-GP(Zaire), single injection,
IM, 300 000 PFU
Antibodies anti GP,
D28
Live attenuated recombinant vaccine protects
nonhuman primates against Ebola and
Marburg viruses (Jones et al., 2005)
Jones 2005 NHP: cynomolgus
macaques; placebo
Recombinant VSV-GP(Zaire Mayinga), single
injection, IM, 10 million PFU
Antibodies anti
virion, D28
Phase 2 Placebo-Controlled Trial of Two
Vaccines to Prevent Ebola in Liberia
(Kennedy et al., 2017)
Kennedy 2017 Humans (Liberia),
phase 2,
randomization and
placebo
Recombinant ChAd3-GP(Saire) 100 billion VP
or VSV-GP(Zaire Kikwit) 20 million PFU, single
injection, IM
Antibodies anti GP
(Kikwit), D28
Safety and immunogenicity of Ebola virus and
Marburg virus glycoprotein DNA vaccines
assessed separately and concomitantly in
healthy Ugandan adults: a phase 1b,
Kibuuka 2015 Humans (Uganda),
phase 1b;
randomization and
placebo
Vaccin ADN GP(Zaire + Sudan +/ Marburg), 3
injections, IM, 4 mg
Antibodies anti GP,
D28
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Table 1 (Continued)
Title First author Year of
publication
Population and study
features
Vaccine(s) Measurement of
antibody response
randomised, double-blind, placebo-
controlled clinical trial (Kibuuka et al.,
2015)
A replication defective recombinant Ad5
vaccine expressing Ebola virus GP is safe
and immunogenic in healthy adults
(Ledgerwood et al., 2010)
Ledgerwood 2010 Humans (USA), phase
1; randomization and
placebo
Recombinant Ad5-GP(Zaire Mayinga + Sudan
Gulu), single injection, IM, 2 to 20 billion VP
Antibodies anti GP
(Mayinga), D28
Chimpanzee Adenovirus Vector Ebola Vaccine
– Preliminary Report (Ledgerwood et al.,
2015)
Ledgerwood 2015 Humans (USA), phase
1, no randomization
and no placebo
Recombinant ChAd3-GP(Zaire
Mayinga + Sudan), single injection, IM, 20 or
200 billion VP
Antibodies anti GP
(Mayinga or Zaire-
Guinea), D28,
results in EC90
Immunity duration of a recombinant
adenovirus type-5 vector-based Ebola
vaccine and a homologous prime-boost
immunisation in healthy adults in China:
ﬁnal report of a randomised, double-blind,
placebo-controlled, phase 1 trial (Li et al.,
2017)
Li 2017 Humans (China),
phase 1;
randomization and
placebo
Recombinant Ad5-GP(Zaire Makona), 2
injections (168 days apart), IM, 40 or 160
billion VP
Antibodies anti GP,
D28, results in
EC90
A DNA vaccine for Ebola virus is safe and
immunogenic in a phase I clinical trial
(Martin et al., 2006)
Martin 2006 Humans (USA), phase
1, randomization and
placebo
Vaccin ADN GP/NP(Zaire Mayinga) + GP
(Sudan Gulu), 3 injections (28 days apart), IM,
2 to 8 mg
Antibodies anti GP
or NP (Mayinga),
D28
Antibodies are necessary for rVSV/ZEBOV-GP-
mediated protection against lethal Ebola
virus challenge in nonhuman primates
(Marzi et al., 2013)
Marzi 2013 NHP: cynomolgus
macaques (with
depletion CD4+ or CD8
+ or CD20+); placebo
Recombinant VSV-GP(Zaire Mayinga), single
injection, IM, 10 million PFU
Antibodies anti GP,
D28
Vesicular stomatitis virus-based vaccines
against Lassa and Ebola viruses (Marzi et al.,
2015a,b,c)
Marzi 2015 NHP: cynomolgus
macaques (vaccinated
with VSV-Lassa);
placebo
Recombinant VSV-GP(Zaire Mayinga), single
injection, IM, 10 million PFU
Antibodies anti GP,
day of
measurement non
speciﬁed
Vaccines. An Ebola whole-virus vaccine is
protective in nonhuman primates (Marzi
et al., 2015a,b,c)
Marzi 2015 NHP: cynomolgus
macaques; placebo
Attenuated whole-virus Zaire Mayinga, single
injection, IM, 10 to 20 million FFU
Antibodies anti GP,
D28
EBOLA VACCINE. VSV-EBOV rapidly protects
macaques against infection with the 2014/
15 Ebola virus outbreak strain (Marzi et al.,
2015a,b,c)
Marzi 2015 NHP: cynomolgus
macaques; placebo
Recombinant VSV-GP(Zaire Kikwit), single
injection, unique, 50 million PFU
Antibodies anti GP,
between D3 and
D28
Cytomegalovirus-based vaccine expressing
Ebola virus glycoprotein protects
nonhuman primates from Ebola virus
infection (Marzi et al., 2016)
Marzi 2016 NHP: rhesus monkeys
(CMV seropositive);
placebo
Recombinant RhCMV-GP(Zaire Mayinga),
boost D84, SC, 10 million PFU
Antibodies anti GP,
D28
Vaccination With a Highly Attenuated
Recombinant Vesicular Stomatitis Virus
Vector Protects Against Challenge With a
Lethal Dose of Ebola Virus (Matassov et al.,
2015)
Matassov 2015 NHP: rhesus monkeys;
placebo
Recombinant VSV-GP(Zaire Mayinga), single
injection, IM, 10 million PFU
Antibodies anti GP,
D21
Aerosolized Ebola vaccine protects primates
and elicits lung-resident T cell responses
(Meyer et al., 2015)
Meyer 2015 NHP: rhesus monkeys;
placebo
Recombinant HPIV3-GP(Zaire Mayinga) 40 to
400 million PFU or VRP(Zaire Mayinga) 10
billion PFU, boost D28, IM or aerosol or IN + IT
Antibodies anti
virion (Mayinga),
D23 or D28
Safety and immunogenicity of novel
adenovirus type 26–and modiﬁed vaccinia
ankara–vectored ebola vaccines: A
randomized clinical trial (Milligan et al.,
2016)
Milligan 2016 Humans (United
Kingdom), phase 1,
randomization and
placebo
Recombinant Ad26-GP(Zaire Mayinga) 50
billion VP or recombinant MVA-GP(Zaire
Mayinga + Sudan Gulu)/NP(Taï Forest) 100
millions TCID50, boost between D15 and D56,
IM
Antibodies anti GP
Kikwit), D28 after
prime and D21
after boost
Vesicular stomatitis virus-based vaccines
protect nonhuman primates against
Bundibugyo ebolavirus (Mire et al., 2013)
Mire 2013 NHP: cynomolgus
macaques; placebo
Recombinant VSV-GP(Zaire Mayinga and/or
Sudan Boniface or Bundibugyo) +/ boost
VSV-GP(Zaire Mayinga) D14, IM, 20 million
PFU
Antibodies anti GP,
between D22 and
D29
Single-dose attenuated Vesiculovax vaccines
protect primates against Ebola Makona
virus (Mire et al., 2015)
Mire 2015 NHP: cynomolgus
macaques; placebo
Recombinant VSV-GP(Zaire Mayinga), single
injection, IM, 20 million PFU
Antibodies anti GP,
D28
Protection of nonhuman primates against two
species of Ebola virus infection with a single
complex adenovirus vector (Pratt et al.,
2010)
Pratt 2010 NHP: cynomolgus
macaques or rhesus
monkeys (+/ Ad5
seropositive); placebo
Recombinant CAdVax-GP(Zaire
Kikwit + Sudan Boniface +/ Marburg), boost
between D65 and D238, IM, 100 million to 20
billion PFU
Antibodies anti
virion, between D7
and D49
A Kunjin Replicon Virus-like Particle Vaccine
Provides Protection Against Ebola Virus
Infection in Nonhuman Primates (Pyankov
et al., 2015)
Pyankov 2015 NHP: African green
monkeys; placebo
Recombinant VLP Kunjin-GP(Zaire Mayinga),
boost D28, SC, 1 billion VLP
Antibodies anti
virion, D21 or D28
A Monovalent Chimpanzee Adenovirus Ebola
Vaccine - Preliminary Report (Rampling
et al., 2015)
Rampling 2015 Humans (United
Kingdom), phase 1, no
randomization, no
placebo
Recombinant ChAd3-GP(Zaire), single
injection, IM, 10 to 50 billions VP
Antibodies anti GP,
D28, results in
EC90
A Recombinant Vesicular Stomatitis Virus
Ebola Vaccine - Preliminary Report (Regules
et al., 2015)
Regules 2015 Humans (USA), phase
1, randomization and
placebo
Recombinant VSV-GP(Zaire Kikwit), single
injection, IM, 3 to 20 million PFU
Antibodies anti GP
(Kikwit or
Mayinga), D28
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presented in Figure 3. The vast majority (82.4%) of human groups
included 8 or more individuals, while only 6 for non-human
primate groups (range 2; 22 with an average of 4.1 individuals by
group).
Characteristics of nonhuman primate and human groups are
described in Tables 2 and 3, respectively.
There is a wide heterogeneity of features among studies
included in the systematic review. Vaccine platforms varied
between studies, especially in NHP (18 different vaccine platforms
in NHP groups versus 8 in human groups). The strain of Ebola virus
used as vaccine insert or for the antibody detection after
vaccination was also variable. For almost a third of the human
Table 1 (Continued)
Title First author Year of
publication
Population and study
features
Vaccine(s) Measurement of
antibody response
Safety and immunogenicity of DNA vaccines
encoding Ebolavirus and Marburgvirus
wild-type glycoproteins in a phase I clinical
trial (Sarwar et al., 2015)
Sarwar 2015 Humans (USA), phase
1, no randomization
and no placebo
Vaccin ADN GP(Zaire + Sudan), 3 injections
(28 days apart) + boost D168, IM, 4 mg
Antibodies anti GP,
D28
Chimpanzee adenovirus vaccine generates
acute and durable protective immunity
against ebolavirus challenge (Stanley et al.,
2014)
Stanley 2014 NHP: cynomolgus
macaques; placebo
Recombinant ChAd3-GP(Zaire + Sudan), 1 to
10 billion VP or recombinant ChAd3-GP
(Zaire + Sudan) or recombinant MVA-GP
(Zaire + Sudan) 100 million VP, single
injection, IM
Antibodies anti GP,
D21, results in EC90
Development of a preventive vaccine for Ebola
virus infection in primates (Sullivan et al.,
2000a,b)
Sullivan 2000 NHP: cynomolgus
macaques; placebo
DNA vaccine GP/NP(Zaire) + GP(Sudan + Taï
Forest), 3 injections, 4 mg (28 days apart),
boost D84 recombinant Ad5-GP(Z) 10 billion
PFU, IM
Nature of viral
antigen non
speciﬁed, D28
Accelerated vaccination for Ebola virus
haemorrhagic fever in non-human primates
(Sullivan et al., 2003)
Sullivan 2003 NHP: cynomolgus
macaques; placebo
Recombinant Ad5-GP/NP(Zaire) +/ boost
D63, IM, 2000 billion VP
Antibodies anti
virion, between D7
and D63
CD8+ cellular immunity mediates rAd5
vaccine protection against Ebola virus
infection of nonhuman primates (Sullivan
et al., 2011)
Sullivan 2011 NHP: cynomolgus
macaques; placebo
Recombinant Ad5-GP(Zaire), single injection,
IM, 10 billion VP
Antibodies anti GP,
day of
measurement non
speciﬁed, results in
EC90
Vaccine to confer to nonhuman primates
complete protection against multistrain
Ebola and Marburg virus infections
(Swenson et al., 2008)
Swenson 2008 NHP: cynomolgus
macaques; placebo
Recombinant Ad5-GP/NP(Zaire) + GP(Sudan
Boniface), boost D63, IM, 40 billion PFU
Antibodies anti
virion, D14 after
prime and D21
after boost
Use of ChAd3-EBO-Z Ebola virus vaccine in
Malian and US adults, and boosting of
Malian adults with MVA-BN-Filo: a phase 1,
single-blind, randomised trial, a phase 1b,
open-label and double-blind, dose-
escalation trial, and a nested, randomised,
double-blind, placebo-controlled trial
(Tapia et al., 2016)
Tapia 2016 Humans (Mali), phase
1, randomization and
placebo
Recombinant ChAd3-GP(Zaire), 10 to 100
billion VP, boost D97 recombinant MVA-GP
(Zaire + Sudan + Marburg) + NP (Taï Forest)
200 millions PFU, IM
Antibodies anti GP,
D28
Ebola virus-like particle-based vaccine
protects nonhuman primates against lethal
Ebola virus challenge (Warﬁeld et al., 2007)
Warﬁeld 2007 NHP: cynomolgus
macaques; placebo
VLP GP/VP40/NP(Zaire), 2 injections (42 days
apart), boost D42, IM, 250 mg
Antibodies anti
virion, D42
Vaccinating captive chimpanzees to save wild
chimpanzees (Warﬁeld et al., 2014)
Warﬁeld 2014 NHP: chimpanzee; no
placebo
VLP (with adjuvant: IDC-1001 ou CpG) GP/
VP40/NP(Zaire), 2 injections (29 days apart),
boost D27, IM, 3 mg
Antibodies anti
GPDTM or VP40,
between D27 and
D29, results in
EC50
Homologous and heterologous protection of
nonhuman primates by Ebola and Sudan
virus-like particles (Warﬁeld et al., 2015)
Warﬁeld 2015 NHP: cynomolgus
macaques; placebo
VLP GP/VP40/NP(Zaire et/ou Sudan), boost
D42, IM, 3 mg
Antibodies anti
GPDTM or VP40,
between D14 and
D28
Immune parameters correlate with protection
against ebola virus infection in rodents and
nonhuman primates (Wong et al., 2012)
Wong 2012 NHP: cynomolgus
macaques; placebo
Recombinant VSV-GP(Zaire Mayinga), single
injection, IM or IT or PO, 20 millions PFU
Antibodies anti GP,
D28
An Adenovirus Vaccine Expressing Ebola
Virus Variant Makona Glycoprotein Is
Efﬁcacious in Guinea Pigs and Nonhuman
Primates (Wu et al., 2016)
Wu 2016 NHP: cynomolgus
macaques; placebo
Recombinant Ad5-GP(Zaire Makona), single
injection, IM, 40 or 200 billion VP
Antibodies anti GP,
D28
Safety and immunogenicity of a novel
recombinant adenovirus type-5 vector-
based Ebola vaccine in healthy adults in
China: preliminary report of a randomised,
double-blind, placebo-controlled, phase 1
trial (Zhu et al., 2015)
Zhu 2015 Humans (China),
phase 1,
randomization and
placebo
Recombinant Ad5-GP(Zaire Makona), single
injection, IM, 40 to 160 billions VP
Antibodies anti GP
(Makona), D28
Safety and immunogenicity of a recombinant
adenovirus type-5 vector-based Ebola
vaccine in healthy adults in Sierra Leone: a
single-centre, randomised, double-blind,
placebo-controlled, phase 2 trial (Zhu et al.,
2017)
Zhu 2017 Humans (Sierra
Leone), phase 2;
randomization and
placebo
Recombinant Ad5-GP(Zaire Makona), single
injection, IM, 40 or 160 billion VP
Antibodies anti GP,
D28
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groups, the detection of antibody response was done with a
heterologous strain. The time interval between the last vaccination
and the antibody detection was also remarkably variable (range 3;
371 days).
Among all the 202 vaccination groups, the mean antibody titre
ranged from 0 (for a group of NHP infected by the simian/human
immunodeﬁciency virus prior to the Ebola vaccination) to 5.81
log10, with an average of 2.97 (95% CI: [2.84; 3.10]).
The NHP groups had a crude antibody response level that was
signiﬁcantly higher than the human groups (p = 0.006): in NHP
groups the log10 geometric mean titre ranged from 0 to 5.81 with
an average of 3.10 (95% CI: [2.93; 3.27]), and in human groups the
titre ranged from 0.90 to 4.60 with an average of 275 (95% CI:
[2.57; 2.93]) Figure S1 (appendix) shows antibody responses in
human groups and in NHP groups.
Meta-regression of factors associated with variability in antibody
response levels in humans and evaluation of between-groups
heterogeneity
Sixty-one human vaccination groups with 8 individuals or more
were included in the meta-regression analysis.
Among these, 32 were vaccinated with a low dose of vaccine, 19
with a high dose (for 10 groups, the dose category was
undeterminable as only one dose level was assessed for the given
vaccine platform).
The distribution of the antibody titres after Ebola vaccination
per vaccination group is shown by vaccine platform in Figure 4. The
antibody response seems to be higher in groups with a prime-
boost strategy (Ad26/MVA or ChAd3/MVA) than in the other
groups. The distribution of the antibody titres by viral strain used
for antibody detection is presented in Figure S2 (appendix).
In univariate meta-regression analyses (appendix: Table S1),
the antibody response after Ebola vaccination was signiﬁcantly
associated with the vaccine platform (p < 0.001), the viral strain
used to detect the antibody response after vaccination (p < 0.001),
the year of publication (for publication in 2014 and after versus
before 2014: +1.15, p < 0.001), the mean age of vaccinated
population (for 39 years versus <32 years: +0.90; p < 0.001),
the vaccine dosage (for high dose versus low dose: +0.57, p = 0.006),
the use of a vaccine boost (for boost versus no boost: +0.63,
p = 0.009), the similarity between the viral strain used as vaccine
insert and the viral strain used to detect the antibody response (for
identical strains versus different strains: 0.74, p = 0.009), the site
of the study (p = 0.014), the time interval between the last vaccine
injection and the antibody measure (for <28 days versus 28 days:
Figure 2. Description of the number of vaccine clinical trials against Ebola per country.
The Ring trial, single phase 3 trial (Guinea), has been excluded from the systematic review.
Several other vaccine clinical trials against Ebola are currently ongoing worldwide but only published trials are reported in the ﬁgure.
Figure 3. Number of vaccination groups of humans and of nonhuman primates,
according to the number of individuals by group.
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Table 2
Main characteristics of included non-human primates (NHP) groups.
Characteristic Vaccination schedule All NHP groups
No boost (n = 98) Boost (n = 30) n = 128
Vaccine platform
DNA vaccine (plasmid) 6 6.1% 0 0.0% 6 4.7%
Adenovirus 26 4 4.1% 0 0.0% 4 3.1%
Adenovirus 26 then adenovirus 35 0 0.0% 1 3.3% 1 0.8%
Adenovirus 35 4 4.1% 0 0.0% 4 3.1%
Adenovirus 5 8 8.2% 3 10.0% 11 8.6%
DNA vaccine (plasmid)/adenovirus 5 0 0.0% 2 6.7% 2 1.6%
CAdVax 6 6.1% 2 6.7% 8 6.2%
Chimpanzee adenovirus 3 2 2.0% 0 0.0% 2 1.6%
Chimpanzee adenovirus 63 1 1.0% 0 0.0% 1 0.8%
HPIV3 12 12.2% 7 23.3% 19 14.8%
MVA 1 1.0% 0 0.0% 1 0.8%
NDV 1 1.0% 1 3.3% 2 1.6%
RhCMV 1 1.0% 0 0.0% 1 0.8%
Whole-virus vaccine 4 4.1% 0 0.0% 4 3.1%
VLP 21 21.4% 10 33.3% 31 24.2%
VLP Kunjin 1 1.0% 1 3.3% 2 1.6%
VRP VEEV 3 3.1% 1 3.3% 4 3.1%
VSV 23 23.5% 2 6.7% 25 19.5%
Route of administration
Intramuscular 78 79.6% 21 70.0% 99 77.3%
Other routes 20 20.4% 9 30.0% 29 22.7%
Vaccine insert: Ebola species
Monovalent Zaire 63 64.3% 17 56.7% 80 62.5%
Monovalent no Zaire 6 6.1% 2 6.7% 8 6.2%
Monovalent no Zaire + monovalent Zaire 0 0.0% 1 3.3% 1 0.8%
Monovalent no Zaire + multivalent 0 0.0% 1 3.3% 1 0.8%
Multivalent 29 29.6% 7 23.3% 36 28.1%
Multivalent + monovalent Zaire 0 0.0% 2 6.7% 2 1.6%
Vaccine insert: Ebola strain (only for Zaire species)
Mayinga 34 64.2% 13 76.5% 47 67.1%
Kikwit 16 30.2% 4 23.5% 20 28.6%
Makona 3 5.7% 0 0.0% 3 4.3%
Missing data 45 – 13 – 58 –
Nonhuman primates species
Cynomolgus macaques 65 66.3% 17 56.7% 82 64.1%
Chimpanzees 10 10.2% 2 6.7% 12 9.4%
Rhesus macaques 22 22.4% 10 33.3% 32 25.0%
African green monkeys 1 1.0% 1 3.3% 2 1.6%
Year of publication
Publication < 2014 49 50.0% 14 46.7% 63 49.2%
Publication  2014 49 50.0% 16 53.3% 65 50.8%
Time interval between last injection and antibody measure
Mean [standard deviation] 29.1 [363] 25.5 [762] 28.3 [319]
Missing data 3 – 0 – 3 –
Antibody measurement method
Maximal dilution 65 66.3% 18 60.0% 83 64.8%
Effective concentration 90 (EC90) 15 15.3% 2 6.7% 17 13.3%
Effective concentration 50 (EC50) 18 18.4% 10 33.3% 28 21.9%
Antigen used for antibody detection: nature
Glycoprotein (GP) 55 56.7% 7 24.1% 62 49.2%
Other nature (virion, viral protein 40) 42 43.3% 22 75.9% 64 50.8%
Missing data 1 – 1 – 2 –
Antigen used for antibody detection: Ebola strain
Mayinga 14 87.5% 8 100.0% 22 91.7%
Kikwit 2 12.5% 0 0.0% 2 8.3%
Missing data 82 – 22 – 104 –
Similarity between strain used as vaccine insert and strain used for antibody detection
Identical strains 12 100.0% 8 100.0% 20 100.0%
Missing data 86 – 22 – 108 –
CAdVax: complex adenovirus-based vector, DNA: deoxyribonucleic acid, GP: glycoprotein, HPIV3: human parainﬂuenza virus 3, MVA: modiﬁed vaccinia Ankara, NDV:
Newcastle disease virus, RhCMV: rhesus cytomegalovirus cytomegalovirus, VLP: virus-like particles, VRP VEEV: Venezuelan equine encephalitis virus replicon particle, VSV:
vesicular stomatitis virus.
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+0.70, p = 0.021), and the Ebola species of vaccine insert (for
multivalent and other species versus monovalent Zaire: 0.47,
p = 0.027).
Alone, the vaccine platform was the factor which explained the
largest part of heterogeneity among all the studied factors (R2 for
vaccine platform = 55%). For all the univariate models, the
heterogeneity was very high with I2 ranging from 97% to 99%.
Results of the ﬁnal multivariate meta-regression model are
shown in Table 4. High heterogeneity was found with a I2 of 95%
and a R2 of 68%, even after adjustment on the factors associated
Table 3
Main characteristics of included human groups.
Characteristics Vaccination schedule All human groups
No boost (n = 48) Boost (n = 26) (n = 74)
Vaccine platform
DNA vaccine (plasmid) 9 18.8% 1 3.8% 10 13.5%
Adenovirus 26 3 6.2% 0 0.0% 3 4.1%
Adenovirus 26/MVA or MVA/adenovirus 26 0 0.0% 5 19.2% 5 6.8%
Adenovirus 5 6 12.5% 2 7.7% 8 10.8%
Chimpanzee adenovirus 3 14 29.2% 0 0.0% 14 18.9%
Chimpanzee adenovirus 3/MVA 0 0.0% 18 69.2% 18 24.3%
MVA 2 4.2% 0 0.0% 2 2.7%
VSV 14 29.2% 0 0.0% 14 18.9%
Route of administration
Intramuscular 48 100.0% 26 100.0% 74 100.0%
Vaccine insert: species
Monovalent Zaire 31 64.6% 19 73.1% 50 67.4%
Monovalent Zaire + multivalent 0 0.0% 4 15.4% 4 5.4%
Multivalent 17 35.4% 1 3.8% 18 24.3%
Multivalent + monovalent Zaire 0 0.0% 2 7.7% 2 2.7%
Vaccine insert: strain (only for Zaire species)
Mayinga 22 71.0% 22 91.7% 44 80.0%
Kikwit 5 16.1% 0 0.0% 5 9.1%
Makona 4 12.9% 0 0.0% 6 10.9%
Missing data 17 – 4 – 19 –
Proportion of women
Mean [standard deviation] 40% [18%] 52% [10%] 44% [17%]
Mean age (years)
Mean [standard deviation] 34.8 [45] 34.6 [54] 34.7 [48]
Geographic location of the study
Africa 14 29.2% 1 3.8% 15 20.3%
China 2 4.2% 2 7.7% 4 5.4%
Europe 15 31.2% 22 84.6% 37 50.0%
USA 17 35.4% 1 3.8% 18 24.3%
Year of publication
Publication < 2014 8 16.7% 0 0.0% 8 10.8%
Publication  2014 40 83.3% 26 100.0% 66 89.2%
Time interval between last injection and antibody measure (days)
Mean [standard deviation] 31.2 [220] 26.1 [32] 29.3 [179]
Antibody measurement method
Maximal dilution 35 72.9% 24 92.3% 59 79.7%
Effective concentration 90 (EC90) 13 27.1% 2 7.7% 15 20.3%
Antigen used for antibody detection: nature
Glycoprotein (GP) 45 93.8% 25 96.2% 70 94.6%
Other nature (virion, nucleoprotein) 3 6.2% 1 3.8% 4 5.4%
Antigen used for antibody detection: Ebola strain
Mayinga 14 36.8% 16 72.7% 30 50.0%
Kikwit 18 47.4% 5 22.7% 23 38.3%
Makona 6 15.8% 1 4.5% 7 11.7%
Missing data 10 – 4 – 14 –
Similarity between strain used as vaccine insert and strain used for antibody detection
Different strains 9 32.1% 6 27.3% 15 30.0%
Identical strains 19 67.9% 16 72.7% 35 70.0%
Missing data 20 – 4 – 24 –
CAdVax: complex adenovirus-based vector, DNA: deoxyribonucleic acid, GP: glycoprotein, HPIV3: human parainﬂuenza virus 3, MVA: modiﬁed vaccinia Ankara, NDV:
Newcastle disease virus, RhCMV: rhesus cytomegalovirus cytomegalovirus, VLP: virus-like particles, VRP VEEV: Venezuelan equine encephalitis virus replicon particle, VSV:
vesicular stomatitis virus.
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Figure 4. Forest plot of antibody titre after Ebola vaccination for each vaccination group by vaccine platform. Colour codes indicate dose levels within a given platform. GP:
glycoprotein. PFU: plaque forming unit. VP: viral particle. TCID: tissue culture infectious dose.
References for Figure 4:
1: Agnandji 2016, VSV vaccine (3.106 PFU) with Zaire insert, Germany, detection with Zaire Kikwit GP
2: Agnandji 2016, VSV vaccine (2.107 PFU) with Zaire insert, Germany, detection with Zaire Kikwit GP
3: Agnandji 2016, VSV vaccine (3.105 PFU) with Zaire insert, Gabon, detection with Zaire Kikwit GP
4: Agnandji 2016, VSV vaccine (3.106 PFU) with Zaire insert, Gabon, detection with Zaire Kikwit GP
5: Agnandji 2016, VSV vaccine (3.106 PFU) with Zaire insert, Kenya, detection with Zaire Kikwit GP
6: Agnandji 2016, VSV vaccine (2.107 PFU) with Zaire insert, Kenya, detection with Zaire Kikwit GP
7: Agnandji 2016, VSV vaccine (1.107 PFU) with Zaire insert, Switzerland, detection with Zaire Kikwit GP
8: Agnandji 2016, VSV vaccine (5.107 PFU) with Zaire insert, Switzerland, detection with Zaire Kikwit GP
9: De Santis 2016, ChAd3 vaccine (2.5.1010 VP) with Zaire Mayinga insert, Switzerland, detection with Zaire Mayinga GP
10: De Santis 2016, ChAd3 vaccine (5.1010 VP) with Zaire Mayinga insert, Switzerland, detection with Zaire Mayinga GP
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with antibody response in this ﬁnal model. This emphasises the
lack of factors that explained the antibody response among the
variables included in the model.
Vaccine platform and viral strain used for detection were the
two factors which were independently associated with antibody
response after vaccination against Ebola. Compared to the MVA
vaccine platform, the recombinant vaccines using DNA or Ad26
(associated or not with an injection of MVA vaccine), ChAd3or VSV
vectors were signiﬁcantly associated with a higher antibody
response after vaccination (more than 1.2 log10 units more
compared to MVA alone). The statistical association between the
vaccine platform and the antibody response was strong and
consistent regardless of which other variables were included in the
model (sensitivity analyses, data not shown). The antibody
response using Makona strain for antibody detection was
signiﬁcantly higher than with use of Mayinga strain (1 log10 unit
more compared to the Mayinga strain). By contrast, the antibody
response with Kikwit detection strain was not signiﬁcantly
different from the ones with Mayinga strain.
The vaccine dosage, analysed as a binary variable of high versus
low dose in the present analyses, was not found to be associated
with antibody response variability. Different classiﬁcations were
tested for this variable (same threshold across the different vaccine
platforms corresponding to the mean dose level for categorizing
into “low-dose” and “high-dose” groups, classiﬁcation into three
categories, classiﬁcation of groups with undifferentiated dosages
into “low-dose” or into “high-dose” groups), but the dosage was
never signiﬁcant in the multivariate models in these sensitivity
analyses (data not shown), nor was the interaction between dose
and vaccine platform.
In additional sensitivity analyses, a full model including all
variables signiﬁcantly associated with the antibody response in
univariate models (i.e. with no forward selection procedure) did
not modify heterogeneity (I2 = 92%) compared to the model
11: Ewer 2016, ChAd3 vaccine (2.5.1010 VP) with Zaire Mayinga insert + boost MVA vaccine at D7 (1.5.108 PFU) with multivalent insert, United Kingdom (UK), detection with
Zaire Mayinga GP (Jenner method)
12: Ewer 2016, ChAd3 vaccine (2.5.1010 VP) with Zaire Mayinga insert + boost MVA vaccine at D7 (1.5.108 PFU) with multivalent insert, UK, detection with Zaire Mayinga GP
(ADI method)
13: Ewer 2016, ChAd3 vaccine (2.5.1010 VP) with Zaire Mayinga insert + boost MVA vaccine at D14 (1.5.108 PFU) with multivalent insert, UK, detection with Zaire Mayinga GP
(Jenner method)
14: Ewer 2016, ChAd3 vaccine (2.5.1010 VP) with Zaire Mayinga insert + boost MVA vaccine at D14 (1.5.108 PFU) with multivalent insert, UK, detection with Zaire Mayinga GP
(ADI method)
15: Ewer 2016, ChAd3 vaccine (1 to 5.1010 VP) with Zaire Mayinga insert + boost MVA vaccine (1.5.108 PFU) with multivalent insert, UK, detection with Zaire Makona virion
16: Huttner 2015, VSV vaccine (3.105 PFU) with Zaire insert, Switzerland, detection with Zaire Kikwit GP
17: Kennedy 2017, ChAd3 vaccine (2.1011 PU) with Zaire insert, Liberia
18: Kennedy 2017, VSV vaccine (2.107 PFU) with Zaire insert, Liberia
19: Kibuuka 2015, 3 injections of DNA vaccine (4 mg) with multivalent insert, Uganda, detection with Zaire GP
20: Kibuuka 2015, 3 injections of DNA vaccine (8 mg) with multivalent insert, Uganda, detection with Zaire GP
21: Ledgerwood 2010, Ad5 vaccine (2.109 VP) with multivalent insert, USA, detection with Zaire GP
22: Ledgerwood 2010, Ad5 vaccine (2.1010 VP) with multivalent insert, USA, detection with Zaire GP
23: Ledgerwood 2014, ChAd3 vaccine (2.1010 PU) with multivalent insert, USA, detection with Zaire Mayinga GP
24: Ledgerwood 2014, ChAd3 vaccine (2.1010 PU) with multivalent insert, USA, detection with Zaire Makona GP
25: Ledgerwood 2014, ChAd3 vaccine (2.1011 PU) with multivalent insert, USA, detection with Zaire Mayinga GP
26: Ledgerwood 2014, ChAd3 vaccine (2.1011 PU) with multivalent insert, USA, detection with Zaire Makona GP
27: Li 2017, 2 injections of Ad5 vaccine (4.1010 VP) with Zaire Makona insert, China
28: Li 2017, 2 injections of Ad5 vaccine (1.6.1011 VP) with Zaire Makona insert, China
29: Martin 2006, 3 injections of DNA vaccine (2 mg) with multivalent insert, USA, detection with Zaire NP
30: Martin 2006, 3 injections of DNA vaccine (4 mg) with multivalent insert, USA, detection with Zaire GP
31: Martin 2006, 3 injections of DNA vaccine (4 mg) with multivalent insert, USA, detection with Zaire NP
32: Martin 2006, 3 injections of DNA vaccine (8 mg) with multivalent insert, USA, detection with Zaire GP
33: Martin 2006, 3 injections of DNA vaccine (8 mg) with multivalent insert, USA, detection with Zaire NP
34: Milligan 2016, MVA vaccine (108 TCID50) with multivalent insert, UK, detection with Zaire Kikwit GP
35: Milligan 2016, MVA vaccine (108 TCID50) with multivalent insert + boost Ad26 vaccine at D28 (5.1010 VP) with Zaire Mayinga insert, UK, detection with Zaire Kikwit GP
36: Milligan 2016, Ad26 vaccine (5.1010 VP) with Zaire Mayinga insert, UK, detection with Zaire Kikwit GP
37: Milligan 2016, Ad26 vaccine (5.1010 VP) with Zaire Mayinga insert + boost MVA vaccine at D28 (108 TCID50) with multivalent insert, UK, detection with Zaire Kikwit GP
38: Milligan 2016, MVA vaccine (108 TCID50) with multivalent insert, UK, detection with Zaire Kikwit GP
39: Milligan 2016, MVA vaccine (108 TCID50) with multivalent insert + boost Ad26 vaccine at D56 (5.1010 VP) with Zaire Mayinga insert, UK, detection with Zaire Kikwit GP
40: Milligan 2016, Ad26 vaccine (5.1010 VP) with Zaire Mayinga insert, UK, detection with Zaire Kikwit GP
41: Milligan 2016, Ad26 vaccine (5.1010 VP) with Zaire Mayinga insert + boost MVA vaccine at D56 (108 TCID50) with multivalent insert, UK, detection with Zaire Kikwit GP
42: Milligan 2016, Ad26 vaccine (5.1010 VP) with Zaire Mayinga insert, UK, detection with Zaire Kikwit GP
43: Milligan 2016, Ad26 vaccine (5.1010 VP) with Zaire Mayinga insert + boost MVA vaccine at D14 (108 TCID50) with multivalent insert, UK, detection with Zaire Kikwit GP
44: Rampling 2015, ChAd3 vaccine (1010 VP) with Zaire Mayinga insert, UK, detection with Zaire GP
45: Rampling 2015, ChAd3 vaccine (2.5.1010 VP) with Zaire Mayinga insert, UK, detection with Zaire GP
46: Rampling 2015, ChAd3 vaccine (5.1010 VP) with Zaire Mayinga insert, UK, detection with Zaire GP
47: Regules 2015, VSV vaccine (3.106 PFU) with Zaire Kikwit insert, USA, detection with Zaire Kikwit GP
48: Regules 2015, VSV vaccine (3.106 PFU) with Zaire Kikwit insert, USA, detection with Zaire Mayinga GP
49: Regules 2015, VSV vaccine (2.107 PFU) with Zaire Kikwit insert, USA, detection with Zaire Kikwit GP
50: Regules 2015, VSV vaccine (2.107 PFU) with Zaire Kikwit insert, USA, detection with Zaire Mayinga GP
51: Sarwar 2015, 3 injections of DNA vaccine (4 mg) with multivalent insert, USA, detection with Zaire GP
52: Sarwar 2015, 4 injections of DNA vaccine (4 mg) with multivalent insert, USA, detection with Zaire GP
53: Tapia 2016, ChAd3 vaccine (1010 VP) with Zaire insert, Mali, detection with Zaire GP
54: Tapia 2016, ChAd3 vaccine (2.5.1010 VP) with Zaire insert, Mali, detection with Zaire GP
55: Tapia 2016, ChAd3 vaccine (5.1011 VP) with Zaire insert, Mali, detection with Zaire GP
56: Tapia 2016, ChAd3 vaccine (1012 VP) with Zaire insert, Mali, detection with Zaire GP
57: Tapia 2016, ChAd3 vaccine (1010 to 1012 VP) with Zaire insert + boost MVA vaccine at D97 (2.108 PFU) with multivalent insert, Mali, detection with Zaire GP
58: Zhu 2015, Ad5 vaccine (4.1010 VP) with Zaire Makona insert, China, detection with Zaire Makona GP
59: Zhu 2015, Ad5 vaccine (1.6.1011 VP) with Zaire Makona insert, China, detection with Zaire Makona GP
60: Zhu 2016, Ad5 vaccine (4.1010 VP) with Zaire Makona insert, Sierra Leone, detection with Zaire Makona GP
61: Zhu 2016, Ad5 vaccine (1.6.1011 VP) with Zaire Makona insert, Sierra Leone, detection with Zaire Makona GP
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presented above. In the full model, the vaccine platform was
signiﬁcantly associated with the antibody response (p = 0.002), but
the viral strain used to detect the antibody response after
vaccination was not (p = 0.996). The other variables were not
associated with the antibody response.
Discussion
This systematic review on preventive Ebola vaccine trials has
found 49 studies conducted in humans or in NHP. The meta-
analysis, using a random-effect inverse variance meta-regression
including 61 human vaccination groups, showed a major part of
antibody response variability in humans that remained unex-
plained by the factors included in the model. Indeed, the between-
group heterogeneity I2 exceeded 90%, even after adjustment for the
factors associated with antibody response. Two signiﬁcant
determinants were independently associated with antibody
response after preventive vaccination against EVD: the Ebola
vaccine platform and the Ebola strain used for antibody detection.
The use of a systematic review methodology, including
solicitation of experts, allowed us to conduct exhaustive descrip-
tive analyses on all Ebola vaccinated groups in NHP or humans
published in the literature up to January 2017. Our descriptive
results showed an extreme variability of study designs and
features, especially in nonhuman primate trials. This variability
is related to the recentness of the research topic. The higher
variability within nonhuman primate studies compared to human
trials is easily explained by the process of vaccine development,
which selects for further clinical trials only the subset of candidate
vaccines proven to be immunogenic in nonhuman primates. The
comparison of antibody response levels between humans and
nonhuman primate only had an indicative purpose. It is indeed
difﬁcult to compare these very different models, mostly because of
potential multiple confounding factors.
Due to the low sample size of each group of nonhuman
primates, we decided to restrict heterogeneity analyses to human
groups. Human groups with small sample size were excluded,
since their between-group variance would have been too low to
contribute to the meta-regression model. It was not possible to
pool small groups together because of high heterogeneity in the
factors likely to inﬂuence the antibody response (vaccine and
population characteristics, and measure of antibody response). The
threshold of at least 8 individuals per group allowed us to include
the majority of human groups in the meta-regression. Sensitivity
analyses using a threshold of 10 individuals led to the same ﬁnal
results.
The very high heterogeneity between vaccination groups could
be explained by various reasons. Firstly, some factors inﬂuencing
the antibody response may be missing, for instance, genetic factors
that are inﬂuencing the immunogenicity of the vaccines (Sridhar,
2015). Secondly, the analysis of grouped data, due to unavailability
of individual data for the groups included in our meta-regression
model, led to a lack of precision in the estimation of inﬂuence of
factors on antibody response, and also in the evaluation of
antibody response heterogeneity across vaccination groups.
Thirdly, the enzyme-linked immunosorbent assay (ELISA) measur-
ing relative antibody concentration of immunoglobulin G against
EBOV glycoprotein used in the different trials could have a
variation of its precision (Logue et al., 2018). Lastly, the extreme
variability of study designs certainly explains parts of the high
between-group variance for antibody response observed in our
results.
Despite the major between-group heterogeneity in our meta-
regression model, two factors signiﬁcantly associated with
antibody response variability could be identiﬁed. The Ebola strain
used for antibody detection seems to inﬂuence the results of ELISA
tests. This demonstrates the importance of harmonisation for the
measurement methods used in vaccines evaluations, and high-
lights the difﬁculty in directly comparing published results across
several trials. The Ebola vaccine platform was also strongly
associated with antibody response.
For the other factors studied in our meta-analysis, no
association was found with the antibody response variability. In
particular, the vaccine dosage did not have any signiﬁcant
inﬂuence on the level of the antibody response in our results.
We acknowledge that the use of a binary variable may have limited
the ability to detect a dose-effect in the meta-regression. However,
the regression result is consistent with the descriptive results that
also did not suggest a clear dose-immunogenicity relationship
within a given vaccine platform.
No population characteristic was independently associated
with the antibody response after Ebola vaccination. It may be
possible that the low diversity of the population, which is directly
related to the strict criteria for selection of trial participants,
prevented the identiﬁcation of a potential impact of these
population characteristics on the antibody response.
Conclusion
Our ﬁndings show that there are still signiﬁcant uncertainties in
the determinants of the antibody response after preventive
vaccination against Ebola virus disease. This emphasises the
interest of harmonizing measurement methods and study designs.
Furthermore, it indicates the impossibility to directly compare
results from one published study to another or to extrapolate
results, due to considerable variations in studies features.
Assessment of immunogenicity between Ebola vaccines needs
randomised controlled multi-arm trials, as performed in PREVAIL
study (NCT02344407) and PREVAC study (NCT02876328).
Table 4
Results of a random-effect meta-regression model (with ﬁxed intragroup variance) of determinants of antibody titre (log10) after Ebola vaccination according to
characteristics of vaccine, population, and measurement techniques. Multivariate analysis. I2 = 95.31%, R2 = 68.45%.
Determinants of antibody response Estimated β [CI 95%] p value
Vaccine platform (reference: MVA vaccine) <0.001
DNA 0.43 [0.52; 1.37] 0.379
Ad26 1.15 [033; 197] 0.006
Ad26/MVA or MVA/Ad26 2.32 [158; 307] <0.001
Ad5 0.54 [0.42; 1.50] 0.268
ChAd3 0.97 [010; 183] 0.028
ChAd3/MVA 0.81 [0.13; 1.76] 0.091
VSV 1.46 [079; 213] <0.001
Viral strain used for antibody detection (reference: Mayinga strain) <0.001
Kikwit 0.30 [0.27; 0.86] 0.301
Makona 0.99 [050; 148] <0.001
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In human immunodeficiency virus–infected patients, antiretroviral therapy
suppresses the viral replication, which is followed in most patients by a restora-
tion of CD4+ T cells pool. For patients who fail to do so, repeated injections of
exogenous interleukin 7 (IL7) are experimented. The IL7 is a cytokine that is
involved in the T cell homeostasis and the INSPIRE study has shown that injec-
tions of IL7 induced a proliferation of CD4+ T cells. Phase I/II INSPIRE 2 and
3 studies have evaluated a protocol in which a first cycle of three IL7 injections
is followed by a new cycle at each visit when the patient has less than 550 CD4
cells/�L. Restoration of the CD4 concentration has been demonstrated, but the
long-term best adaptive protocol is yet to be determined. Amechanisticmodel of
the evolution of CD4 after IL7 injections has been developed, which is based on a
system of ordinary differential equations and includes random effects. Based on
the estimation of this model, we use a Bayesian approach to forecast the dynam-
ics of CD4 in new patients. We propose four prediction-based adaptive protocols
of injections tominimize the time spent under 500CD4 cells/�L for each patient,
without increasing the number of injections received too much. We show that
our protocols significantly reduce the time spent under 500 CD4 over a period
of two years, without increasing the number of injections. These protocols have
the potential to increase the efficiency of this therapy.
KEYWORDS
adaptive protocols, HIV, interleukine 7, mechanistic models
1 INTRODUCTION
Infection by the human immunodeficiency virus (HIV) leads to a decrease of the concentration of CD4+ T lymphocytes
(CD4) associated with a deficiency of the immune system, which increases the risk of opportunistic infections.1 With
an effective combination antiretroviral treatment, the viral load becomes undetectable. The CD4 pool is then reconsti-
tuted in most cases.2 However, this does not happen for some patients3 who are low immunological responders. These
patients, who present CD4 counts below 500 cells/�L of blood, have a lower life expectancy4 and an increase of nonac-
quired immunodeficiency syndrome conditions, such as cancer or cardiovascular diseases.5 To help the reconstitution
of the CD4 pool, a treatment based on injections of exogenous interleukin 7 (IL7) has been experimented. The IL7 is a
cytokine produced by thymus stromal cells and lymph nodes and is involved in the CD4 homeostasis.6,7 Several trials
Statistics in Medicine. 2018;1–15. wileyonlinelibrary.com/journal/sim © 2018 John Wiley & Sons, Ltd. 1
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have demonstrated the safety and the beneficial effect of exogenous IL7 on immunemarkers.8,9,10 Repeated cycles of three
injections of IL7 have been evaluatedwith the aim ofmaintaining the CD4 counts above 500 cells/�L because, in this case,
HIV infected subjects have about the same life expectancy as the general population.11 In the phase I/II trials INSPIRE 2
and 3,12 the repeated cycles of IL7 could indeed maintain CD4 concentration above the limit of 500 cells/�L most of the
time, although the best adaptive protocol is yet to be determined.
Mechanistic models, based on ordinary differential equations (ODEs), have been applied to model different infec-
tious diseases, eg, modeling of the HIV,13-15 the hepatitis C,16,17 or the human cytomegalovirus,18 and other health-related
processes.19 They have also been used to understand and predict the effects of IL7. A first work quantified the effect of
exogenous IL7 on the proliferation rate of CD4 cells and showed an additional effect on the cells' survival.20 The model
was then extended to fit repeated injections.21 Thanks to a population approachwith random effects, themodels were able
to predict future individual responses to new injections of IL7 with a very good accuracy. This opened the opportunity to
individualize the strategy of IL7 administration.
Dynamical adaptation of the treatment as a function of the response of the patient has been proposed by Murphy22
and Robins23 who developed the optimal treatment regime theory. Many papers have followed in this field.24-27 Methods
based on semi parametric models and dynamic treatment regimens exist.28 However, as Rich et al28 underlined, these
methods are not realistic enough and they often miss some important confounders. This issue can be solved by using
mechanistic models.29 When an ODE-based mechanistic model is available, the modeled treatment can be adapted using
this model. This has been described by Rosenberg et al30 for the supervised treatment interruption strategies, or in the
pharmacokinetic-pharmacodynamic field.17,31 The optimal control theory can be applied for globally optimizing the treat-
ment regime, which has been proposed by Castiglione and Piccoli,32 and applied to optimizing the treatment of HIV
infected patients.33,34 However, as noted by Chakraborty and Murphy35 these works do not sufficiently take into account
the statistical issues of the problem, ie, model parameters have to be estimated and for efficient estimation and random
effects have to be introduced in the statistical model. Such random effect mechanistic model has been applied to tune the
dose of an antiretroviral treatment by Prague et al.36
In the present paper, we aim to find efficient adaptive protocols for IL7 administration based on predictions from a ran-
dom effect mechanistic model proposed in the work of Jarne et al.21 Here, we propose realistic protocols that shorten the
time spent under the limit of 500 CD4 cells/�L and limit the number of IL7 injections. Two approaches will be compared,
ie, adapting the criterion for a new cycle based on the risk of falling under 500 CD4 cells/�L before the next visit, and
adapting the times of control visits. Both of these approaches are based on predictions generated with our random effect
mechanistic model at relatively short term to locally optimize the protocols. This is less ambitious than optimal control
but is more feasible and the proposed protocols could soon be proposed to real patients. In both approaches, we may or
may not adapt also the number of injections per cycle, leading to four possible protocols.
This paper is organized as follows. Section 2 describes the data from INSPIRE 1, 2, and 3, and the design of the protocol
for repeated cycles. Section 3 presents themathematical and statistical features of themodel. In Section 4, we describe two
prediction-based adaptive protocols and their two variants adapting the number of injections per cycle or not. Section 5
presents the simulation study and its results, while Section 6 shows what the method would have predicted for real data.
Section 6 concludes this paper.
2 DATA
The data used for the mechanistic model are drawn from the INSPIRE 1, 2, and 3 studies.8,12 These studies evaluated
the effect of injections of IL7 on the CD4 concentration in low immunological responders aged 18 years or more. The
patients were included in the study if they were under stable combination antiretroviral treatment for at least one year,
had CD4 counts between 100 and 400 cells∕�L of blood, and had an undetectable viral load for at least 6 months before
the beginning of the protocol.
The first study, INSPIRE 1 (initially called simply “INSPIRE”), evaluated the effect of one cycle of injection, which is
defined as three injections with oneweek between each one. Three doses (10, 20, and 30 �g/Kg) were tested, and a placebo
was included, for a total of 21 patients. The INSPIRE 2 and 3 studies evaluated the effect of repeated cycles of injections,
using only the 20 �g/Kg, which was determined to be the most effective without too many side effects.
Overall, the data from 128 patients are used, with regular measurements of the CD4 counts and the marker of prolif-
eration Ki67. The patients had visits at weeks 1, 2, 3, 4, 5, 6, 9, and 12, and then visited every 3 months. The CD4 counts
were measured at each visit, while Ki67 counts were measured only at weeks 1, 2, 3, 5, and 12. For the repeated cycles,
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FIGURE 1 Design of INSPIRE 2 study. The screening phase determines the concentrations of CD4 at baseline to include or not the
patient. The induction phase starts with a first cycle of three interleukin 7 (IL7) injections at weeks 1, 2, and 3. The maintenance phase then
controls the patient every 3 months with a new cycle if the patient is under 550 CD4. The green dots represent the measures of CD4 counts,
and blue dots the measures of Ki67 [Colour figure can be viewed at wileyonlinelibrary.com]
the maintenance phase consisted in repeated visits every 3 months. When the CD4 counts were below 550, a new cycle
of injections was administered. The durations of the studies were 12, 24 and 21 months for INSPIRE, INSPIRE 2, and 3,
respectively. The design of INSPIRE 2 is presented in Figure 1.
The high heterogeneity of the data in terms of number of injections per cycles, number of cycles received and dose, and
the availability of regular measurements of different immunological markers makes this an interesting dataset for mod-
eling. Overall, 197 cycles were administered for 128 patients, with 41 incomplete cycles (one or two injections instead
of three). Because the patients had different trajectories of CD4 counts, they had different times of injections in the
maintenance phase.
3 MECHANISTIC MODEL FOR IL7 TREATMENT
3.1 Modeling of the effect of IL7 injections on CD4 concentration
A mechanistic model for the evolution of the CD4 concentration after repeated IL7 injections was proposed in the work
of Jarne et al.21 In this paper, a two compartment model was described, with the compartment P for the proliferating cells
and the compartmentQ for the quiescent cells. This model and the different effects on the parameters have been selected
with the approximate Likelihood Cross Validation criteria (LCVa),37 as described in the works of Thiebaut et al20 and
Jarne et al.21 The mathematical structure of the model is written as⎧⎪⎨⎪⎩
dQ
dt
= � + 2�P − �Q − �QQ
dP
dt
= �Q − �P − �PP.
We allow the parameters to be different from one subject to another. Thus, we denote by �i the vector of parameters of
the ODE system, ie, �i = [�i, �i, �i, �i
Q
, �i
P
] for patient i (i = 1, … ,n) and by Xi = (Q(t, �i),P(t, �i)) his state vector. All
of the parameters are positive because they are rates of proliferation, production, and death for cells. Hence, we use a log
transformation denoted by a tilde, ie, �̃
i
l = log(�
i
l
). The meaning and units of each parameter are detailed in Table 1.
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TABLE 1 Parameters of the model and their estimates from the work of Jarne et al21 [Correction
added on 4 October 2018, after first online publication: the Name and Unit in rows 6-8 and 10 have
been corrected]
Parameter Name Units Estimate mean (sd)
� Production rate cells.days−1 5.32 (0.33)
� Reversion rate days−1 2.44 (0.23)
� Proliferation rate days−1 0.06 (0.004)
�P Death rate of P cells days
−1 0.07 (0.005)
�Q Death rate of Q cells days
−1 0.08 (0.02)
��1 Effect of IL7 on � (Injection 1) days
−1.�g−1 0.93 (0.04)
��2 Effect of IL7 on � (Injection 2) days
−1.�g−1 0.71 (0.04)
��3 Effect of IL7 on � (Injection 3) days
−1.�g−1 0.23 (0.04)
��Q Effect of IL7 on �Q days
−1.�g−1 -0.08 (0.006)
�C Cycle effect of IL7 days
−1 -0.16 (0.02)
�� Standard deviation of random effect on � cells.days−1 0.24 (0.03)
�� Standard deviation of random effect on � days−1 0.52 (0.08)
�1 Noise parameter on CD4 cells cells0.25 0.29 (0.003)
�2 Noise parameter on P cells cells0.25 0.28 (0.02)
Abbreviations: IL7, interleukin 7.
The initial condition for subject i is the equilibrium point, ie, dQ
dt
(0, �i) = 0, dP
dt
(0, �i) = 0, which gives the initial points
Q(0, �i) =
�i(�i+�i
P
)
�i(�i
P
−�i)+�i
Q
(�i+�i
P
)
,P(0, �i) = �
i�i
�i(�i
P
−�i)+�i
Q
(�i+�i
P
)
.
A patient-by-patient inference is inefficient if there is not enough information for each subject; hence, we need a sta-
tistical model of the variability of the parameters using both explanatory variables with fixed effects and random effects.
It can be written as ⎧⎪⎪⎪⎪⎨⎪⎪⎪⎪⎩
�̃i(t) = �̃0 + li
�̃i(t) = �̃0 +
[
�C1{Ci(t)>1} +
3∑
k=1
1{N it=k}
��k d
0.25
i
]
1{N it−N
i
t−7=1}
�̃i(t) = �̃0 + ri
�̃i
Q
(t) = �̃Q0 + ��Q�
i(t)d0.25
i
�̃i
P
(t) = �̃P0 ,
(1)
where li and ri are normally distributed random effects li ∼ (0, �2�) and ri ∼ (0, �
2
�); C
i(t) counts the number of cycles
and �C represents the cycle effect, meaning that, after one cycle, the effect of IL7 on the proliferation can be lower; ��k is
the effect of the injection on the proliferation, k being 1, 2, or 3 depending on whether the injection is the first, second, or
third of the cycle. The effects on � are constant during 7 days after each injection, and they then disappear. N it counts the
number of injections that patient i has received until time t; thus, 1{N it−N it−7=1} is an indicator function taking the value 1
if an injection was administered in the last 7 days. Let Tit be the time of the last injection received by the patient i at the
time t; the effect on �Q is represented by ��Q� (t), with f written as
� i(t) =
⎧⎪⎨⎪⎩
1, if 2 + Tit < t ≤ 360 + T
i
t
1 − (t − 360)∕360, if 360 + Tit < t ≤ 720 + T
i
t
0, if 720 + Tit < t.
In our data, the variables P andQ are not directly observed. The observations correspond to the total number of CD4 and
the number of proliferating cells; hence, we also need an observation model. The observation ofM biomarkers are related
to the solution of the ODE with the function g, ie, Y imq = gm(�
i, tq)0.25 + �
i
m� ,m = 1, … ,M. Here,M = 2, as we observe
the CD4 counts and the Ki67 counts. Denoting by Y i1� the fourth root of the CD4 counts, and by Y
i
2k
, the Ki67 counts for
patient i at times tij ( j = 1, … , J
i) and tik (k = 1, … ,K
i), respectively. This gives the following observation model:{
Yi1� =
[
P
(
ti� , �
i
)
+ Q
(
ti� , �
i
)]0.25
+ �i1�
Yi
2k
= P
(
tik, �
i
)0.25
+ �i
2k
.
(2)
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We assume that noises variables are normally distributed, ie, �i1� ∼ (0, �
2
1), �
i
2k
∼ (0, �22). This parameter includes the
measurement error and the biological variation not taken into account in the model, eg, the diurnal variation of the CD4
concentration. The fourth root transformation has been applied to make homoscedasticity and normality acceptable.20
3.2 Inference and estimation
To estimate the parameters of themodel, Jarne et al21 used the NIMROD program.38 The implemented estimationmethod
is based on penalized log-likelihoodmaximization. This is a quasi-Bayesian approach in the sense that penalization is built
from a priori values for the parameters found in the literature. Then, this penalized log-likelihood is maximized using a
Newton-Raphson like algorithm, called robust variance scoring.39 The iterative algorithm stops when the relative distance
to maximum criterion is satisfied. The results of this inference are displayed in Table 1. There are enough observations to
consider that the posterior distributions are close to normal distribution (in virtue of the Bernstein-vonMises theorem40),
so that results in Table 1 can be interpreted as summarizing the (marginal) posterior distributions of the parameters by
their expectations and their standard deviations.
4 PREDICTION-BASED ADAPTIVE PROTOCOLS
4.1 General method
In the original protocol of INSPIRE 2 and 3 studies, which is called the “original” (ORI) protocol, patients start a first
cycle of injections, with CD4 counts measurements at the times of injections. There are visits every 3 months. A new
cycle is administered if the CD4 counts are below 550 CD4. The aim is to prevent CD4 concentration to fall under 500.
Thus, the original protocol is already an adaptive protocol, but because the patients have different CD4 dynamics, this
fixed criterion is not always appropriate. If a patient tends to return quickly to his or her baseline concentration, then the
margin can be too small and the decision not to administer a new cycle can lead to cross the limit of 500 CD4 shortly after
the control. In contrast, for some patients, the CD4 concentration decreases slowly after an injection, and the criterion of
550 CD4 for a new cycle may be too high, which results in unnecessary cycles and visits. Here, we propose protocols that
are based on the prediction that can be done with a mechanistic model with the aim of decreasing the time spent under
the limit of 500 CD4, while controlling the number of IL7 injections.
Weuse amechanisticmodel that fits the dynamics of CD4 following a cycle of IL7 injections; the fixed effects parameters
have been estimated using all observations of the three INSPIRE studies. For the mixed effect parameters, � and �, we
have an estimation of the mean of the parameters on the population and the variance of their random effects (�2
�
and �2�).
With these estimates and the information for the patient i available at the time k, calledH
tk
i
, we used anMCMC algorithm
to sample the posterior distribution of the individual parameters �i and �i. For given values of the parameters of a patient,
we can predict the evolution of his or her CD4 concentration.36 Taking into account the uncertainty on the parameters,
we can also compute the distribution of any quantity related to the future CD4 concentration dynamic. This prediction
can be used to adapt the treatment. Every time that the patient comes for a control visit, we have access to new data so
that H
tk
i
⊂ H
tk+1
i
; thus, the prediction is more precise as time goes on.
The algorithm used for sampling the random effects of the patient is a Metropolis within Gibbs.41 At each iteration,
� and � are successively sampled. In the Metropolis part of the algorithm, the instrumental function used for the first
estimation of the protocol (3-month control) is the posterior law estimated with NIMROD. The standard error of the prior
for � and � is the one estimated with NIMROD (respectively, sd� = 0.33 and sd� = 0.23; see Table 1) added with the
standard error associated with the random effect (respectively, �� = 0.24 and �� = 0.52; see Table 1), as the variability
comes from both the error of estimation and the interindividuals variability. Then, for each control visit after the first one,
the distribution given by the previous MCMC is used as the new prior. The likelihood used in the MCMC procedure is42
Li =
M∏
m=1
Km∏
�=1
1
�m
√
2�
exp
⎡⎢⎢⎣−12
⎛⎜⎜⎝
Y i
��
− gm
(
t� , �i
)0.25
�m
⎞⎟⎟⎠
2⎤⎥⎥⎦ .
As presented in the work of van der Vaart,40 according to Doob's theorem, the distribution of the parameters �̂i with the
data from patient i at time tk (H
tk
i
) converges to the Dirac of the true value of the parameters, �(�i), when k tends to infinity.
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FIGURE 2 Flowchart of the two protocols. Adaptive criterion of injection (ACI) protocol: adaptive criterion protocol, the visits are every 3
months and the decision to administer a new cycle is based on the predicted risk R to fall under 500 CD4 before the next visit. Adaptive time
of injection (ATI) protocol: adaptive times protocol, the times of visit are predicted based on the time at which the patient is supposed to
reach the 500 CD4 limit, and a new cycle is administered if this predicted time is too short
Wepropose two prediction-based adaptive approaches; the first is based on an adaptive criterion of injections (ACIs); the
second is based on an adaptive time of injections (ATIs). Both approaches have a variant where the number of injections
per cycle can be adapted. Figure 2 presents the flowchart of the two approaches.
4.2 Prediction ability on real data
Before developing and studying prediction-based adaptive protocols, it is essential to study the prediction ability of our
model. In this aim, we randomly excluded 10 patients from the data and estimated the parameters of the model on the
reduced data set. For each excluded patient, we ran the MCMC algorithm using the estimates from the diminished data
set. For an excluded patient i, at each time of control (every 3 months), the MCMC algorithm gives a distribution of
CD4 concentration at every time of observation tj. At each iteration q of the MCMC, we can generate the predicted dis-
tribution of observation at each time tij by computing CD4
i
�q = P(ti� , �
iq) + Q(ti� , �
iq), and adding a noise variable, ie,
Yi1�q = (CD4
i
�q)
0.25 + �i1�q. Figure 3 shows examples of these predicted distributions for four (out of the 10) patients. The
black line represents themean of the future trajectories and the light blue band represents 95% credible intervals; the dark
blue band represents 95% predictive interval of observations, and the black dots are the observed values. The 95% credible
and predictive intervals were computed by excluding the 2.5%most extreme values of each side of the distribution. If the
model is well calibrated, then the black dots should be inside the dark blue band, which is the case here.
To show the good calibration of the predicted distributions, a quantile analysis was done. The process of studying the
prediction for 10 excluded patients was repeated 10 times leading to a total of 100 patients, and we analyzed the distri-
butions of the observed data with respect to the predicted distributions by a quantile-quantile plot. The quantiles of the
predicted distributions should be the same as the observed quantiles, which was indeed essentially the case, as shown in
the quantile-quantile plot presented in the Web Supplementary 1.
4.3 Protocol with ACIs
The ACI protocol is similar to the original protocol, ie, the patients come every 3 months for a control visit. However,
instead of using the fixed criterion of CD4 counts below 550, we predict the risk R that the CD4 concentration will fall
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FIGURE 3 Prediction intervals for four random patients. Light blue band: 95% credible interval of trajectories. Dark blue band: 95%
predictive interval of observations. Black line: mean of predicted trajectories. Black dots: real-data observations [Colour figure can be viewed
at wileyonlinelibrary.com]
below500 before the next visit.With the distribution of parameters given by theMCMCalgorithmpresented in Section 4.1,
we can directly have the distribution of CD4 concentration at 3 months, which allows us to compute R
R
(
�̂i|Htk
i
)
= P
(
g1
(
tk + tvisit, �̂
i
)
> 500|Htk
i
)
,
where tvisit is the time between two controls (3 months in INSPIRE studies). If R is larger than a limit risk called Rlim (for
instance, 10%), a new cycle of injections is administered. If R < Rlim, then the patients simply comes back 3months later.
At each visit, the MCMC algorithm is done with new data, and the decision is made with the value of the risk R.
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4.4 Protocol with ATIs
In theATI protocol, the injections times are adaptive. The patient starts his or her first cycle and then comes back 3months
later. We denote tinj such as g1(tinj, �̂
i) = 500, the time at which the patient will reach the 500 CD4 limit. Then, with the
MCMC algorithm, we sample the distribution of tinj and select tinjp as the p quantile (for instance the 0.1 quantile) of this
distribution, ie,� (tinj < tinjp ) = p. If t
inj
p is larger than a fixed limit (here, 1 month), the patient comes for a new visit at
the time tinjp . If not, then a new cycle is administered immediately and the next time of visit is computed again at the end
of the cycle. The time between two cycles is chosen here to be at least 1 month because it is clinically relevant.
4.5 Adaptive number of injections: ACIC and ATIC protocols
Up to now, the proposed protocols used cycles of three injections. In the work of Jarne et al,21 the usefulness of the third
injection was questioned. The estimation of the effect of this injection, ��3, showed that the impact of this injection on
the proliferation rate is much smaller compared to the first two injections. A comparison of the simulation of protocols
showed that the original protocol with only two injections per cycle reduced the number of injections without impacting
the time spent under 500 CD4 or the mean number of CD4. We propose a modification of the ACI and ATI protocols for
adapting the number of injections per cycle, a C is added in the end of their names to represent the adaptation inside a
cycle, leading to the ACIC and ATIC protocols.
• Protocol ACIC: When a decision for a new cycle is taken, the aim is to decide if the decision to diminish the number of
injections will change the decision to inject or not at the next time of control. To do this, we compare the risks to fall
under 500 CD4 at the next control visit for a cycle of three, two, or one injection, ie, R(�̂i�|Htki ) = � (g1(�̂i� , tk + 2tvisit) >
500|Htk
i
), with j ( j = 1, … , 3) being the number of injections of the cycle, and �̂i� depending on this number of injection
as presented in Equation 1. If in any case a cycle of injections would be necessary at the next time of visit, meaning
that R(�̂i3|Htki ) is superior to the chosen Rlim, then we consider that the patient needs a cycle of three injections. If this
is not the case, and if both R(�̂i2|Htki ) and R(�̂i1|Htki ) are inferior to Rlim, then a cycle of one injection is administered. If
R(�̂i2|Htki ) is inferior to Rlim but not R(�̂i1|Htki ), a cycle of two injections is administered. Moreover, if only R(�̂i3|Htki ) is
inferior to Rlim, a cycle of three injections is administered.
• Protocol ATIC: When a decision for a new cycle is taken, the next tinj∗ is calculated for one, two or three injections:
tinj1p , tinj2p and tinj3p . The relative difference between two and three injections is calculated, ie, d3 =
tinj2p−tinj3p
tinj3p
. If d3 is
superior to dlim, then three injections are administered. If not, then the same process is repeated to choose between
one or two injections, ie, d2 =
tinj1p−tinj2p
tinj2p
, and if d2 is superior to dlim, here taken at 10% as it is clinically relevant, then
two injections are administered; if not, then one injection is administered.
5 SIMULATION
5.1 General description
We simulated the different protocols for 150 “pseudopatients” on a 2-year period. The parameter values of these patients
were sampled from the posterior distribution of the parameters estimated with NIMROD over the 138 patients of the
INSPIRE studies. Because � and � vary between patients, random effects were generated for all patients for these param-
eters, using the estimated variance of the random effects on the population. Moreover, we applied the inclusion criterion
of the INSPIRE studies, keeping only those patients with baseline CD4 counts between 100 and 400. The simulations of
the trajectories were done with R with the DeSolve package.43 This package numerically solves the ODE for a given set
of parameter values �i, using the “lsodes” method, an interface to the FORTRAN ODE solver bearing the same name.44
Observations were generated at times (0, 7, 14, 21, and 55) before the first time of control (day 90) by adding a noise vari-
able (according to Equation (2)) to the value of the trajectories at these times. Each time that we make a decision, the
observations are generated to take into account the decision. If a cycle is administered, then the next observations are at
the time of injections and at the next time of control; if not, then the next generated observation is only at the next time
of control. The total number of CD4 and the number of proliferating cells are observed each time.
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For the ACI and ACIC protocols, the values of the risk limit Rlim used were 0.05, 0.1, and 0.2. For the ATI and ATIC
protocols, we used the 0.05, 0.1, and 0.2 quantiles to obtain tinjp . The MCMC algorithm was performed with a total of 5000
iterations each time, with a burn-in phase of 1000 and a thinning of 2. The convergence of the chain was controlled with
the Heidel diagnostic; the results of the convergence are presented in Web Supplementary 2.
5.2 Results for the adaptive protocols
To compare the different protocols, we used eight criteria, ie, the mean number of CD4 over the protocol, the time spent
under 500 CD4, the number of cycles administered, the number of visits (including the visits for the injections inside
a cycle), the number of injections, and the number of cycles of one, two, and three injections (the number of cycles of
three injections includes the first cycle, which is not decided by the protocol because it is the start of the protocol and
automatically of three injections). The results are presented in Table 2.We considered the value of Rlim(for ACI andACIC)
and the p quantile (for ATI and ATIC) as “threshold” because they both represent the limit value for the decision.
Compared to the original protocol (ORI), the proposed protocols highly reduce the time spent under 500 CD4, while the
number of visits is comparable (slightly increased for the ACI protocol, and decreased for the ATI and ATIC protocols).
The number of injections is increased for the ACI protocol but this increase is not as important when the number of
injections per cycle is also adapted (ACIC) while the time spent under 500 CD4 is similar in both ACI and ACIC protocols.
The number of injections is similar between the ATI and ORI protocols, while it is reduced by the ATIC protocol.
The mean of CD4 is higher for the ACI and ACIC protocols than the ATI and ATIC protocols (which are similar to the
ORI protocol), because the aim of the ATI and ATIC protocols is to start a cycle just before the patient reaches 500 CD4,
while the ACI and ACIC protocols have visits of control only every 3 months, which means that the decision to start a
new cycle can be taken while the patient could wait before he or she reaches 500 CD4 but not 3 months. This means
that, when a new cycle is started, we expect CD4 concentration to be around 500 in the ATI and ATIC protocols, while
these concentrations can be higher in the ACI and ACIC protocols. This induces a higher mean of CD4 for ACI and ACIC
protocols. This is consistent with the choice of the criterion of interest, namely, the time spent with CD4 concentrations
under 500. This choice is justified by clinical results11 and consistency with INSPIRE studies. However, our method can
be modified by using other criteria. If it is clinically relevant to consider the mean number of CD4, it could be easily
implemented in the decision criterion for adapting the protocol.
The sensitivity analysis on the threshold parameter shows that for the ACI and ACIC protocols, the risk Rlim does not
significantly impact the results in any of the criteria. For the ATI and ATIC protocols, the p-quantile at 0.05 does not
increase the frequency of cycles or visits, but it does reduce the time spent under 500 CD4 on average. The p-quantile 0.2
is no better because it increases the time spent under 500 CD4 but does not reduce the number of cycles.
Figure 4 presents the boxplot of the time spent under 500 CD4, the number of visits, the mean of CD4, and the number
of injections for each protocol at the threshold 0.05. This shows that the median of time spent under 500 CD4 is at 0 for
each of the proposed protocols. TheATI andATIC protocols have higher third quantiles than the ACI andACIC protocols,
but the outliers are smaller. This means that the ATI and ATIC protocols are more suitable for patients with difficulties to
maintain their CD4 concentrations above 500. Indeed, the ATI and ATIC protocols allowmore frequent visits for patients
with a fast decrease of CD4 after the end of a cycle compared to the ACI and ACIC protocols, where a minimum delay
of 3 months between visits has to be respected. Globally, it is clear that all four protocols have better results for the time
spent under 500 CD4 than the ORI protocol. We can also see that all protocols have similar distributions for the three
other criteria, but the ACI and ACIC induce higher CD4 means, and the ATIC is lower in number of visits and number
of injections.
Figure 5 shows the plot of the dynamic of CD4 for three protocols (ORI, ACI, and ATI) with the threshold 0.1 for two
pseudopatients. In this figure, the real trajectory is represented by a dark line and the simulated observations are the black
dots. The ORI protocol uses those observations for the decision to administer a new cycle with the criterion of 550 CD4.
The proposed adaptive protocols predict a distribution of the random effects, which gives a distribution of CD4 at each
time point using those observations. The adaptive protocols use those predicted distributions for the decisions while the
ORI protocol relies only on the observation at the current time of control. The 95% credible interval of CD4 is represented
by the light blue band, and the decision taken by the proposed adaptive protocols are based on this prediction. For each of
those distributions of CD4, the distribution of the observations is also predicted by adding a noise variable to the predicted
CD4, as it was done in Section 4.2. The 95% predictive interval of observations is represented by the dark blue band.
At each time of control, new information is available; it induces adjustment of the prediction of the random effects, the
predicted distribution of CD4, and the predicted observations.
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TABLE 2 Comparison of the protocols original (ORI), adaptive criterion of injection (ACI), ACIC, adaptive time of injection (ATI), and ATIC. Eight criteria are
presented: the mean number of CD4 (CD4), the time spent under 500 CD4 (T500), the number of cycle (Nb Cycles), the number of visits (Nb visits), the number of
injections (Nb inj), and the number of cycle of, respectively, one, two, and three injections (C1, C2, and C3). These are calculated per patient over the two year protocols,
and their means and quartiles (or standard error for the mean of CD4) are presented. “Threshold” means Rlim (for ACI and ACIC) or p-quantile (for ATI and ATIC)
Protocol Threshold CD4 T500 (days) Nb Cycles Nb visits Nb inj C1 C2 C3
mean (sd) mean [Q1;Q3] mean [Q1;Q3] mean [Q1;Q3] mean [Q1;Q3] mean [Q1;Q3] mean [Q1;Q3] mean [Q1;Q3]
ORI - 722 (112) 107 [6;173] 4.5 [3;6] 18 [15;20] 13 [9;18] 0 0 4.5 [3;6]
ACI 0.05 882 (146) 18[0;7] 5.9 [4;8] 20 [17;24] 18 [12;24] 0 0 5.9 [4;8]
0.1 866 (143) 19 [0;18] 5.8 [4;8] 20 [17;24] 17 [12;24] 0 0 5.8 [4;8]
0.2 837(137) 21 [0;25] 5.6 [4;8] 20 [17;24] 17 [12;24] 0 0 5.6 [4;8]
ACIC 0.05 853 (124) 17 [0;7] 6.1 [5;8] 18 [12;24] 15 [8;24] 0.8 [0;2] 1.3 [0;2] 4.0 [1;8]
0.1 830 (146) 19[0;20] 6.0 [5;8] 18 [12;24] 15 [7;24] 0.9 [0;2] 1.2 [0;2] 3.9 [1;8]
0.2 804 (130) 23[0;26] 5.8 [4;8] 17 [11;23] 14 [7;23] 0.9 [0;2] 1.1 [0;2] 3.8 [1;7]
ATI 0.05 785 (71) 13[0;18] 5.0 [4;7] 16 [13;20] 15 [12;21] 0 0 5 [4;7]
0.1 764(67) 19 [0;32] 4.9 [3;6] 15 [12;18] 15 [9;18] 0 0 4.9 [3;6]
0.2 743 (64) 28[0;48] 4.7 [3;6] 15 [11;18] 14 [9;18] 0 0 4.7 [3;6]
ATIC 0.05 769 (72) 16 [0;24] 5.4 [4;7] 12 [10;14] 12 [8;14] 0.6 [0;1] 3.5 [2;5] 1.4 [1;2]
0.1 744 (71) 23[0;33] 5.1 [4;7] 12 [9;14] 11 [8;14] 0.6 [0;1] 3.3[2;5] 1.3 [1;2]
0.2 716 (72) 36 [0;60] 4.9 [3;7] 12 [9;14] 11 [6;14] 0.5 [0;1] 3.0 [1;5] 1.4 [1;2]
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FIGURE 4 Boxplot of time spent under 500 CD4, number of visits, mean number of CD4, and number of injections for each protocol at
the threshold 0.05. ACI, adaptive criterion of injection protocol; ATI, adaptive time of injection protocol; ORI, original protocol [Colour figure
can be viewed at wileyonlinelibrary.com]
For Patient 1, the ORI protocol predicts a cycle of injection at the second, third, and seventh visits. However, these
cycles are unnecessary as the decrease of CD4 in this patient is very slow. The ACI protocol correctly predicts that a new
cycle will be necessary only at the fifth visit. The ATI protocol predicts a new cycle at a slightly larger time and has the
advantage of having only two visits for a control, instead of eight for the other protocols.
Patient 2 has an opposite problem, as the ORI protocol fails to detect that a new cycle was necessary, eg, at the first visit,
resulting in a long time spent under 500 CD4. In contrast, the ACI and ATI protocols correctly predict that a new cycle is
necessary. Again, the number of control visits is reduced in the ATI protocol, which yields accurate times of control.
In Web Supplementary 3, the rate of error, defined as the number of times the decision made is not the optimal, is
analyzed. Overall, the rate of time when the algorithm made a decision causing the patient to spend some time under
500 CD4 is extremely low for the ACI and ACIC protocols (between 0.1% and 6%). For the ATI and ATIC protocols, it
corresponds to the risk taken (5% at the p-quantile of 0.05), while this rate was at 47% for the ORI protocol. The rate of
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FIGURE 5 Comparison of the three protocols for two random patients. Dots: observations. Black line: simulated trajectory. Horizontal
line: limit of 500 CD4. Vertical dashed lines: times of controls. Light band: 95% credible interval of trajectories. Dark band: 95% predictive
interval of observations. ACI, adaptive criterion of injection protocol; ATI, adaptive time of injection protocol; ORI, original protocol [Colour
figure can be viewed at wileyonlinelibrary.com]
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mistake when the algorithm predicts a new cycle for the ACI and ACIC protocols while it could have waited is higher
than the ORI protocol; although, this has less impact because this decision can be compensated at the next visit. The rate
of time when the ATI and ATIC predicted a time of visit too short is around 10%, but this also has less impact because it
simply means that the patient has one visit without injections.
Overall, the ATIC protocol with the p-quantile at 0.05 achieves the best balance between all criteria, with a time spent
under 500 CD4 among the lowest, and with the number of injections and visits also among the lowest. Compared with
the ORI protocol, the ATIC divided the time spend under 500 CD4 by around six, and spared six visits and one injection
over a period of two years. However, an analysis done in Web Supplementary 4 shows that, for the patients who have low
CD4 at baseline, the ATI protocol with the p-quantile at 0.05 is the best protocol because, in these patients, we cannot
afford to reduce the number of injections per cycle.
6 CONCLUSION
The very good ability of the mechanistic model to predict CD4 concentrations after a short learning phase to identify
individual parameters allows us to embark on optimizing the IL7 administration for each individual patient. Based on
this model, we have proposed adaptive protocols with the aim to optimize a criterion, here, the time spent under 500 CD4
cells/�L, using the minimum number of IL7 injections. The simulation of pseudopatients showed that the four proposed
protocols succeeded in doing so, reducing the time spent under 500 CD4 cells/�L with a number of injections similar or
lower compared to the original protocol.
Compared with classical approaches that are based on optimal control, our approach presents several advantages. First,
the parameters are not considered to be known and the adaptation of the IL7 injections is donewhile the estimations of the
individual parameters and the predictions are improved with new observations. This dynamic approach is also referred
as dynamic drug monitoring in the work of Murphy et al.25 Second, the statistical approach of treatment optimization
that we propose is less computationally demanding because we are not looking for an optimal strategy over the space
of all potential strategies.45 Rather, we are optimizing the strategy according to that patient's characteristics, by learning
the random effects values as information increases. In our application, this was very relevant because we could take into
account the diversity of response of the patients.
The success of the proposed approach in this application is due to the validity of the predictions that are obtained after
a short learning phase for every patient. However, model misspecification could seriously weaken any optimization of
the treatment strategy. Here, the model used was clearly the best model over a series of models tested in this context.21
The stochasticity was mainly due to inter-individuals variability captured through two parameters (� and �), the other
parameters are fixed at the value estimated in Jarne et al21 and presented in Table 1. Any additional stochasticity, requiring,
for instance, to deal with stochastic differential equations, would compromise the feasibility of the approach in a real
clinical setting.
The clinical perspective is an evaluation of the adaptive strategy with a standard protocol of injection to confirm the
benefit of this intervention on all other immunological markers, such as in the work of Lévy et al,9 before going to a
larger trial to evaluate the impact on clinical outcomes. More generally, this work shows howmechanistic model can help
increasing the efficiency of therapies in realistic contexts where patients may respond differently to treatments.
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Modélisation et optimisation de la réponse à des vaccins et à des
interventions immunothérapeutiques. Application au virus Ebola et au VIH.
Résumé : Les vaccins ont été une grande réussite en matière de santé publique au cours
des dernières années. Cependant, le développement de vaccins efficaces contre les maladies
infectieuses telles que le VIH ou le virus Ebola reste un défi majeur. Cela peut être attribué
à notre manque de connaissances approfondies en immunologie et sur le mode d’action
de la mémoire immunitaire. Les modèles mathématiques peuvent aider à comprendre les
mécanismes de la réponse immunitaire, à quantifier les processus biologiques sous-jacents
et à déveloper des vaccins fondés sur un rationnel scientifique. Nous présentons un modèle
mécaniste de la dynamique de la réponse immunitaire humorale après injection d’un vac-
cin Ebola basé sur des équations différentielles ordinaires. Les paramètres du modèle sont
estimés par maximum de vraisemblance dans une approche populationnelle qui permet de
quantifier le processus de la réponse immunitaire et ses facteurs de variabilité. Le schéma
vaccinal n’a d’impact que sur la réponse à court terme, alors que des différences significa-
tives entre des sujets de différentes régions géographiques sont observées à plus long terme.
Cela pourrait avoir des implications dans la conception des futurs essais cliniques. En-
suite, nous développons un outil numérique basé sur la programmation dynamique pour
optimiser des schémas d’injections répétées. Nous nous intéressons en particulier à des
patients infectés par le VIH sous traitement mais incapables de reconstruire leur système
immunitaire. Des injections répétées d’un produit immunothérapeutique (IL-7) sont en-
visagées pour améliorer la santé de ces patients. Le processus est modélisé par un modèle
de Markov déterministe par morceaux et des résultats récents de la théorie du contrôle
impulsionnel permettent de résoudre le problème numériquement à l’aide d’une suite ité-
rative. Nous montrons dans une preuve de concept que cette méthode peut être appliquée
à un certain nombre de pseudo-patients. Dans l’ensemble, ces résultats s’intègrent dans
un effort de développer des méthodes sophistiquées pour analyser les données d’essais
cliniques afin de répondre à des questions cliniques concrètes.
Mots clés : Modèles mécanistes ; Equations différentielles ordinaires ; Maximisation de la vrai-
semblance ; Modèles linéaires mixtes ; Contrôle optimal ; Processus de Markov déterministes par
morceaux ; Programmation dynamique ; Vaccin ; Ebola ; Réponse immunitaire ; Durabilité ; Fac-
teurs de variabilité ; VIH ; Immunothérapie ; Injections répétées.
Modeling and optimizing the response to vaccines and immunotherapeutic
interventions. Application to Ebola virus and HIV.
Abstract: Vaccines have been one of the most successful developments in public health
in the last years. However, a major challenge still resides in developing effective vaccines
against infectious diseases such as HIV or Ebola virus. This can be attributed to our lack of
deep knowledge in immunology and the mode of action of immune memory. Mathematical
models can help understanding the mechanisms of the immune response, quantifying
the underlying biological processes and eventually developing vaccines based on a solid
rationale. First, we present a mechanistic model for the dynamics of the humoral immune
response following Ebola vaccine immunizations based on ordinary differential equations.
The parameters of the model are estimated by likelihood maximization in a population
approach, which allows to quantify the process of the immune response and its factors of
variability. The vaccine regimen is found to impact only the response on a short term,
while significant differences between subjects of different geographic regions are found at
a longer term. This could have implications in the design of future clinical trials. Then,
we develop a numerical tool based on dynamic programming for optimizing schedule of
repeated injections. In particular, we focus on HIV-infected patients under treatment but
unable to recover their immune system. Repeated injections of an immunotherapeutic
product (IL-7) are considered for improving the health of these patients. The process is
first modeled by a piecewise deterministic Markov model and recent results of the impulse
control theory allow to solve the problem numerically with an iterative sequence. We show
in a proof-of-concept that this method can be applied to a number of pseudo-patients. All
together, these results are part of an effort to develop sophisticated methods for analyzing
data from clinical trials to answer concrete clinical questions.
Key words: Mechanistic modeling; Ordinary differential equations; Likelihood maximization;
Linear mixed models; Optimal control; Piecewise deterministic Markov processes; Dynamic pro-
gramming; Vaccine; Ebola; Immune response; Durability; Variability factors; HIV; Immunother-
apy; Repeated injections.
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